6-K - MDXH - Equibles

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TORULE 13a-16 OR 15d-16UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2023

Commission File Number 001-40996

MDXHEALTH SA

(Translation of registrant’s name into English)

CAP Business Center

Zone Industrielle des Hauts-Sarts

4040 Herstal, Belgium

+32 4 257 70 21

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

MDXHEALTH SA

MDxHealth SA (the “Company”) hereby furnishes the attached documents in connection with its Ordinary and Extraordinary General Shareholders’ Meetings to be held on Thursday, May 25, 2023 at 3:00 p.m., Belgian time, at the offices of the notary public Stijn Raes, at Kortrijksesteenweg 1147, 9051 Ghent, Belgium, or at such other place as will be indicated at that place at that time.

The informationin the attached Exhibits 99.1-99.10 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of theSecurities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section,nor shall they be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, orthe Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

Exhibit No.	Description of Exhibit
99.1	Convening Notice
99.2	Attendance Form
99.3	Proxy Form
99.4	Voting by Mail Form
99.5	Outstanding Shares and Voting Rights
99.6	2022 Annual Report – Consolidated Financial Statements
99.7	Board Report in relation to the 2023 Share Option Plan
99.8	2023 Share Option Plan
99.9	Board Report in relation to authorized capital
99.10	Press Release, dated April 25, 2023

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	MDXHEALTH SA
Date: April 26, 2023	By:	/s/ Michael McGarrity
		Name:	Michael McGarrity
		Title:	Chief Executive Officer

Exhibit 99.1

Unofficial English translation – For informationalpurposes only

MDxHealth SA

Limited Liability Company(société anonyme)

CAP Business Center

Zone Industrielle des Hauts-Sarts

Rue d’Abhooz 31

4040 Herstal, Belgium

VAT BE 0479.292.440 (RLP Liège, division Liège)

INVITATION

ORDINARY andextraordinary GENERAL MEETINGS

to be held on Thursday, 25 May 2023, at 3:00 p.m.

The holders of securities issued by MDxHealth SA (the “Company”) are invited to the ordinary general shareholders’ meeting of the Company. After the agenda of the ordinary general shareholders’ meeting has been treated, the meeting will be shortly suspended in order to be continued as an extraordinary general shareholders’ meeting before a notary public.

GENERAL INFORMATION

Date, hour and venue: The ordinary and extraordinary general shareholders’ meetings will be held on Thursday, 25 May 2023 at 3:00 p.m. at the offices of the notary public Stijn Raes, at Kortrijksesteenweg 1147, 9051 Ghent, Belgium, or at such other place as will be indicated at that place at that time. There is no attendance quorum requirement for the ordinary general shareholders’ meeting. There is, however, an attendance quorum requirement for the items on the agenda of the extraordinary general shareholders’ meeting (see also below under “—Extraordinary general meeting”). If the attendance quorum for the items on the agenda of the extraordinary general shareholders’ meeting were not to be reached, a second extraordinary general shareholders’ meeting will be held for these items on Friday, 30 June 2023, unless, as the case may be, decided otherwise on behalf of the board of directors.

Opening of the doors: In order to facilitate the keeping of the attendance list on the day of the ordinary and extraordinary general shareholders’ meetings, holders of securities and their representatives are invited to register as of 2:15 p.m.

ORDINARY GENERAL MEETING

Agenda and proposed resolutions: The agenda and proposed resolutions of the ordinary general shareholders’ meeting of the Company which, as the case may be, can be amended at the meeting on behalf of the board of directors, are as follows:

1.	Report on the annual statutory financial statements and on the consolidated financial statements

Submission of, and discussion on, (a) the combined annual report of the board of directors on the consolidated and (non-consolidated) statutory financial statements of the Company for the financial year ended on 31 December 2022, (b) the report of the statutory auditor on the (non-consolidated) statutory financial statements of the Company for the financial year ended on 31 December 2022, and (c) the report of the statutory auditor on the consolidated financial statements of the Company for the financial year ended on 31 December 2022.

2.	Approval of the annual (non-consolidated) statutory financial statements

Submission of, discussion on, and approval of the annual (non-consolidated) statutory financial statements for the financial year ended on 31 December 2022, and approval of the allocation of the result as proposed by the board of directors.

Proposed resolution: The general shareholders’ meeting resolves to approve the annual (non-consolidated) statutory financial statements of the Company for the financial year ended on 31 December 2022 and to approve the allocation of the annual result as proposed by the board of directors.

1
*Unofficial English translation – For informational purposes only*

3.	Consolidated financial statements

Submission of, and discussion on, the consolidated financial statements of the Company for the financial year ended on 31 December 2022.

4.	Discharge from liability of the directors

Discharge from liability of the directors for the exercise of their mandates during the financial year ended on 31 December 2022.

Proposed resolution: The general shareholders’ meeting resolves to grant discharge from liability to each of the directors who was in office during the financial year ended on 31 December 2022, for the performance of its, his or her mandate during that financial year.

5.	Discharge from liability of the statutory auditor

Discharge from liability of the statutory auditor for the exercise of its mandate during the financial year ended on 31 December 2022.

Proposed resolution: The general shareholders’ meeting resolves to grant discharge from liability to the statutory auditor which was in office during the financial year ended on 31 December 2022, for the performance of its mandate during that financial year.

6.	Remuneration report

Submission of, discussion on, and approval of the remuneration report prepared by the nomination and remuneration committee and approved by the board of directors, and included in the combined annual report of the board of directors on the consolidated and (non-consolidated) statutory financial statements of the Company for the financial year ended on 31 December 2022.

Proposed resolution: The general shareholders’ meeting resolves to approve the remuneration report included in the combined annual report of the board of directors on the consolidated and (non-consolidated) statutory financial statements of the Company for the financial year ended on 31 December 2022.

7.	Re-appointment of directors

Taking into account the recommendation of the nomination and remuneration committee, the board of directors recommends that (a) Hilde Windels BV, represented by Hilde Windels as permanent representative, (b) Regine Slagmulder BV, represented by Regine Slagmulder as permanent representative, and (c) Eric Bednarski, be re-appointed as directors of the Company, each for a term of two years, and (d) Michael K. McGarrity be re-appointed as director of the Company for a term of three years.

For further information regarding these proposed directors, reference is made to the corporate governance statement included in the the combined annual report of the board of directors on the consolidated and (non-consolidated) statutory financial statements of the Company for the financial year ended on 31 December 2022.

Based on information made available by respectively Hilde Windels BV, represented by Hilde Windels as permanent representative, and Regine Slagmulder BV, represented by Regine Slagmulder as permanent representative, it appears that respectively each of Hilde Windels BV and Hilde Windels, and each of Regine Slagmulder BV and Regine Slagmulder, satisfy the applicable requirements in order to be nominated as independent directors in accordance with article 7:87 of the Belgian Companies and Associations Code and provision 3.5 of the 2020 Belgian Corporate Governance Code.

2
*Unofficial English translation – For informational purposes only*

Proposed resolutions:

(a)	The general shareholders’ meeting resolves to re-appoint Hilde Windels BV, represented by Hilde Windels<br>as permanent representative, as independent director of the Company within the meaning of article 7:87 of the Belgian Companies and Associations<br>Code and provision 3.5 of the 2020 Belgian Corporate Governance Code, for a term of two years, up to and including the closing of the<br>ordinary general shareholders’ meeting to be held in 2025 which will have decided upon the financial statements for the financial year<br>ended on 31 December 2024. The remuneration of the director is as set out in the Company’s remuneration policy, as approved from<br>time to time by the general shareholders’ meeting, and (subject to the provisions of the remuneration policy) as decided by the<br>special general shareholders’ meeting held on 30 July 2020 and the ordinary general shareholders’ meeting held on 27 May 2021.
(b)	The general shareholders’ meeting resolves to re-appoint Regine Slagmulder BV, represented by Regine Slagmulder<br>as permanent representative, as independent director of the Company within the meaning of article 7:87 of the Belgian Companies and Associations<br>Code and provision 3.5 of the 2020 Belgian Corporate Governance Code, for a term of two years, up to and including the closing of the<br>ordinary general shareholders’ meeting to be held in 2025 which will have decided upon the financial statements for the financial year<br>ended on 31 December 2024. The remuneration of the director is as set out in the Company’s remuneration policy, as approved from<br>time to time by the general shareholders’ meeting, and (subject to the provisions of the remuneration policy) as decided by the<br>special general shareholders’ meeting held on 30 July 2020 and the ordinary general shareholders’ meeting held on 27 May 2021.
---	---
(c)	The general shareholders’ meeting resolves to re-appoint Eric Bednarski as director of the Company, for<br>a term of two years, up to and including the closing of the ordinary general shareholders’ meeting to be held in 2025 which will have<br>decided upon the financial statements for the financial year ended on 31 December 2024. The remuneration of the director is as set out<br>in the Company’s remuneration policy, as approved from time to time by the general shareholders’ meeting, and (subject to<br>the provisions of the remuneration policy) as decided by the special general shareholders’ meeting held on 30 July 2020 and the ordinary<br>general shareholders’ meeting held on 27 May 2021.
---	---
(d)	The general shareholders’ meeting resolves to re-appoint Michael K. McGarrity as director of the Company,<br>for a term of three years, up to and including the closing of the ordinary general shareholders’ meeting to be held in 2026 which will<br>have decided upon the financial statements for the financial year ended on 31 December 2025. The remuneration of the director is as set<br>out in the Company’s remuneration policy, as approved from time to time by the general shareholders’ meeting, and (subject<br>to the provisions of the remuneration policy) as decided by the special general shareholders’ meeting held on 30 July 2020 and the ordinary<br>general shareholders’ meeting held on 27 May 2021.
---	---

Note: If the proposed resolutions set out in point 7 are approved by the general shareholders’ meeting, the Company’s board of directors will be composed of (1) Michael K. McGarrity, chief executive officer (CEO), executive director and managing director (until 2026), (2) Ahok BV, represented by Koen Hoffman, independent director and chair of the board of directors (until 2024), (3) Donnie M. Hardison JR, independent director (until 2025), (4) Hilde Windels BV, represented by Hilde Windels, independent director (until 2025), (5) Qaly-Co BV, represented by Lieve Verplancke, independent director (until 2024), (6) Valiance Advisors LLP, represented by Jan Pensaert, non-executive director (until 2024), (7) Regine Slagmulder BV, represented by Regine Slagmulder, independent director (until 2025), and (9) Eric Bednarski, non-executive director (until 2025).

3
*Unofficial English translation – For informational purposes only*

8.	Re-appointment of the statutory auditor

Taking into account the recommendation and preference of the audit committee, the board of directors recommends that BDO Réviseurs d’Entreprises SRL, represented by Bert Kegels as permanent representative, be re-appointed as statutory auditor of the Company for a term of three years up to and including the closing of the ordinary general shareholders’ meeting to be held in 2026 which will have decided upon the financial statements for the financial year ended on 31 December 2025, subject to, and in accordance with, the provisions of article 3:61 of the Belgian Companies and Associations Code and Regulation (EU) No. 537/2014 of the European Parliament and of the Council of 16 April 2014 on specific requirements regarding statutory audit of public-interest entities and repealing Commission Decision 2005/909/EC.

Proposed resolution: Taking into account the recommendation of the board of directors upon recommendation and preference of the audit committee, the general shareholders’ meeting resolves to re-appoint BDO Réviseurs d’Entreprises SRL, represented by Bert Kegels as permanent representative, as statutory auditor of the Company for a term of three years up to and including the closing of the ordinary general shareholders’ meeting to be held in 2026 which will have decided upon the financial statements for the financial year ended on 31 December 2025, subject to, and in accordance with, the provisions of article 3:61 of the Belgian Companies and Associations Code and Regulation (EU) No. 537/2014 of the European Parliament and of the Council of 16 April 2014 on specific requirements regarding statutory audit of public-interest entities and repealing Commission Decision 2005/909/EC. For the duration of its mandate, the annual remuneration of the statutory auditor of the Company shall be EUR 260,000.00 (excluding VAT, taxes and expenses, as applicable) for the audit of the consolidated accounts of the group and the audit of the (non-consolidated) statutory financial statements of the Company. These fees are subject to a yearly indexation based on the standard index.

9.	Approval in accordance with article 7:151 of the Belgian Companies and Associations Code with respectto the loan and security agreement entered into by the Company and Innovatus Life Sciences Lending Fund I, LP

On 2 August 2022, the Company entered into a loan and security agreement with Innovatus Life Sciences Lending Fund I, LP, pursuant to which Innovatus Life Sciences Lending Fund I, LP agreed to provide a loan facility for up to USD 70,000,000.00, which can be drawn in multiple tranches. Sections 2.2(c), 7.2, 7.3 and 8.2 of the loan and security agreement allow Innovatus Life Sciences Lending Fund I, LP to terminate the loan and security agreement and demand immediate (re)payment of all amounts outstanding under the loan and security agreement in case of a change of control over the Company or any subsidiaries of the Company.

Proposed resolution: The general shareholders’ meeting resolves to approve and ratify, in accordance with article 7:151 of the Belgian Companies and Associations Code, all clauses in the loan and security agreement entered into by the Company and Innovatus Life Sciences Lending Fund I, LP (including, but not limited to, Sections 2.2(c), 7.2, 7.3 and 8.2) that are applicable at the time a change of control occurs and which fall or could be considered to fall within the scope of article 7:151 of the Belgian Companies and Associations Code (relating to the granting of rights to third parties that substantially affect the Company’s assets and liabilities, or give rise to a substantial debt or commitment on its behalf, when the exercise of these rights is subject to the launching of a public takeover bid on the shares of the Company or to a change in the control exercised over it). The general shareholders’ meeting also grants a special power of attorney to each Director of the Company, the Chief Financial Officer and the Executive Vice President of Corporate Development and General Counsel (each a “Proxy Holder”), each Proxy Holder acting individually and with the right of substitution, to complete the formalities required by article 7:151 of the Belgian Companies and Associations Code with regard to this resolution, including, but not limited to, the execution of all documents and forms required for the publication of this resolution in the annexes to the Belgian Official Gazette.

No attendance quorum: There is no attendance quorum requirement for the deliberation and voting on the respective items referred to in the aforementioned agenda of the ordinary general shareholders’ meeting.

Voting and majority: Subject to applicable legal provisions, each share shall have one vote. In accordance with applicable law, the proposed resolutions referred to in the aforementioned agenda of the ordinary general shareholders’ meeting shall be passed if they are approved by a simple majority of the votes validly cast by the shareholders. Pursuant to article 7:135 of the Belgian Companies and Associations Code, the holders of subscription rights have the right to participate to the ordinary general shareholders’ meeting, but only with an advisory vote.

4
*Unofficial English translation – For informational purposes only*

extraordinary****GENERAL MEETING

Agenda and proposed resolutions: The agenda and proposed resolutions of the extraordinary general shareholders’ meeting of the Company which, as the case may be, can be amended at the meeting on behalf of the board of directors, are as follows:

1.	Submission of reports - 2023 Share Option Plan

Submission of, discussion on:

(a)	the report of the board of directors of the Company in accordance with articles 7:180 and 7:191 of the<br>Belgian Companies and Associations Code in relation to the proposal to issue 5,000,000 new subscription rights for shares of the Company<br>(the “2023 Share Options”), pursuant to a share option plan named “the 2023 Share Option Plan”, and to dis-apply,<br>in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required,<br>of the holders of outstanding subscription rights (share options) or American Depositary Shares (“ADSs”) of the Company,<br>for the benefit of the members of the personnel of the Company and its subsidiaries from time to time, within the meaning of article 1:27<br>of the Belgian Companies and Associations Code (the “Selected Participant”); and
(b)	the report of the statutory auditor of the Company in accordance with articles 7:180 and 7:191 of the<br>Belgian Companies and Associations Code in relation to the proposal to issue 5,000,000 2023 Share Options, and to dis-apply, in the interest<br>of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of the holders<br>of outstanding subscription rights (share options) or ADSs of the Company, to the benefit of the Selected Participants.
---	---

(a)

the report of the board of directors of the Company in accordance with articles 7:180 and 7:191 of the Belgian Companies and Associations Code in relation to the proposal to issue 5,000,000 new subscription rights for shares of the Company (the “2023 Share Options”), pursuant to a share option plan named “the 2023 Share Option Plan”, and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) or American Depositary Shares (“ADSs”) of the Company, for the benefit of the members of the personnel of the Company and its subsidiaries from time to time, within the meaning of article 1:27 of the Belgian Companies and Associations Code (the “Selected Participant”); and

(b)

the report of the statutory auditor of the Company in accordance with articles 7:180 and 7:191 of the Belgian Companies and Associations Code in relation to the proposal to issue 5,000,000 2023 Share Options, and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) or ADSs of the Company, to the benefit of the Selected Participants.

---

2.	Proposal to issue 5,000,000 2023 Share Options

Proposed resolution: The general shareholders’ meeting resolves to approve the issuance of 5,000,000 2023 Share Options, pursuant to a share option plan named the “2023 Share Option Plan”, and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) or ADSs of the Company, for the benefit of Selected Participant. In view thereof, the general shareholders’ meeting resolves as follows:

(a)	Terms and conditions of the 2023 Share Options: The terms and conditions of the 2023 Share Options<br>(including, but not limited to, the exercise price of the 2023 Share Options) shall be as set out in the annex to the report of the board<br>of directors referred to in item 1.(a) of the agenda (for the purpose of this resolution, the “Plan”), a copy of which<br>shall remain attached to the minutes reflecting the present resolution. The 2023 Share Options have a term of ten years as from their<br>issue date.
(b)	Underlying shares: Each 2023 Share Option shall entitle the holder thereof to subscribe for one<br>new share to be issued by the Company. The new shares to be issued at the occasion of the exercise of the 2023 Share Options shall have<br>the same rights and benefits as, and rank pari passu in all respects, including as to entitlements to dividends and other distributions,<br>with the existing and outstanding shares of the Company at the moment of their issuance, and will be entitled to dividends and other distributions<br>in respect of which the relevant record date or due date falls on or after the date of issue of the shares.
---	---
(c)	Dis-application of the preferential subscription right for the benefit of the Selected Participants:<br>The general shareholders’ meeting resolves, in accordance with article 7:191 of the Belgian Companies and Associations Code, to dis-apply,<br>in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required,<br>of the holders of outstanding subscription rights (share options) or ADSs of the Company, for the benefit of the Selected Participants,<br>and to approve the possibility for the Company to grant the 2023 Share Options to the Selected Participants, as further explained in the<br>report of the board of directors referred to in item 1.(a) of the agenda and the terms and conditions of the Plan.
---	---

5
*Unofficial English translation – For informational purposes only*

(d)	Confirmation of the subscription of 2023 Share Options by the Company: The general shareholders’<br>meeting resolves to approve and confirm that the Company will be able to subscribe for the 2023 Share Options, with a view to creating<br>a pool of outstanding 2023 Share Options available for further grants to Selected Participants. The Company may not, however, exercise<br>the 2023 Share Options for its own account.
(e)	Conditional capital increase and issue of new shares: The general shareholders’ meeting resolves,<br>subject to, and to the extent of the exercise of 2023 Share Options, to increase the Company’s share capital and to issue the relevant<br>number of new shares issuable upon the exercise of the 2023 Share Options. Subject to, and in accordance with, the provisions of the Plan,<br>upon exercise of the 2023 Share Options and issue of new shares, the aggregate amount of the exercise price of the 2023 Share Options<br>will be allocated to the share capital of the Company. To the extent that the amount of the exercise price of the 2023 Share Options,<br>per share to be issued upon exercise of the 2023 Share Options, exceeds the fractional value of the then existing shares of the Company<br>existing immediately prior to the issue of the new shares concerned, a part of the exercise price, per share to be issued upon exercise<br>of the 2023 Share Options, equal to such fractional value shall be booked as share capital, whereby the balance shall be booked as issue<br>premium. Following the capital increase and issuance of new shares, each new and existing share shall represent the same fraction of the<br>share capital of the Company.
---	---
(f)	Issue premium: Any issue premium that will be booked in connection with the 2023 Share Options<br>shall be accounted for on a non-distributable account on the liabilities side of the Company’s balance sheet under its net equity, and<br>the account on which the issue premium will be booked shall, like the share capital, serve as a guarantee for third parties and can only<br>be reduced on the basis of a lawful resolution of the general shareholders’ meeting passed in the manner required for an amendments to<br>the Company’s articles of association.
---	---
(g)	Powers of attorney: The board of directors is authorised to implement and execute the resolutions<br>passed by the general shareholders’ meeting in connection with the 2023 Share Options, and to take all steps and carry out all formalities<br>that shall be required by virtue of the Plan, the Company’s articles of association and applicable law in order to issue or transfer the<br>shares upon exercise of the 2023 Share Options. Furthermore, each of the Company’s directors, Joe Sollee and Ron Kalfus, each such person<br>acting individually and with possibility of sub-delegation and the power of subrogation, shall have the power, upon exercise of the 2023<br>Share Options, (i) to proceed with the recording of (A) the capital increase and issue of new shares resulting from such exercise, (B)<br>the allocation of the share capital and (as applicable) the issue premium, and (C) the amendment of the Company’s articles of association<br>in order to reflect the new share capital and number of outstanding shares following the exercise of the 2023 Share Options, (ii) to sign<br>and deliver, on behalf of the Company, the relevant Euroclear, Euronext and bank documentation, the share register and all necessary documents<br>in connection with the issuance and delivery of the shares to the beneficiary, and (iii) to do whatever may be necessary or useful (including<br>but not limited to the preparation and execution of all documents and forms) for the admission of the shares issued upon the exercise<br>of the 2023 Share Options to trading on the regulated market of Euronext Brussels (or such other markets on which the Company’s shares<br>will be trading at that time).
---	---
(h)	Waiver: The general shareholders’ meeting acknowledges that the 2023 Share Options to be granted<br>under the “2023 Share Option Plan” shall not be considered “variable remuneration”, “fixed remuneration”<br>or “annual remuneration” within the meaning of the Belgian Companies and Associations Code (including, without limitation, for<br>the purpose of articles 3:6, §3, 7:89/1, 7:90, 7:91, 7:92, 7:100, 7:108 and 7:121 of the Belgian Companies and Associations Code)<br>and the 2020 Corporate Governance Code (including, without limitation, for the purpose of provision 11 of the 2020 Corporate Governance<br>Code). The general shareholders’ meeting approves the vesting conditions and mechanisms of the 2023 Share Options, as included in the<br>Plan. The provisions of articles 7:91, 7:108 and 7:121 (as applicable) of the Belgian Companies and Associations Code are expressly dis-applied<br>in relation to the 2023 Share Option Plan.
---	---

6
*Unofficial English translation – For informational purposes only*

(i)

Approval in accordance with article 7:151 of the Belgian Companies and Associations Code: The general shareholders’ meeting resolves to take note, approve and ratify, insofar as required in accordance with article 7:151 of the Belgian Companies and Associations Code, all clauses included in the Plan, which come into effect at the moment a change of control occurs and which fall or could be considered to fall within the scope of article 7:151 of the Belgian Companies and Associations Code (relating to the granting of rights to third parties that substantially affect the Company’s assets and liabilities, or give rise to a substantial debt or commitment on its behalf, when the exercise of these rights is subject to the launching of a public takeover bid on the shares of the Company or to a change in the control exercised over it), including, without limitation, the automatic accelerated vesting mechanism upon acquisition as defined in the Plan. The general shareholders’ meeting grants a special power of attorney to each director of the Company, acting alone and with power of substitution, for the purpose of carrying out the formalities required by article 7:151 of the Belgian Companies and Associations Code with respect to this resolution.

3.	Submission of the special report of the board of directors in accordance with article 7:199 of theBelgian Companies and Associations Code relating to the proposal to renew the authorised capital

Consideration, discussion and submission of the special report of the board of directors in accordance with article 7:199 of the Belgian Companies and Associations Code relating to the proposal to renew the powers granted to the board of directors under the authorised capital, as set out below in item 4 of the agenda of the extraordinary general shareholders’ meeting, and setting out the specific circumstances in which the board of directors will be able to use its powers under the authorised capital, and the purposes that it should pursue.

4.	Renewal of the authorisation to the board of directors to increase the share capital within the frameworkof the authorised capital

In order to allow the board of directors the flexibility to raise additional equity-based financing as and when the need may arise or an opportunity would present itself, the board of directors proposes that it be granted limited powers under the authorised capital to increase the Company’s share capital by a maximum amount of 100% during a term of five (5) years, all as further set out below. For further information on the circumstances in which the board of directors could make use of the authorised capital and the objectives that the board of directors would pursue with the authorised capital, see also the special report referred to in item 3 of the agenda of the extraordinary general shareholders’ meeting.

Proposed resolution: The general shareholders’ meeting resolves to renew the authorisation to the board of directors to increase the share capital in one or several times, during a period of five (5) years as from the publication in the Annexes to the Belgian Official Gazette of this authorisation, with an aggregate amount equal to up to 100% of the amount of the share capital of the Company, and this in accordance with the terms and conditions set forth in the special report of the board of directors prepared in accordance with article 7:199 of the Belgian Companies and Associations Code, as referred to in agenda item 3 of this extraordinary general shareholders’ meeting. Consequently, the general shareholders’ meeting resolves to delete article 6 “Authorised capital” of the articles of association of the Company entirely and to replace it with the following text (whereby the date referred to in the sub-section between square brackets shall be the date of the general shareholders’ meeting approving the renewed authorised capital, and the amount referred to in the sub-section between brackets shall be the amount of the Company’s share capital at the time of the general shareholders’ meeting approving the authorised capital):

7
*Unofficial English translation – For informational purposes only*

“Article 6: Authorised capital

The board of directors is authorisedto increase the share capital of the company on one or several occasions by a maximum aggregate amount of [100% of the company’s sharecapital at the time of the adoption of the new authorised capital].

The board of directors may increasethe share capital by contributions in cash or in kind, by capitalisation of reserves, whether available or unavailable for distribution,and capitalisation of issue premiums, with or without the issuance of new shares, with or without voting rights, that will have the rightsas will be determined by the board of directors. The board of directors is also authorised to use this authorisation for the issuanceof convertible bonds or subscription rights, bonds with subscription rights or other securities.

This authorisation is valid for aperiod of five years as from the date of publication in the Annexes to the Belgian Official Gazette of an extract of the minutes of theextraordinary general shareholders’ meeting of the company held on [date of the general shareholders’ meeting approving the authorisedcapital].

In the event of a capital increasedecided by the board of directors within the framework of the authorised capital, all issue premiums booked, if any, will be accountedfor in accordance with the provisions of these articles of association.

The board of directors is authorised,when exercising its powers within the framework of the authorised capital, to restrict or cancel, in the interest of the company, thepreferential subscription rights of the shareholders. This restriction or cancellation of the preferential subscription rights can alsobe done in favour of members of the personnel of the company or of its subsidiaries, or in favour of one or more persons other than membersof the personnel of the company or of its subsidiaries.

The board of directors is authorised,with the right of substitution, to amend the articles of association, after each capital increase that has occurred within the frameworkof the authorised capital, in order to bring them in conformity with the new situation of the share capital and the shares.”

Attendance quorum: According to the Belgian Companies and Associations Code, an attendance quorum of at least 50% of the outstanding shares must be present or represented at the extraordinary general shareholders’ meeting for the deliberation and voting the items of the aforementioned agenda of the extraordinary general shareholders’ meeting. If such attendance quorum is not reached, a second extraordinary general shareholders’ meeting will be convened for these agenda items, unless, as the case may be, decided otherwise on behalf of the board of directors, and the attendance quorum requirement will not apply to such second meeting.

Voting and majority: Subject to applicable legal provisions, each share shall have one vote. In accordance with applicable law, the proposed resolutions referred to in the aforementioned agenda of the extraordinary general shareholders’ meeting shall be passed if they are approved by a majority of 75% of the votes validly cast by the shareholders. Pursuant to article 7:135 of the Belgian Companies and Associations Code, the holders of subscription rights have the right to participate to the extraordinary general shareholders’ meeting, but only with an advisory vote.

Participationto the meetings

Introduction: Holders of securities issued by the Company who wish to participate to the ordinary and extraordinary general shareholders’ meetings of the Company should take into account the formalities and procedures described below.

Registration date: The registration date for the ordinary and extraordinary general shareholders’ meetings shall be Thursday 11 May 2023, at midnight (12:00 a.m., Belgian time). Only persons owning securities issued by the Company on Thursday 11 May 2023, at midnight (12:00 a.m., Belgian time) shall be entitled to participate to, and, as the case may be, vote at the ordinary and extraordinary general shareholders’ meetings. Only shareholders are entitled to vote. The holders of subscription rights can participate to the ordinary and extraordinary general shareholders’ meetings but only with an advisory vote. Shareholders, as well as holders of subscription rights must satisfy the formalities that are described under “—Participation to the meetings”.

Participation to the meetings: In order to be able to participate to the ordinary and extraordinary general meetings, a holder of securities issued by the Company must satisfy two conditions: (a) be registered as holder of such securities on the registration date, and (b) notify the Company, as described below:

(a)

Registration: Firstly, the right for a holder of securities issued by the Company to participate to and, as applicable, to vote at the ordinary and extraordinary general shareholders’ meetings is only granted on the basis of the registration of the securities concerned on the aforementioned registration date at midnight, via registration, in the applicable register book for the securities concerned (for registered securities) or in the accounts of a certified account holder or relevant settlement institution for the securities concerned (for dematerialised shares).

8
*Unofficial English translation – For informational purposes only*

(b)

Notification: Secondly, in order to participate to the ordinary and extraordinary general shareholders’ meetings, the holders of securities issued by the Company must notify the Company whether they want to participate to the meetings and must do so prior to or at the latest on Friday, 19 May 2023. The holders of securities who wish to make such notification can make use of the attendance form that can be obtained at the Company’s registered office and on the Company’s website (http://www.mdxhealth.com). The notice must reach the Company by mail at its registered office (MDxHealth SA, CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d’Abhooz 31, 4040 Herstal, Belgium, Attention: Mr. Ron Kalfus) or by e-mail at agsm@mdxhealth.com, at the latest on the sixth calendar day prior to the ordinary and extraordinary general shareholders’ meetings, i.e., on or before Friday, 19 May 2023 at the latest. For the holders of dematerialised securities, the notification should include a certificate confirming the number of securities that have been registered in their name on the registration date. The certificate can be obtained by the holders of the dematerialised securities with the certified account holder, the applicable settlement institution, or the relevant financial intermediary for the securities concerned.

Voting by mail: The shareholders can vote by mail in accordance with article 39 of the Company’s articles of association. Votes by mail must be cast by means of the form prepared by the Company. The voting by mail form can be obtained on the Company’s website (http://www.mdxhealth.com). The voting by mail form must be signed in writing or electronically. The electronic signature must be a qualified electronic signature in the sense of Regulation (EU) No 910/2014 of the European Parliament and of the Council of 23 July 2014 on electronic identification and trust services for electronic transactions in the internal market and repealing Directive 1999/93/EC, as amended. Signed voting by mail forms must reach the Company by mail at its registered office (MDxHealth SA, CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d’Abhooz 31, 4040 Herstal, Belgium, Attention: Mr. Ron Kalfus), or by e-mail at agsm@mdxhealth.com, at the latest on the sixth calendar day prior to the ordinary and extraordinary general shareholders’ meetings, i.e., on or before Friday, 19 May 2023 at the latest. Holders of securities who wish to vote by mail must in any case comply with the formalities to participate to the meetings as explained under “—Participation to the meetings”.

Representation by proxy: The holders of securities can participate to the meetings and vote, as applicable, through a written proxy, as the case may be, to the chair of the board of directors. Written proxy must contain specific voting instructions for each proposed resolution. Proxy forms can be obtained on the Company’s website (http://www.mdxhealth.com). The proxy must be signed in writing or electronically. The electronic signature must meet the same requirements as the electronic signature for the voting by mail form (see also “—Voting by mail”). Signed proxies must reach the Company by mail at its registered office (MDxHealth SA, CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d’Abhooz 31, 4040 Herstal, Belgium, Attention: Mr. Ron Kalfus) or by e-mail at agsm@mdxhealth.com, at the latest on the sixth calendar day prior to the ordinary and extraordinary general shareholders’ meetings, i.e., on or before Friday, 19 May 2023 at the latest. The appointment of a proxy holder must be made in accordance with the applicable rules of Belgian law, including in relation to conflicts of interests and the keeping of a register. Holders of securities who wish to be represented by proxy must, in any case comply with the formalities to participate to the meetings, as explained under “—Participation to the meetings”.

Amendments to the agenda and additional proposedresolutions: Shareholders who alone or together with other shareholders hold at least 3% of the share capital of the Company have the right to put additional items on the agenda of the ordinary and extraordinary general shareholders’ meetings and to table draft resolutions in relation to items that have been or are to be included in the agenda. If the required attendance quorum for the items on the agenda of the extraordinary general shareholders’ meeting is not reached and a second extraordinary general shareholders’ meeting is convened to deliberate and vote on such items, this right will not apply in relation to the agenda of the second extraordinary general shareholders’ meeting. Shareholders that wish to exercise this right must prove on the date of their request that they own at least 3% of the outstanding shares. The ownership must be based, for dematerialised shares, on a certificate issued by the applicable settlement institution for the securities concerned, or by a certified account holder, confirming the number of securities that have been registered in the name of the relevant shareholders, and, for registered shares, on a certificate of registration of the relevant shares in the share register book of the Company. In addition, the shareholders concerned must, in any case, comply with the formalities to participate to the meetings, as explained under “—Participation to the meetings”, with at least 3% of the outstanding shares. A request to put additional items on the agenda and/or to table draft resolutions must be submitted in writing, and must contain, in the event of an additional agenda item, the text of the agenda item concerned and, in the event of a draft resolution, the text of the draft resolution. The request must also mention the mail or e-mail address to which the Company will send the confirmation of receipt of the request. The request must reach the Company by mail at its registered office (CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d’Abhooz 31, 4040 Herstal, Belgium, Attention: Mr. Ron Kalfus) or by e-mail at agsm@mdxhealth.com at the latest on the twenty-second calendar day prior to the ordinary and extraordinary general shareholders’ meetings, i.e., on or before Wednesday, 3 May 2023 at the latest. In case of amendments to the agenda and proposed additional resolutions as aforementioned, the Company will publish an amended agenda with, as the case may be, additional agenda items and additional draft resolutions no later than on the fifteenth calendar day prior to the ordinary and extraordinary general shareholders’ meetings, i.e., on or before Wednesday, 10 May 2023 at the latest. In addition, the Company shall make amended forms available for votes by proxy. Proxies that reach the Company prior to the publication of an amended agenda remain valid for the agenda items to which the proxies apply, subject, however, to applicable law and the further clarifications set out on the proxy forms.

9
*Unofficial English translation – For informational purposes only*

Right to ask questions: Each holder of securities issued by the Company has the right to ask questions to the directors and the statutory auditor related to items on the agenda of a general shareholders’ meeting. Questions can be asked during the meetings or can be submitted in writing prior to the meetings. Written questions must reach the Company by mail at its registered office (CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d’Abhooz 31, 4040 Herstal, Belgium, Attention: Mr. Ron Kalfus) or by e-mail at agsm@mdxhealth.com at the latest on the sixth calendar day prior to the ordinary and extraordinary general shareholders’ meetings, i.e., on or before Friday, 19 May 2023 at the latest. Answers to written questions will be provided in writing and will be published on the Company’s website (http://www.mdxhealth.com) on or before Thursday, 25 May 2023 at the latest, but before the vote on items on the respective agendas of the meetings concerned in accordance with applicable law. Oral questions will be answered during the meetings concerned in accordance with applicable law. In addition, in order for written questions to be considered, the holders of securities issued by the Company who submitted the written questions concerned must comply with the formalities to participate to the meetings, as explained under “—Participation to the meetings” and/or under “—Voting by mail” or “—Representation by proxy”.

Access to the meeting room: The natural persons who attend the ordinary and extraordinary general shareholders’ meetings in their capacity as owner of securities, holder of proxies or representative of a legal entity must be able to provide evidence of their identity in order to be granted access to the meeting room (subject to what is shared above under “—General information”). In addition, the representatives of legal entities must hand over the documents establishing their capacity as corporate representative or attorney-in-fact. These documents will be verified immediately before the start of the meetings.

Recommendation to use e-mail: The Company recommends the holders of its securities to use e-mail for all communication with the Company regarding the general shareholders’ meetings. The Company’s e-mail address for such communication is: agsm@mdxhealth.com. The Company also points at that, in addition to be physically available at the Company’s registered office and distributed by mail, all forms and other documentation in relation to the general shareholders’ meetings will be available on the Company’s website (http://www.mdxhealth.com). See also “—Available documentation”.

DataProtection

The Company is responsible for the processing of personal data it receives from, or collects about, holders of securities issued by the Company and proxy holders in the context of general shareholders’ meetings. The processing of such data will be carried out for the purposes of the organisation and conduct of the relevant general shareholders’ meeting, including the convening notices, registrations, participation and voting, as well as for maintaining lists or registers of security holders, and the analysis of the investor and security holder base of the Company. The data include, amongst others, identification data, the number and nature of securities of a holder of securities issued by the Company, proxies and voting instructions. This data may also be transferred to third parties for the purposes of assistance or services to the Company in connection with the foregoing. The processing of such data will be carried out, mutatis mutandis, in accordance with the Company’s Privacy Policy, available on the Company’s website (https://mdxhealth.com/privacy-policy). The Company draws the attention of the holders of securities issued by the Company and proxy holders to the description of the rights they may have as data subjects, such as, among others, the right to access, the right to rectify and the right to object to processing, which are outlined in the aforementioned Privacy Policy. All this does not affect the rules that apply in connection with the registration and participation to the general shareholders’ meeting. To exercise rights as a data subject and for all other information regarding the processing of personal data by or on behalf of the Company, the Company can be contacted by e-mail at dataprotection@mdxhealth.com.

10
*Unofficial English translation – For informational purposes only*

availabledocumentation

The following documentation is available on the Company’s website (http://www.mdxhealth.com): the notice convening the ordinary and extraordinary general shareholders’ meetings, updates of the agenda and proposed resolutions, in case of amendments to the agenda and proposed resolutions, the documents to be submitted to the ordinary and extraordinary general shareholders’ meetings as referred to in the agenda of the meetings, the attendance form, the voting by mail form, and the proxy form. Prior to the ordinary and extraordinary general shareholders’ meetings, holders of securities of the Company can also obtain at the registered office of the Company (CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d’Abhooz 31, 4040 Herstal, Belgium), free of cost, a copy of this documentation. The aforementioned website also mentions the total number of outstanding shares and voting rights of the Company.

Please address any correspondence on this matter to MDxHealth SA, Mr. Ron Kalfus CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d’Abhooz 31, 4040 Herstal, Belgium. The facsimile number is +32 (0)4 259 78 75 and the e-mail address is agsm@mdxhealth.com.

On behalf of the board of directors

This document is not an offer to sell or a solicitation of an offer to buy shares or other securities of mdxhealth sa.

Exhibit 99.2

MDxHealth SA

Limited Liability Company(société anonyme)

CAP Business Center

Zone Industrielle des Hauts-Sarts

Rue d’Abhooz 31

4040 Herstal, Belgium

VAT BE 0479.292.440 (RLP Liège, division Liège)

ATTENDANCE FORM FOR SECURITY HOLDERS<br><br> <br>ordinary and Extraordinary General Meetings**** to be held on Thursday, 25 May 2023, at 15:00 p.m. (Belgian time)
This attendance form should be used by holders<br> of securities of MDxHealth SA (the “Company”) who want to attend the ordinary and extraordinary general shareholders’<br> meetings in person. More information regarding the requirements for, and the modalities of, participation in the meetings can be found<br> in the convening notice of the ordinary and extraordinary general shareholders’ meetings.<br><br> <br><br><br> <br>The signed and completed form must reach the Company<br> at the latest on the sixth calendar day prior to the ordinary and extraordinary general shareholders’ meetings, i.e., on or before Friday, 19 May 2023 at the latest, by mail to:<br><br> <br><br><br> <br>MDxHealth SA<br><br> Attention Mr. Ron Kalfus<br><br> Company Secretary<br><br> <br>CAP Business Center<br><br> <br>Zone Industrielle des Hauts-Sarts<br><br> Rue d’Abhooz, 31<br><br> 4040 Herstal,<br><br> Belgium<br><br> <br>or by e-mail to:<br><br> <br><br><br> <br>agsm@mdxhealth.com<br><br> <br><br><br> <br>The use of e-mail<br> is strongly encouraged.<br><br> <br><br><br> <br>Holders of dematerialised<br> securities must attach to the present form a certificate issued by the certified account holder, the applicable settlement institution,<br> or the relevant financial intermediary for the securities concerned, confirming the number of securities that have been registered in<br> their name on the registration date (i.e., Thursday, 11 May 2023, at midnight (12:00 a.m., Belgian time)), with which they want<br> to participate to the ordinary and extraordinary general shareholders’ meetings.
---

ATTENDANCE FORM FOR SECURITY HOLDERS ordinary and Extraordinary General Meetings**** to be held on Thursday, 25 May 2023, at 15:00 p.m. (Belgian time)

This attendance form should be used by holders of securities of MDxHealth SA (the “Company”) who want to attend the ordinary and extraordinary general shareholders’ meetings in person. More information regarding the requirements for, and the modalities of, participation in the meetings can be found in the convening notice of the ordinary and extraordinary general shareholders’ meetings. The signed and completed form must reach the Company at the latest on the sixth calendar day prior to the ordinary and extraordinary general shareholders’ meetings, i.e., on or before Friday, 19 May 2023 at the latest, by mail to: MDxHealth SA Attention Mr. Ron Kalfus Company Secretary CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz, 31 4040 Herstal, Belgium or by e-mail to: agsm@mdxhealth.com The use of e-mail is strongly encouraged. Holders of dematerialised securities must attach to the present form a certificate issued by the certified account holder, the applicable settlement institution, or the relevant financial intermediary for the securities concerned, confirming the number of securities that have been registered in their name on the registration date (i.e., Thursday, 11 May 2023, at midnight (12:00 a.m., Belgian time)), with which they want to participate to the ordinary and extraordinary general shareholders’ meetings.

---

Ordinary and ExtraordinaryGeneral Shareholders’ Meetings of MDxHealth SA - Attendance form for security holders

The undersigned,

First Name:	………………………………………………………………….……………………
Family Name:	………………………………………………………………….……………………
Address:	………………………………………………………………….……………………
or
Corporate name:	………………………………………………………………….……………………
Corporate form:	………………………………………………………………….……………………
Registered office:	………………………………………………………………….……………………
	………………………………………………………………….……………………
Represented by (first name, family name and capacity):	………………………………………………………………….……………………
	………………………………………………………………….……………………
	………………………………………………………………….……………………

owner of the following number of securities issued by MDxHealth SA, with registered office at CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d’Abhooz 31, 4040 Herstal, Belgium:

………………………………………………………………….<br><br> <br><br><br> <br>(Number of shares)
………………………………………………………………….<br><br> <br><br><br> <br>(Number of subscription rights)^(1)^
Note:
(1)	Pursuant to article 7:135 of the Belgian Companies and Associations Code, the holders of subscription rights have the right to attend the shareholders’ meetings, but only with an advisory vote.

Hereby notifies his/her/its intent to attend the ordinary and extraordinary general shareholders’ meetings of MDxhealth SA to be held on Thursday, 25 May 2023, at 15:00 p.m. (Belgian time) at the offices of the notary public Stijn Raes, at Kortrijksesteenweg 1147, 9051 Ghent, Belgium, or at such other place indicated at that place at that time.

The undersigned agrees that the English translation of the present attendance form is a free translation and for information purposes only, and that the French version shall prevail over the English translation.

The undersigned hereby confirms that the Company can send all confirmations and information required for participation in the ordinary and extraordinary general shareholders’ meetings to the following e-mail address of the undersigned:

………………………………………………………………….<br><br> <br><br><br> <br>(E-mail address of security holder)

Done at ……………………………………., on ………………………………2023

Signature……………………………

Ordinary and Extraordinary General Shareholders’ Meetings of MDxHealthSA - Attendance form for security holders

Exhibit 99.3

AssemblÉes gÉnÉrales ordinaire et extraordinaire des Actionnaires<br><br> <br>25 mai 2023	ordinary and extraordinary general shareholders’ meetings 25 May 2023
Procuration	Proxy
Cette procuration doit être utilisée<br> par les titulaires de titres de MDxHealth SA (la “Société”) qui désirent être représentés<br> par un mandataire spécial aux assemblées générales ordinaire et extraordinaire des actionnaires de la Société<br> à tenir le jeudi 25 mai 2023 à 15h00 (heure belge).<br><br> <br><br><br> <br><br><br> <br>Cette procuration ne constitue pas une demande<br> de procuration au sens des articles 7:144 et 7:145 du Code des sociétés et des associations.<br><br> <br><br><br> <br><br><br> <br>La procuration doit être signée de<br> façon écrite ou électroniquement. Si une signature électronique est utilisée, elle doit être<br> une signature électronique qualifiée au sens du Règlement (UE) n° 910/2014 du Parlement européen et du<br> Conseil du 23 juillet 2014 sur l’identification électronique et les services de confiance pour les transactions électroniques<br> au sein du marché intérieur et abrogeant la directive 1999/93/CE, tel que modifié.<br><br> <br><br><br> <br><br><br> <br>La procuration signée et complétée<br> doit parvenir à la Société au plus tard le sixième jour calendrier qui précède les assemblées<br> générales ordinaire et extraordinaire des actionnaires, soit le, ou avant le, vendredi 19 mai 2023 au plus<br> tard. Jusqu’à cette date, les procurations peuvent être envoyées à l’adresse suivante :<br><br> <br><br><br> <br>MDxHealth SA<br><br> A l’attention de M. Ron Kalfus<br><br> Secrétaire de la Société<br><br> CAP Business Center<br><br> <br>Zone Industrielle des Hauts-Sarts<br><br> <br>Rue d’Abhooz 31,<br><br> 4040 Herstal<br><br> <br>Belgique<br><br> <br><br><br> <br>ou par courrier électronique à :<br><br> <br>agsm@mdxhealth.com<br><br> <br><br><br> <br>Les titulaires de titres de la Société<br> qui désirent être représentés par procuration doivent aussi s’enregistrer aux assemblées générales<br> ordinaire et extraordinaire des actionnaires, tel que décrit dans l’invitation aux assemblées générales ordinaire<br> et extraordinaire des actionnaires. Les titulaires de titres dématérialisés doivent joindre à ce formulaire<br> un certificat délivré par le teneur de compte agréé, l’organisme de liquidation compétent, ou de l’intermédiaire<br> financier pour les titres concernés, confirmant le nombre de titres ayant été enregistrés à leur nom<br> à la date d’enregistrement (soit le jeudi 11 mai 2023, à minuit (00h00, heure belge)) et avec lesquelles ils veulent participer<br> aux assemblées générales ordinaire et extraordinaire des actionnaires.<br><br> <br><br><br> <br><br><br> <br>En cas de modification de l’ordre du jour ou si<br> des nouvelles propositions de résolutions sont déposées, la Société publiera un ordre du jour complété<br> avec, le cas échéant, les sujets à traiter additionnels de l’ordre du jour et les propositions de résolutions<br> additionnelles. Ceci sera fait au plus tard le quinzième jour calendrier avant les assemblées générales ordinaire<br> et extraordinaire des actionnaires, soit le, ou avant le, mercredi 10 mai 2023 au plus tard. En outre, la Société mettra<br> aussi à disposition un formulaire modifié de vote par procuration. Les procurations qui parviennent à la Société<br> antérieurement à la publication d’un ordre du jour complété demeurent valides pour les sujets à traiter<br> inscrits à l’ordre du jour auxquels les procurations s’appliquent, sous réserve, cependant, du droit applicable et des clarifications<br> complémentaires décrites dans les formulaires de procuration.<br><br> <br><br><br> <br>La Société recommande d’utiliser<br> le courrier électronique pour toute communication avec la Société concernant les assemblées générales<br> d’actionnaires.	This proxy should be used by holders of securities<br> of MDxHealth SA (the “Company”) who want to be represented by a proxy holder at the ordinary and extraordinary general<br> shareholders’ meetings of the Company to be held on Thursday, 25 May 2023, at 15:00 p.m. (Belgian time).<br><br> <br><br><br> <br>This proxy does not constitute a proxy solicitation<br> in the sense of articles 7:144 and 7:145 of the Belgian Companies and Associations Code.<br><br> <br><br><br> <br>The proxy must be signed in writing or electronically.<br> In the event an electronic signature is used, it must be a qualified electronic signature in the sense of Regulation (EU) No 910/2014<br> of the European Parliament and of the Council of 23 July 2014 on electronic identification and trust services for electronic transactions<br> in the internal market and repealing Directive 1999/93/EC, as amended.<br><br> <br><br><br> <br>The signed and completed proxy must reach the<br> Company at the latest on the sixth calendar day prior to the ordinary and extraordinary general shareholders’ meetings, i.e. on or before Friday, 19 May 2023 at the latest. Until this date, proxies can be sent to the following address:<br><br> <br><br><br> <br><br><br> <br><br><br> <br><br><br> <br><br><br> <br>MDxHealth SA<br><br> Attention Mr. Ron Kalfus<br><br> Company Secretary<br><br> <br>CAP Business Center<br><br> <br>Zone Industrielle des Hauts-Sarts<br><br> Rue d’Abhooz, 31<br><br> 4040 Herstal,<br><br> Belgium<br><br> <br><br><br> <br>or by e-mail to:<br><br> <br>agsm@mdxhealth.com<br><br> <br><br><br> <br>Holders of securities of the Company who wish<br> to be represented by proxy must also register for the ordinary and extraordinary general shareholders’ meetings, as described in the notice<br> convening the ordinary and extraordinary general shareholders’ meetings. Holders of dematerialised securities must attach to the present<br> form a certificate issued by the certified account holder, the applicable settlement institution, or the relevant financial intermediary<br> for the securities concerned, confirming the number of securities that have been registered in their name on the registration date, (i.e.,<br> Thursday, 11 May 2023, at midnight (12:00 a.m., Belgian time)) with which they want to participate to the ordinary and extraordinary general<br> shareholders’ meetings.<br><br> <br><br><br> <br>In case of amendments to the agenda or if new<br> draft resolutions are tabled, the Company will publish an amended agenda with, as the case may be, additional agenda items and additional<br> draft resolutions. This will be done no later than on the fifteenth calendar day prior to the ordinary and extraordinary general shareholders’<br> meetings, i.e. on or before Wednesday, 10 May 2023 at the latest. In addition, the Company will also make amended forms available for<br> votes by proxy. Proxies that reach the Company prior to the publication of an amended agenda remain valid for the agenda items to which<br> the proxies apply, subject, however, to applicable law and the further clarifications set out on the proxy form.<br><br> <br><br><br> <br><br><br> <br>The Company recommends to use e-mail for all communication<br> with the Company regarding the general shareholders’ meetings.

AssemblÉes gÉnÉrales ordinaire et extraordinaire des Actionnaires 25 mai 2023

ordinary and extraordinary general shareholders’ meetings 25 May 2023

Procuration

Proxy

Cette procuration doit être utilisée par les titulaires de titres de MDxHealth SA (la “Société”) qui désirent être représentés par un mandataire spécial aux assemblées générales ordinaire et extraordinaire des actionnaires de la Société à tenir le jeudi 25 mai 2023 à 15h00 (heure belge). Cette procuration ne constitue pas une demande de procuration au sens des articles 7:144 et 7:145 du Code des sociétés et des associations. La procuration doit être signée de façon écrite ou électroniquement. Si une signature électronique est utilisée, elle doit être une signature électronique qualifiée au sens du Règlement (UE) n° 910/2014 du Parlement européen et du Conseil du 23 juillet 2014 sur l’identification électronique et les services de confiance pour les transactions électroniques au sein du marché intérieur et abrogeant la directive 1999/93/CE, tel que modifié. La procuration signée et complétée doit parvenir à la Société au plus tard le sixième jour calendrier qui précède les assemblées générales ordinaire et extraordinaire des actionnaires, soit le, ou avant le, vendredi 19 mai 2023 au plus tard. Jusqu’à cette date, les procurations peuvent être envoyées à l’adresse suivante : MDxHealth SA A l’attention de M. Ron Kalfus Secrétaire de la Société CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz 31, 4040 Herstal Belgique ou par courrier électronique à : agsm@mdxhealth.com Les titulaires de titres de la Société qui désirent être représentés par procuration doivent aussi s’enregistrer aux assemblées générales ordinaire et extraordinaire des actionnaires, tel que décrit dans l’invitation aux assemblées générales ordinaire et extraordinaire des actionnaires. Les titulaires de titres dématérialisés doivent joindre à ce formulaire un certificat délivré par le teneur de compte agréé, l’organisme de liquidation compétent, ou de l’intermédiaire financier pour les titres concernés, confirmant le nombre de titres ayant été enregistrés à leur nom à la date d’enregistrement (soit le jeudi 11 mai 2023, à minuit (00h00, heure belge)) et avec lesquelles ils veulent participer aux assemblées générales ordinaire et extraordinaire des actionnaires. En cas de modification de l’ordre du jour ou si des nouvelles propositions de résolutions sont déposées, la Société publiera un ordre du jour complété avec, le cas échéant, les sujets à traiter additionnels de l’ordre du jour et les propositions de résolutions additionnelles. Ceci sera fait au plus tard le quinzième jour calendrier avant les assemblées générales ordinaire et extraordinaire des actionnaires, soit le, ou avant le, mercredi 10 mai 2023 au plus tard. En outre, la Société mettra aussi à disposition un formulaire modifié de vote par procuration. Les procurations qui parviennent à la Société antérieurement à la publication d’un ordre du jour complété demeurent valides pour les sujets à traiter inscrits à l’ordre du jour auxquels les procurations s’appliquent, sous réserve, cependant, du droit applicable et des clarifications complémentaires décrites dans les formulaires de procuration. La Société recommande d’utiliser le courrier électronique pour toute communication avec la Société concernant les assemblées générales d’actionnaires.

This proxy should be used by holders of securities of MDxHealth SA (the “Company”) who want to be represented by a proxy holder at the ordinary and extraordinary general shareholders’ meetings of the Company to be held on Thursday, 25 May 2023, at 15:00 p.m. (Belgian time). This proxy does not constitute a proxy solicitation in the sense of articles 7:144 and 7:145 of the Belgian Companies and Associations Code. The proxy must be signed in writing or electronically. In the event an electronic signature is used, it must be a qualified electronic signature in the sense of Regulation (EU) No 910/2014 of the European Parliament and of the Council of 23 July 2014 on electronic identification and trust services for electronic transactions in the internal market and repealing Directive 1999/93/EC, as amended. The signed and completed proxy must reach the Company at the latest on the sixth calendar day prior to the ordinary and extraordinary general shareholders’ meetings, i.e. on or before Friday, 19 May 2023 at the latest. Until this date, proxies can be sent to the following address: MDxHealth SA Attention Mr. Ron Kalfus Company Secretary CAP Business Center Zone Industrielle des Hauts-Sarts Rue d’Abhooz, 31 4040 Herstal, Belgium or by e-mail to: agsm@mdxhealth.com Holders of securities of the Company who wish to be represented by proxy must also register for the ordinary and extraordinary general shareholders’ meetings, as described in the notice convening the ordinary and extraordinary general shareholders’ meetings. Holders of dematerialised securities must attach to the present form a certificate issued by the certified account holder, the applicable settlement institution, or the relevant financial intermediary for the securities concerned, confirming the number of securities that have been registered in their name on the registration date, (i.e., Thursday, 11 May 2023, at midnight (12:00 a.m., Belgian time)) with which they want to participate to the ordinary and extraordinary general shareholders’ meetings. In case of amendments to the agenda or if new draft resolutions are tabled, the Company will publish an amended agenda with, as the case may be, additional agenda items and additional draft resolutions. This will be done no later than on the fifteenth calendar day prior to the ordinary and extraordinary general shareholders’ meetings, i.e. on or before Wednesday, 10 May 2023 at the latest. In addition, the Company will also make amended forms available for votes by proxy. Proxies that reach the Company prior to the publication of an amended agenda remain valid for the agenda items to which the proxies apply, subject, however, to applicable law and the further clarifications set out on the proxy form. The Company recommends to use e-mail for all communication with the Company regarding the general shareholders’ meetings.

| **Assemblée Générale Ordinaire et Extraordinaire des Actionnaires de MDxHealth SA - Procuration**<br><br>**Ordinary and Extraordinary General Shareholders’ Meetings of MDxHealth SA - Proxy** | 1/11 |

☐ M./Mme / Mr./Ms. …………………………………………………………………………………………^2^

☐ Président du conseil d’administration / Chair of the board of directors^3^

^1^Conformément à l’article 7:135 du Code des sociétés et des associations, les titulaires de droits de souscription ont le droit de participer à l’assemblée générale des actionnaires mais seulement avec voix consultative.<br><br> <br><br><br> <br>^2^Veuillez compléter tel qu’approprié. Une absence d’instruction sera interprétée comme une nomination du président du conseil d’administration en tant que mandataire.	^1^Pursuant to article 7:135 of the Belgian Companies and Associations Code, the holders of subscription rights have the right to attend the shareholders’ meetings, but only with an advisory vote.<br><br> <br><br><br> <br>^2^Please complete as appropriate. An absence of instruction shall be tantamount to an appointment of the chair of the board of directors as proxy holder.
^3^Le président du conseil d’administration de la Société a le pouvoir de nommer un autre administrateur, un employé ou remplaçant désigné de la Société comme suppléant en vertu d’une sous-délégation si le président est empêché d’assister aux assemblées générales des actionnaires. Veuillez noter que le président du conseil d’administration de la Société ou, le cas échéant, son suppléant, est un administrateur, un employé ou un remplaçant désigné de la Société et a donc un conflit d’intérêts potentiel tel que défini dans l’article 7:143, §4 du Code des sociétés et des associations. Le président ou son suppléant ne vote qu’en exécution de la procuration, conformément aux instructions de vote spécifiques figurant dans la procuration. Voir également la note 2 ci-dessous.	^3^The chair of the board of directors of the Company has the power to appoint another director, employee or substitute of the Company as a substitute pursuant to a sub delegation if the chair is hindered to attend the general shareholders’ meetings. Please note that the chair of the board of directors of the Company or, as the case may be, his substitute, is a director, employee or substitute of the Company and therefore has a potential conflict of interest as defined in article 7:143, §4 of the Belgian Companies and Associations Code. The chair or his substitute may only vote in execution of the proxy, in accordance with the specific voting instructions included in the proxy. See also note 2 below.
lequel accepte ainsi d’être nommé, et à qui le/la soussigné(e) donne les pouvoirs et instructions de vote spécifiques suivants:^4^	who agrees to be so appointed, and to whom the undersigned gives the following powers and specific voting instructions:^4^
^4^Veuillez indiquer l’instruction de vote dans les cases appropriées pour les points à l’ordre du jour. En l’absence d’une instruction de vote pour un point de l’ordre du jour, ou dans le cas où, pour quelque raison que ce soit, il y aurait un manque de clarté concernant les instructions de vote, le mandataire sera présumé avoir voté “en faveur” des résolutions proposées soutenues par le conseil d’administration et cela sera considéré comme une instruction de vote spécifique au sens de l’article 7:143 §4 2° du Code des sociétés et des associations.<br><br> <br>^^	^4^Please indicate the voting instructions in the appropriate boxes of the agenda items. In the absence of voting instructions for any agenda item or in the event that, for any reason whatsoever, any uncertainty would arise with regards to the voting instructions, the proxy holder will be presumed to have voted “in favour” of the proposed resolutions supported by the board of directors and that this will be deemed to be a specific voting instruction in the sense of article 7:143 §4 2° of the Belgian Companies and Associations Code.
I.De représenter<br> le/la soussigné(e) aux assemblées générales ordinaire et extraordinaire des actionnaires à tenir le<br> jeudi 25 mai 2023 à 15h00 (heure belge), dans les bureaux de Maître Stijn Raes, notaire, à Kortrijksesteenweg 1147,<br> 9051 Gand, Belgique, ou à tout autre endroit qui sera indiqué à cette occasion.	I.To<br> represent the undersigned at the ordinary and extraordinary general meetings of shareholders to be held on Thursday, 25 May 2023 at 15:00<br> p.m. (Belgian time), at the offices of the notary public Stijn Raes, at Kortrijksesteenweg 1147, 9051 Ghent, Belgium, or at such place<br> as will be indicated at that place at that time.

| **Assemblée Générale Ordinaire et Extraordinaire des Actionnaires de MDxHealth SA - Procuration**<br><br>**Ordinary and Extraordinary General Shareholders’ Meetings of MDxHealth SA - Proxy** | 2/11 |

---	---
---	---
1. Rapport<br> sur les comptes annuels statutaires et sur les comptes annuels consolidés<br><br> <br>Communication et discussion (a) du<br> rapport annuel combiné du conseil d’administration sur les comptes annuels consolidés et statutaires (non consolidés)<br> de la Société pour l’exercice social clôturé au 31 décembre 2022, (b) du rapport du commissaire sur<br> les comptes annuels statutaires (non consolidés) de la Société pour l’exercice social clôturé au 31<br> décembre 2022, et (c) du rapport du commissaire sur les comptes annuels consolidés de la Société pour l’exercice<br> social clôturé au 31 décembre 2022.	1. Report<br> on the annual statutory financial statements and on the consolidated financial statements<br><br> <br>Submission of, and discussion on, (a)<br> the combined annual report of the board of directors on the consolidated and (non-consolidated) statutory financial statements of the<br> Company for the financial year ended on 31 December 2022, (b) the report of the statutory auditor on the (non-consolidated) statutory<br> financial statements of the Company for the financial year ended on 31 December 2022, and (c) the report of the statutory auditor on the<br> consolidated financial statements of the Company for the financial year ended on 31 December 2022.
2. Approbation<br> des comptes annuels statutaires (non consolidés)<br><br> <br>Communication, discussion et approbation<br> des comptes annuels statutaires (non consolidés) pour l’exercice social clôturé au 31 décembre 2022 et approbation<br> de l’affectation du résultat tel que proposé par le conseil d’administration.	2. Approval<br> of the annual (non-consolidated) statutory financial statements<br><br> <br>Submission of, discussion on, and approval<br> of the annual (non-consolidated) statutory financial statements for the financial year ended on 31 December 2022, and approval of the<br> allocation of the result as proposed by the board of directors.
► Proposition de résolution:<br><br> <br>L’assemblée générale<br> des actionnaires décide d’approuver les comptes annuels statutaires (non consolidés) de la Société pour l’exercice<br> social clôturé le 31 décembre 2022 et d’approuver l’affectation du résultat annuel tel que proposé<br> par le conseil d’administration.	► Proposed resolution:<br><br> <br>The general shareholders’ meeting resolves<br> to approve the annual (non-consolidated) statutory financial statements of the Company for the financial year ended on 31 December 2022<br> and to approve the allocation of the annual result as proposed by the board of directors.
► Instruction de vote:		► Voting instruction:
---	---	---	---
0 Pour / For	0 Contre / Against		0 Abstention
3. Comptes<br> annuels consolidés<br><br> <br>Communication et discussion des comptes<br> annuels consolidés de la Société pour l’exercice social clôturé le 31 décembre 2022.	3. Consolidated<br> financial statements<br><br> <br>Submission of, and discussion on, the<br> consolidated financial statements of the Company for the financial year ended on 31 December 2022.
---	---
4. Décharge<br> de responsabilité des administrateurs<br><br> <br>Décharge de responsabilité<br> des administrateurs pour l’exercice de leur mandat au cours de l’exercice social clôturé le 31 décembre 2022.	4. Discharge<br> from liability of the directors<br><br> <br>Discharge from liability of the directors<br> for the exercise of their mandates during the financial year ended on 31 December 2022.
► Proposition de résolution:	► Proposed resolution:
L’assemblée générale des actionnaires décide d’accorder la décharge à chacun des administrateurs qui était en fonction au cours de l’exercice social clôturé le 31 décembre 2022 pour l’exercice de son mandat au cours de cet exercice social.	The general shareholders’ meeting resolves to grant discharge from liability to each of the directors who was in office during the financial year ended on 31 December 2022, for the performance of its, his or her mandate during that financial year.
► Instruction de vote:		► Voting instruction:
---	---	---	---
0 Pour / For	0 Contre / Against		0 Abstention
5. Décharge<br> de responsabilité du commissaire<br><br> <br>Décharge de responsabilité<br> du commissaire pour l’exercice de son mandat au cours de l’exercice social clôturé le 31 décembre 2022.	5. Discharge<br> from liability of the statutory auditor<br><br> <br>Discharge from liability of the statutory<br> auditor for the exercise of its mandate during the financial year ended on 31 December 2022.
---	---
► Proposition de résolution:	► Proposed resolution:
L’assemblée générale des actionnaires décide d’accorder la décharge au commissaire qui était en fonction au cours de l’exercice social clôturé le 31 décembre 2022 pour l’exercice de son mandat au cours de cet exercice social.	The general shareholders’ meeting resolves to grant discharge from liability to the statutory auditor which was in office during the financial year ended on 31 December 2022, for the performance of its mandate during that financial year.
► Instruction de vote:		► Voting instruction:
---	---	---	---
0 Pour / For	0 Contre / Against		0 Abstention
6. Rapport<br> de rémunération<br><br> <br>Communication, discussion, et approbation<br> du rapport de rémunération préparé par le comité de nomination et de rémunération et<br> approuvé par le conseil d’administration, et inclus dans le rapport annuel combiné du conseil d’administration sur les comptes<br> annuels consolidés et statutaires (non consolidés) pour l’exercice social clôturé le 31 décembre 2022.	6. Remuneration<br> report<br><br> <br>Submission of, discussion on, and approval<br> of the remuneration report prepared by the nomination and remuneration committee and approved by the board of directors, and included<br> in the combined annual report of the board of directors on the consolidated and (non-consolidated) statutory financial statements of the<br> Company for the financial year ended on 31 December 2022.
---	---
► Proposition de résolution:	► Proposed resolution:
L’assemblée générale des actionnaires décide d’approuver le rapport de rémunération inclus dans le rapport annuel du conseil d’administration sur les comptes annuels statutaires (non consolidés) pour l’exercice social clôturé le 31 décembre 2022.	The general shareholders’ meeting resolves to approve the remuneration report included in the combined annual report of the board of directors on the consolidated and (non-consolidated) statutory financial statements of the Company for the financial year ended on 31 December 2022.

| **Assemblée Générale Ordinaire et Extraordinaire des Actionnaires de MDxHealth SA - Procuration**<br><br>**Ordinary and Extraordinary General Shareholders’ Meetings of MDxHealth SA - Proxy** | 3/11 |

| --- | --- | | ► Instruction de vote: | | ► votING INSTRUCTION: | | | --- | --- | --- | --- | | 0 Pour / For | 0 Contre / Against | | 0 Abstention | | 7. Renouvellement de mandats d’administrateurs En tenant compte de la recommandation du comité de nomination et de rémunération, le conseil d’administration recommande que (a) Hilde Windels BV, représentée par Hilde Windels en tant que représentante permanente, (b) Regine Slagmulder BV, représentée par Regine Slagmulder en tant que représentante permanente, et (c) Eric Bednarski, soient renouvelés en tant qu’administrateurs de la Société, chacun pour une durée de deux ans, et que (d) Michael K. McGarrity soit renouvelé en tant qu’administrateur de la Société pour une durée de trois ans. Pour de plus amples informations concernant ces administrateurs proposés, il est fait référence à la déclaration de gouvernement d’entreprise incluse dans le rapport annuel combiné du conseil d’administration pour l’exercice clôturé le 31 décembre 2022. Sur la base des informations fournies par Hilde Windels BV, représentée par Hilde Windels en tant que représentante permanente, et Regine Slagmulder BV, représentée par Regine Slagmulder, il apparaît que Hilde Windels BV et Hilde Windels, ainsi que Regine Slagmulder BV et Regine Slagmulder, respectivement, satisfont aux exigences applicables pour être nommés en tant qu’administrateurs indépendants conformément à l’article 7:87 du Code des sociétés et des associations et à la disposition 3.5 du Code belge de gouvernance d’entreprise 2020. | 7. Re-appointment of directors Taking into account the recommendation of the nomination and remuneration committee, the board of directors recommends that (a) Hilde Windels BV, represented by Hilde Windels as permanent representative, (b) Regine Slagmulder BV, represented by Regine Slagmulder as permanent representative, and (c) Eric Bednarski, be re-appointed as directors of the Company, each for a term of two years, and (d) Michael K. McGarrity be re-appointed as director of the Company for a term of three years. For further information regarding these proposed directors, reference is made to the corporate governance statement included in the combined annual report of the board of directors on the consolidated and (non-consolidated) statutory financial statements of the Company for the financial year ended on 31 December 2022. Based on information made available by respectively Hilde Windels BV, represented by Hilde Windels as permanent representative, and Regine Slagmulder BV, represented by Regine Slagmulder as permanent representative, it appears that respectively each of Hilde Windels BV and Hilde Windels, and each of Regine Slagmulder BV and Regine Slagmulder, satisfy the applicable requirements in order to be nominated as independent directors in accordance with article 7:87 of the Belgian Companies and Associations Code and provision 3.5 of the 2020 Belgian Corporate Governance Code. | | --- | --- | | ► Propositions de résolutions: | ► Proposed resolutions: | | (a) L’assemblée générale des actionnaires décide de renouveler le mandat de Hilde Windels BV, représentée par Hilde Windels en tant que représentant permanente, en tant qu’administrateur indépendant de la Société au sens de l’article 7:87 du Code des sociétés et des associations et de la disposition 3.5 du Code belge de gouvernance d’entreprise 2020, pour une durée de deux ans, s’étendant jusqu’à, et y compris, la clôture de l’assemblée générale ordinaire des actionnaires à tenir en 2025 qui statuera sur les comptes annuels de l’exercice social clôturé le 31 décembre 2024. La rémunération de l’administrateur est telle que déterminée dans la politique de rémunération de la Société, telle qu’approuvée de temps à autre par l’assemblée générale des actionnaires, et (sous réserve des dispositions de la politique de rémunération) telle que décidée par l’assemblée générale extraordinaire des actionnaires tenue le 30 juillet 2020 et l’assemblée générale ordinaire des actionnaires tenue le 27 mai 2021. | (a) The general shareholders’ meeting resolves to re-appoint Hilde Windels BV, represented by Hilde Windels as permanent representative, as independent director of the Company within the meaning of article 7:87 of the Belgian Companies and Associations Code and provision 3.5 of the 2020 Belgian Corporate Governance Code, for a term of two years, up to and including the closing of the ordinary general shareholders’ meeting to be held in 2025 which will have decided upon the financial statements for the financial year ended on 31 December 2024. The remuneration of the director is as set out in the Company’s remuneration policy, as approved from time to time by the general shareholders’ meeting, and (subject to the provisions of the remuneration policy) as decided by the special general shareholders’ meeting held on 30 July 2020 and the ordinary general shareholders’ meeting held on 27 May 2021. | | ► Instruction de vote: | | ► votING INSTRUCTION: | | | --- | --- | --- | --- | | 0 Pour / For | 0 Contre / Against | | 0 Abstention | | (b) L’assemblée générale des actionnaires décide de renouveler le mandat de Regine Slagmulder BV, représentée par Regine Slagmulder en tant que représentant permanente, en tant qu’administrateur indépendant de la Société au sens de l’article 7:87 du Code des sociétés et des associations et de la disposition 3.5 du Code belge de gouvernance d’entreprise 2020, pour une durée de deux ans, s’étendant jusqu’à, et y compris, la clôture de l’assemblée générale ordinaire des actionnaires à tenir en 2025 qui statuera sur les comptes annuels de l’exercice social clôturé le 31 décembre 2024. La rémunération de l’administrateur est telle que déterminée dans la politique de rémunération de la Société, telle qu’approuvée de temps à autre par l’assemblée générale des actionnaires, et (sous réserve des dispositions de la politique de rémunération) telle que décidée par l’assemblée générale extraordinaire des actionnaires tenue le 30 juillet 2020 et l’assemblée générale ordinaire des actionnaires tenue le 27 mai 2021. | (b) The general shareholders’ meeting resolves to re-appoint Regine Slagmulder BV, represented by Regine Slagmulder as permanent representative, as independent director of the Company within the meaning of article 7:87 of the Belgian Companies and Associations Code and provision 3.5 of the 2020 Belgian Corporate Governance Code, for a term of two years, up to and including the closing of the ordinary general shareholders’ meeting to be held in 2025 which will have decided upon the financial statements for the financial year ended on 31 December 2024. The remuneration of the director is as set out in the Company’s remuneration policy, as approved from time to time by the general shareholders’ meeting, and (subject to the provisions of the remuneration policy) as decided by the special general shareholders’ meeting held on 30 July 2020 and the ordinary general shareholders’ meeting held on 27 May 2021. | | --- | --- | | ► Instruction de vote: | | ► votING INSTRUCTION: | | | --- | --- | --- | --- | | 0 Pour / For | 0 Contre / Against | | 0 Abstention | | (c) L’assemblée générale des actionnaires décide de renouveler le mandat d’Eric Bednarski en tant qu’administrateur de la Société pour une durée de deux ans, s’étendant jusqu’à, et y compris, la clôture de l’assemblée générale ordinaire des actionnaires à tenir en 2025 qui statuera sur les comptes annuels de l’exercice social clôturé le 31 décembre 2024. La rémunération de l’administrateur est telle que déterminée dans la politique de rémunération de la Société, telle qu’approuvée de temps à autre par l’assemblée générale des actionnaires, et (sous réserve des dispositions de la politique de rémunération) telle que décidée par l’assemblée générale extraordinaire des actionnaires tenue le 30 juillet 2020 et l’assemblée générale ordinaire des actionnaires tenue le 27 mai 2021. | (c) The general shareholders’ meeting resolves to re-appoint Eric Bednarski as director of the Company, for a term of two years, up to and including the closing of the ordinary general shareholders’ meeting to be held in 2025 which will have decided upon the financial statements for the financial year ended on 31 December 2024. The remuneration of the director is as set out in the Company’s remuneration policy, as approved from time to time by the general shareholders’ meeting, and (subject to the provisions of the remuneration policy) as decided by the special general shareholders’ meeting held on 30 July 2020 and the ordinary general shareholders’ meeting held on 27 May 2021. | | --- | --- |

| **Assemblée Générale Ordinaire et Extraordinaire des Actionnaires de MDxHealth SA - Procuration**<br><br>**Ordinary and Extraordinary General Shareholders’ Meetings of MDxHealth SA - Proxy** | 4/11 |

| --- | --- | | ► Instruction de vote: | | ► votING INSTRUCTION: | | | --- | --- | --- | --- | | 0 Pour / For | 0 Contre / Against | | 0 Abstention | | (d) L’assemblée générale des actionnaires décide de renouveler le mandat de Michael K. McGarrity en tant qu’administrateur de la Société pour une durée de deux ans, s’étendant jusqu’à, et y compris, la clôture de l’assemblée générale ordinaire des actionnaires à tenir en 2026 qui statuera sur les comptes annuels de l’exercice social clôturé le 31 décembre 2025. La rémunération de l’administrateur est telle que déterminée dans la politique de rémunération de la Société, telle qu’approuvée de temps à autre par l’assemblée générale des actionnaires, et (sous réserve des dispositions de la politique de rémunération) telle que décidée par l’assemblée générale extraordinaire des actionnaires tenue le 30 juillet 2020 et l’assemblée générale ordinaire des actionnaires tenue le 27 mai 2021. | (d) The general shareholders’ meeting resolves to re-appoint Michael K. McGarrity as director of the Company, for a term of three years, up to and including the closing of the ordinary general shareholders’ meeting to be held in 2026 which will have decided upon the financial statements for the financial year ended on 31 December 2025. The remuneration of the director is as set out in the Company’s remuneration policy, as approved from time to time by the general shareholders’ meeting, and (subject to the provisions of the remuneration policy) as decided by the special general shareholders’ meeting held on 30 July 2020 and the ordinary general shareholders’ meeting held on 27 May 2021. | | --- | --- | | ► Instruction de vote: | | ► votING INSTRUCTION: | | | --- | --- | --- | --- | | 0 Pour / For | 0 Contre / Against | | 0 Abstention | | Note: Si la résolution proposée au point 7 est approuvée par l’assemblée générale des actionnaires, le conseil d’administration de la Société sera composé de (1) Michael K. McGarrity, Chief Executive Officer (CEO), administrateur exécutif et administrateur délégué (jusqu’en 2026), (2) Ahok BV, représentée par Koen Hoffman, administrateur indépendant et président du conseil d’administration (jusqu’en 2025), (3) Donnie M. Hardison Jr., administrateur indépendant (jusqu’en 2025), (4) Hilde Windels BV, représentée par Hilde Windels, administrateur indépendant (jusqu’en 2025), (5) Qaly-Co BV, représentée par Lieve Verplancke, administrateur indépendant (jusqu’en 2024), (6) Valiance Advisors LLP, représentée par Jan Pensaert, administrateur non-exécutif (jusqu’en 2024), (7) Regine Slagmulder BV, représentée par Regine Slagmulder, administrateur indépendant (jusqu’en 2025), et (8) Eric Bednarski, administrateur non-exécutif (jusqu’en 2025). 8. Renouvellement du mandat du commissaire En tenant compte de la recommandation et de la préférence du Comité d’Audit, le conseil d’administration recommande que le mandat de BDO Réviseurs d’Entreprises SRL, représentée par Bert Kegels en tant que représentant permanent, en tant que commissaire de la Société soit renouvelé pour la durée légale de trois ans jusqu’à et y compris la clôture de l’assemblée générale ordinaire des actionnaires qui se tiendra en 2026 et qui aura statué sur les comptes annuels de l’exercice social clôturé le 31 décembre 2025, sous réserve des, et conformément aux, dispositions de l’article 3:61 du Code des sociétés et des associations et du règlement (UE) n° 537/2014 du Parlement européen et du Conseil du 16 avril 2014 relatif aux exigences spécifiques concernant le contrôle légal des comptes des entités d’intérêt public et abrogeant la décision 2005/909/CE de la Commission. ► Proposition de résolution*:* En tenant compte de la recommandation du conseil d’administration sur recommandation et préférence du comité d’audit, l’assemblée générale des actionnaires décide de renouveler le mandat de BDO Réviseurs d’Entreprises SRL, représentée par Bert Kegels en tant que représentant permanent, en tant que commissaire de la Société pour une durée de trois ans jusqu’à et y compris la clôture de l’assemblée générale annuelle des actionnaires qui se tiendra en 2026 et qui aura statué sur les comptes annuels de l’exercice social clôturé le 31 décembre 2025, sous réserve des, et conformément aux, dispositions de l’article 3:61 du Code des sociétés et des associations et du règlement (UE) n° 537/2014 du Parlement européen et du Conseil du 16 avril 2014 relatif aux exigences spécifiques concernant le contrôle légal des comptes des entités d’intérêt public et abrogeant la décision 2005/909/CE de la Commission. Pour la durée de son mandat, la rémunération annuelle du commissaire de la Société sera de EUR 260.000,00 (hors TVA, taxes et frais, selon le cas) pour le contrôle des comptes consolidés du groupe et le contrôle des comptes annuels statutaires (non consolidés) de la Société. Ces honoraires sont soumis à une indexation annuelle basée sur l’indice standard. | Note: If the proposed resolutions set out in point 7 are approved by the general shareholders’ meeting, the Company’s board of directors will be composed of (1) Michael K. McGarrity, chief executive officer (CEO), executive director and managing director (until 2026), (2) Ahok BV, represented by Koen Hoffman, independent director and chair of the board of directors (until 2024), (3) Donnie M. Hardison JR, independent director (until 2025), (4) Hilde Windels BV, represented by Hilde Windels, independent director (until 2025), (5) Qaly-Co BV, represented by Lieve Verplancke, independent director (until 2024), (6) Valiance Advisors LLP, represented by Jan Pensaert, non-executive director (until 2024), (7) Regine Slagmulder BV, represented by Regine Slagmulder, independent director (until 2025), and (9) Eric Bednarski, non-executive director (until 2025). 8. Re-appointment of the statutory auditor Taking into account the recommendation and preference of the audit committee, the board of directors recommends that BDO Réviseurs d’Entreprises SRL, represented by Bert Kegels as permanent representative, be re-appointed as statutory auditor of the Company for a term of three years up to and including the closing of the ordinary general shareholders’ meeting to be held in 2026 which will have decided upon the financial statements for the financial year ended on 31 December 2025, subject to, and in accordance with, the provisions of article 3:61 of the Belgian Companies and Associations Code and Regulation (EU) No. 537/2014 of the European Parliament and of the Council of 16 April 2014 on specific requirements regarding statutory audit of public-interest entities and repealing Commission Decision 2005/909/EC. ► Proposed resolution: Taking into account the recommendation of the board of directors upon recommendation and preference of the audit committee, the general shareholders’ meeting resolves to re-appoint BDO Réviseurs d’Entreprises SRL, represented by Bert Kegels as permanent representative, as statutory auditor of the Company for a term of three years up to and including the closing of the ordinary general shareholders’ meeting to be held in 2026 which will have decided upon the financial statements for the financial year ended on 31 December 2025, subject to, and in accordance with, the provisions of article 3:61 of the Belgian Companies and Associations Code and Regulation (EU) No. 537/2014 of the European Parliament and of the Council of 16 April 2014 on specific requirements regarding statutory audit of public-interest entities and repealing Commission Decision 2005/909/EC. For the duration of its mandate, the annual remuneration of the statutory auditor of the Company shall be EUR 260,000.00 (excluding VAT, taxes and expenses, as applicable) for the audit of the consolidated accounts of the group and the audit of the (non-consolidated) statutory financial statements of the Company. These fees are subject to a yearly indexation based on the standard index. | | --- | --- |

| **Assemblée Générale Ordinaire et Extraordinaire des Actionnaires de MDxHealth SA - Procuration**<br><br>**Ordinary and Extraordinary General Shareholders’ Meetings of MDxHealth SA - Proxy** | 5/11 |

| --- | --- | | ► Instruction de vote: | | ► votING INSTRUCTION: | | | --- | --- | --- | --- | | 0 Pour / For | 0 Contre / Against | | 0 Abstention | | 9. Approbation conformément à l’article 7:151 du Code des sociétés et des associations en ce qui concerne le loan and security agreement conclu par et entre la Société et Innovatus Life Sciences Lending Fund I, LP Le 2 août 2022, la Société a conclu un loan and security agreement avec Innovatus Life Sciences Lending Fund I, LP, en vertu duquel Innovatus Life Sciences Lending Fund I, LP a accepté de fournir une facilité de prêt d’un montant maximal de USD 70.000.000,00, qui peut être utilisée en plusieurs tranches. Les Sections 2.2(c), 7.2, 7.3 et 8.2 du loan and security agreement permettent à Innovatus Life Sciences Lending Fund I, LP de résilier le loan and security agreement et d’exiger le paiement/remboursement immédiat de tous les montants impayés dans le cadre du loan and security agreement en cas de changement de contrôle de la Société ou de toute filiale de la Société. ► Proposition de résolution: L’assemblée générale des actionnaires décide d’approuver et de ratifier, conformément à l’article 7:151 du Code belge des sociétés et des associations, toutes les clauses du loan and security agreement conclu par la Société et Innovatus Life Sciences Lending Fund I, LP (y compris, mais sans s’y limiter, les Sections 2.2(c), 7.2, 7.3 et 8.2) qui sont applicables au moment où un changement de contrôle se produit et qui tombent ou pourraient être considérés comme tombant dans le champ d’application de l’article 7:151 du Code belge des sociétés et des associations (relatif à l’octroi de droits à des tiers qui affectent substantiellement l’actif et le passif de la Société, ou qui donnent lieu à une dette ou un engagement substantiel pour son compte, lorsque l’exercice de ces droits est subordonné au lancement d’une offre publique d’achat sur les actions de la Société ou à un changement dans le contrôle exercé sur elle). L’assemblée générale des actionnaires donne également une procuration spéciale à chaque administrateur de la société, au Chief Financial Officer et à l’Executive Vice President of Corporate Development and General Counsel (chacun un “Mandataire”), chaque Mandataire agissant individuellement et avec droit de substitution, pour accomplir les formalités requises par l’article 7:151 du Code belge des sociétés et des associations en ce qui concerne la présente résolution, y compris, mais sans s’y limiter, la signature de tous les documents et formulaires requis pour la publication de la présente résolution dans les annexes du Moniteur Belge. | 9*.* Approval in accordance with article 7:151 of the Belgian Companies and Associations Code with respect to the loan and security agreement entered into by the Company and Innovatus Life Sciences Lending Fund I, LP On 2 August 2022, the Company entered into a loan and security agreement with Innovatus Life Sciences Lending Fund I, LP, pursuant to which Innovatus Life Sciences Lending Fund I, LP agreed to provide a loan facility for up to USD 70,000,000.00, which can be drawn in multiple tranches. Sections 2.2(c), 7.2, 7.3 and 8.2 of the loan and security agreement allow Innovatus Life Sciences Lending Fund I, LP to terminate the loan and security agreement and demand immediate (re)payment of all amounts outstanding under the loan and security agreement in case of a change of control over the Company or any subsidiaries of the Company. ► Proposed resolution: The general shareholders’ meeting resolves to approve and ratify, in accordance with article 7:151 of the Belgian Companies and Associations Code, all clauses in the loan and security agreement entered into by the Company and Innovatus Life Sciences Lending Fund I, LP (including, but not limited to, Sections 2.2(c), 7.2, 7.3 and 8.2) that are applicable at the time a change of control occurs and which fall or could be considered to fall within the scope of article 7:151 of the Belgian Companies and Associations Code (relating to the granting of rights to third parties that substantially affect the Company’s assets and liabilities, or give rise to a substantial debt or commitment on its behalf, when the exercise of these rights is subject to the launching of a public takeover bid on the shares of the Company or to a change in the control exercised over it). The general shareholders’ meeting also grants a special power of attorney to each Director of the Company, the Chief Financial Officer and the Executive Vice President of Corporate Development and General Counsel (each a “ProxyHolder”), each Proxy Holder acting individually and with the right of substitution, to complete the formalities required by article 7:151 of the Belgian Companies and Associations Code with regard to this resolution, including, but not limited to, the execution of all documents and forms required for the publication of this resolution in the annexes to the Belgian Official Gazette. | | --- | --- | | ► Instruction de vote: | | ► Voting instruction: | | | --- | --- | --- | --- | | 0 Pour / For | 0 Contre / Against | | 0 Abstention | | ORDRE DU JOUR assemblée générale extraordinaire | agenda extraordinary general meeting | | --- | --- | | 1. Communication des rapports - Plan d’Option sur Action de 2023 Communication des, discussion sur: a) le rapport du conseil d’administration de la Société conformément aux articles 7:180 et 7:191 du Code des sociétés et associations relatif à la proposition d’émettre 5.000.000 nouveaux droits de souscription de la Société (les “2023 Share Options”), en vertu d’un plan d’option sur action dénommé “le Plan d’Option sur Action de 2023”, et de supprimer, dans l’intérêt de la Société, le droit de préférence des actionnaires existants de la Société et, pour autant que de besoin, des détenteurs de droits de souscription en circulation (share options) ou American Depositary Shares (“ADSs”) de la Société, en faveur des membres du personnel de la Société et de ses filiales de temps à autre, au sens de l’article 1:27 du Code des sociétés et des associations (les “Participants Sélectionnés”); et b) le rapport du commissaire de la Société conformément aux articles 7:180 et 7:191 du Code des sociétés et des associations concernant la proposition d’émettre 5.000.000 2023 Share Options et de supprimer, dans l’intérêt de la Société, le droit de préférence des actionnaires existants de la Société et, pour autant que de besoin, des détenteurs de droits de souscription en circulation (share options) ou ADSs de la Société, en faveur des Participant Sélectionnés. | 1. Submission of reports - 2023 Share Option Plan Submission of, discussion on: a) the report of the board of directors of the Company in accordance with articles 7:180 and 7:191 of the Belgian Companies and Associations Code in relation to the proposal to issue 5,000,000 new subscription rights for shares of the Company (the “2023 Share Options”), pursuant to a share option plan named “the 2023 Share Option Plan”, and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) or American Depositary Shares (“ADSs”) of the Company, for the benefit of the members of the personnel of the Company and its subsidiaries from time to time, within the meaning of article 1:27 of the Belgian Companies and Associations Code (the “Selected Participant”); and b) the report of the statutory auditor of the Company in accordance with articles 7:180 and 7:191 of the Belgian Companies and Associations Code in relation to the proposal to issue 5,000,000 2023 Share Options, and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) or ADSs of the Company, to the benefit of the Selected Participants. | | --- | --- |

| **Assemblée Générale Ordinaire et Extraordinaire des Actionnaires de MDxHealth SA - Procuration**<br><br>**Ordinary and Extraordinary General Shareholders’ Meetings of MDxHealth SA - Proxy** | 6/11 |

| --- | --- | | 2. Proposition d’émettre 5.000.000 2023 Share Options | 2. Proposal to issue 5,000,000 2023 Share Options | | --- | --- | | ► Proposition de résolution: | ► Proposed resolution: | | L’assemblée générale des actionnaires décide d’approuver l’émission de 5.000.000 2023 Share Options, en vertu d’un plan d’option sur action dénommé “le Plan d’Option sur Action de 2023”, et de supprimer, dans l’intérêt de la Société, le droit de préférence des actionnaires existants de la Société et, pour autant que de besoin, des détenteurs de droits de souscription en circulation (share options) ou ADSs de la Société, en faveur des Participants Sélectionnés. En conséquence, le conseil d’administration décide de ce qui suit: (a) Termes et conditions des 2023 Share Options: Les termes et conditions des 2023 Share Options (inclus, mais sans s’y limiter, le prix d’exercice des 2023 Share Options) seront tels que figurant dans l’annexe au rapport du conseil d’administration visé au point 1.(a) de l’ordre du jour (aux fins de la présente résolution, le “Plan”), dont une copie restera jointe au présent procès-verbal. Les 2023 Share Options ont une durée de 10 ans à partir de leur date d’émission. (b) Actions sous-jacentes: Chaque 2023 Share Option donne à son détenteur le droit de souscrire à une nouvelle action qui sera émise par la Société. Les nouvelles actions à émettre lors de l’exercice des 2023 Share Options auront les mêmes droits et avantages, et seront à tous égards pari passu, en ce compris en ce qui concerne les droits aux dividendes et autres distributions, avec les actions existantes et en circulation de la Société au moment de leur émission, et auront droit aux dividendes et autres distributions pour lesquelles la date d’enregistrement ou la date d’échéance tombe à, ou après la date d’émission des actions. (c) Suppression du droit de préférence en faveur des Participants Sélectionnés: L’assemblée générale des actionnaires décide, conformément à l’article 7:191 du Code des sociétés et des associations, de supprimer, dans l’intérêt de la Société, le droit de préférence des actionnaires existants de la Société et, pour autant que de besoin, des détenteurs de droits de souscription en circulation (share options) de la Société, en faveur des Participants Sélectionnés, et d’approuver la possibilité pour la Société d’octroyer les 2023 Share Options aux Participants Sélectionnés, comme expliqué plus en détail dans le rapport du conseil d’administration visé au point 1.(a) de l’ordre du jour et dans les termes et conditions du Plan. (d) Confirmation de la souscription de 2023 Share Options par la Société: L’assemblée générale des actionnaires décide d’approuver et de confirmer que la Société sera en mesure de souscrire aux 2023 Share Options, en vue de créer un pool de 2023 Share Options disponible pour des octrois ultérieurs aux Participants Sélectionnés. La Société ne peut cependant pas exercer les 2023 Share Options pour son compte propre. (e) Augmentation de capital conditionnelle et émission de nouvelles actions: L’assemblée générale des actionnaires décide, sous réserve et dans la mesure de l’exercice des 2023 Share Options, d’augmenter le capital de la Société et d’émettre le nombre approprié de nouvelles actions pouvant être émises lors de l’exercice des 2023 Share Options. Sous réserve et conformément aux dispositions du Plan, lors de l’exercice des 2023 Share Options et de l’émission de nouvelles actions, le montant total du prix d’exercice des 2023 Share Options sera affecté au capital de la Société. Dans la mesure où le montant du prix d’exercice des 2023 Share Options, par action à émettre lors de l’exercice des 2023 Share Options, excède le pair comptable des actions de la Société existantes alors immédiatement avant l’émission des nouvelles actions concernées, une partie du prix d’exercice, par action à émettre lors de l’exercice des 2023 Share Options, égale à ce pair comptable sera comptabilisée en capital, le solde étant comptabilisé en prime d’émission. Suite à l’augmentation de capital et à l’émission de nouvelles actions, chaque action nouvelle et existante représentera la même fraction du capital de la Société. | The general shareholders’ meeting resolves to approve the issuance of 5,000,000 2023 Share Options, pursuant to a share option plan named “the 2023 Share Option Plan”, and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) or ADSs of the Company, for the benefit of Selected Participant. In view thereof, the general shareholders’ meeting resolves as follows: (a) Terms and conditions of the 2023 Share Options: The terms and conditions of the 2023 Share Options (including, but not limited to, the exercise price of the 2023 Share Options) shall be as set out in the annex to the report of the board of directors referred to in item 1.(a) of the agenda (for the purpose of this resolution, the “Plan”), a copy of which shall remain attached to the minutes reflecting the present resolution. The 2023 Share Options have a term of ten years as from their issue date. (b) Underlying shares: Each 2023 Share Option shall entitle the holder thereof to subscribe for one new share to be issued by the Company. The new shares to be issued at the occasion of the exercise of the 2023 Share Options shall have the same rights and benefits as, and rank pari passu in all respects, including as to entitlements to dividends and other distributions, with the existing and outstanding shares of the Company at the moment of their issuance, and will be entitled to dividends and other distributions in respect of which the relevant record date or due date falls on or after the date of issue of the shares. (c) Dis-application of the preferential subscription right for the benefit of the Selected Participants: The general shareholders’ meeting resolves, in accordance with article 7:191 of the Belgian Companies and Associations Code, to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) or ADSs of the Company, for the benefit of the Selected Participants, and to approve the possibility for the Company to grant the 2023 Share Options to the Selected Participants, as further explained in the report of the board of directors referred to in item 1.(a) of the agenda and the terms and conditions of the Plan. (d) Confirmation of the subscription of 2023 Share Options by the Company: The general shareholders’ meeting resolves to approve and confirm that the Company will be able to subscribe for the 2023 Share Options, with a view to creating a pool of outstanding 2023 Share Options available for further grants to Selected Participants. The Company may not, however, exercise the 2023 Share Options for its own account. (e) Conditional capital increase and issue of new shares: The general shareholders’ meeting resolves, subject to, and to the extent of the exercise of 2023 Share Options, to increase the Company’s share capital and to issue the relevant number of new shares issuable upon the exercise of the 2023 Share Options. Subject to, and in accordance with, the provisions of the Plan, upon exercise of the 2023 Share Options and issue of new shares, the aggregate amount of the exercise price of the 2023 Share Options will be allocated to the share capital of the Company. To the extent that the amount of the exercise price of the 2023 Share Options, per share to be issued upon exercise of the 2023 Share Options, exceeds the fractional value of the then existing shares of the Company existing immediately prior to the issue of the new shares concerned, a part of the exercise price, per share to be issued upon exercise of the 2023 Share Options, equal to such fractional value shall be booked as share capital, whereby the balance shall be booked as issue premium. Following the capital increase and issuance of new shares, each new and existing share shall represent the same fraction of the share capital of the Company. | | --- | --- |

| **Assemblée Générale Ordinaire et Extraordinaire des Actionnaires de MDxHealth SA - Procuration**<br><br>**Ordinary and Extraordinary General Shareholders’ Meetings of MDxHealth SA - Proxy** | 7/11 |

| --- | --- | | (f) Prime d’émission: Toute prime d’émission qui sera comptabilisée en relation avec les 2023 Share Options sera comptabilisée sur un compte indisponible au passif du bilan de la Société dans ses capitaux propres, et le compte sur lequel la prime d’émission sera comptabilisée constituera, au même titre que le capital de la Société, la garantie des tiers et, sauf possibilité de capitalisation de ces réserves, ne pourra être réduit ou supprimé que par une décision de l’assemblée générale des actionnaires statuant dans les conditions requises pour la modification des statuts de la Société. (g) Procurations: Le conseil d’administration est autorisé à mettre en œuvre et à exécuter les décisions prises par l’assemblée générale des actionnaires en rapport avec les 2023 Share Options, et à prendre toutes les mesures et à accomplir toutes les formalités requises en vertu du Plan, des statuts de la Société et de la loi applicable afin d’émettre ou transférer les actions lors de l’exercice des 2023 Share Options. En outre, chaque administrateur de la Société, Joe Sollee et Ron Kalfus, chacun agissant individuellement et avec possibilité de subdélégation et pouvoir de subrogation, auront le pouvoir, lors de l’exercice des 2023 Share Options, (i) de procéder à la constatation (A) de l’augmentation de capital et de l’émission de nouvelles actions résultant de cet exercice, (B) de l’allocation du capital et (le cas échéant) de la prime d’émission, et (C) de la modification des statuts de la Société afin de refléter le nouveau capital et nombre d’actions en circulation suite à l’exercice des 2023 Share Options, (ii) de signer et remettre, au nom de la Société, la documentation Euroclear, Euronext et bancaire pertinente, le registre des actions et tous les documents nécessaires en relation avec l’émission et la livraison des actions au Participant Sélectionné, et (iii) faire tout ce qui peut être nécessaire ou utile (y compris, mais sans s’y limiter, la préparation et l’exécution de tous les documents et formulaires) pour l’admission des actions émises lors de l’exercice des 2023 Share Options à la négociation sur le marché réglementé d’Euronext Brussels (ou tout autre marché sur lequel les actions de la Société seront négociées à ce moment). (h) Renonciation: L’assemblée générale des actionnaires reconnaît que les 2023 Share Options qui seront octroyés dans le cadre du “Plan d’Option sur Action de 2023” ne seront pas considérées comme une “rémunération variable”, une “rémunération fixe” ou une “rémunération annuelle” au sens du Code des sociétés et associations (y compris, sans limitation, aux fins des articles 3:6, §3, 7:89/1, 7:90, 7:91, 7:92, 7:100, 7:108 et 7:121 du Code des sociétés et associations) et du Code belge de gouvernance d’entreprise 2020 (y compris, sans limitation, aux fins de la disposition 11 du Code belge de gouvernance d’entreprise 2020). L’assemblée générale des actionnaires approuve les conditions et mécanismes d’acquisition définitive des 2023 Share Options, telles qu’elles sont inclues dans le Plan. Les dispositions des articles 7:91, 7:108 et 7:121 (selon le cas) du Code des sociétés et associations sont expressément écartées en ce qui concerne le Plan des 2023 Share Options. (i) Approbation conformément à l’article 7:151 du Code des sociétés et des associations: L’assemblée générale des actionnaires décide de prendre note, d’approuver et de ratifier, pour autant que de besoin conformément à l’article 7:151 du Code des sociétés et des associations, toutes les clauses incluses dans le Plan, qui entrent en vigueur au moment où un changement de contrôle se produit et qui tombent ou pourraient être considérées comme tombant sous le coup de l’article 7:151 du Code des sociétés et associations (relatif à l’octroi de droits à des tiers affectant substantiellement le patrimoine de la Société ou donnant naissance à une dette ou à un engagement substantiel à sa charge, lorsque l’exercice de ces droits dépend du lancement d’une offre publique d’acquisition sur les actions de la Société ou d’un changement du contrôle exercé sur), y compris, sans limitation, le mécanisme d’acquisition accélérée automatique lors d’une acquisition tel que défini dans le Plan. L’assemblée générale des actionnaires accorde une procuration spéciale à chaque administrateur de la Société, agissant seul et avec pouvoir de substitution, aux fins d’accomplir les formalités requises par l’article 7:151 du Code des sociétés et des associations en ce qui concerne la présente résolution. | (f) Issue premium: Any issue premium that will be booked in connection with the 2023 Share Options shall be accounted for on a non-distributable account on the liabilities side of the Company’s balance sheet under its net equity, and the account on which the issue premium will be booked shall, like the share capital, serve as a guarantee for third parties and can only be reduced on the basis of a lawful resolution of the general shareholders’ meeting passed in the manner required for an amendments to the Company’s articles of association. (g) Powers of attorney: The board of directors is authorised to implement and execute the resolutions passed by the general shareholders’ meeting in connection with the 2023 Share Options, and to take all steps and carry out all formalities that shall be required by virtue of the Plan, the Company’s articles of association and applicable law in order to issue or transfer the shares upon exercise of the 2023 Share Options. Furthermore, each of the Company’s directors, Joe Sollee and Ron Kalfus, each such person acting individually and with possibility of sub-delegation and the power of subrogation, shall have the power, upon exercise of the 2023 Share Options, (i) to proceed with the recording of (A) the capital increase and issue of new shares resulting from such exercise, (B) the allocation of the share capital and (as applicable) the issue premium, and (C) the amendment of the Company’s articles of association in order to reflect the new share capital and number of outstanding shares following the exercise of the 2023 Share Options, (ii) to sign and deliver, on behalf of the Company, the relevant Euroclear, Euronext and bank documentation, the share register and all necessary documents in connection with the issuance and delivery of the shares to the beneficiary, and (iii) to do whatever may be necessary or useful (including but not limited to the preparation and execution of all documents and forms) for the admission of the shares issued upon the exercise of the 2023 Share Options to trading on the regulated market of Euronext Brussels (or such other markets on which the Company’s shares will be trading at that time). (h) Waiver: The general shareholders’ meeting acknowledges that the 2023 Share Options to be granted under the “2023 Share Option Plan” shall not be considered “variable remuneration”, “fixed remuneration” or “annual remuneration” within the meaning of the Belgian Companies and Associations Code (including, without limitation, for the purpose of articles 3:6, §3, 7:89/1, 7:90, 7:91, 7:92, 7:100, 7:108 and 7:121 of the Belgian Companies and Associations Code) and the 2020 Corporate Governance Code (including, without limitation, for the purpose of provision 11 of the 2020 Corporate Governance Code). The general shareholders’ meeting approves the vesting conditions and mechanisms of the 2023 Share Options, as included in the Plan. The provisions of articles 7:91, 7:108 and 7:121 (as applicable) of the Belgian Companies and Associations Code are expressly dis-applied in relation to the 2023 Share Option Plan. (i) Approval in accordance with article 7:151 of the Belgian Companies and Associations Code: The general shareholders’ meeting resolves to take note, approve and ratify, insofar as required in accordance with article 7:151 of the Belgian Companies and Associations Code, all clauses included in the Plan, which come into effect at the moment a change of control occurs and which fall or could be considered to fall within the scope of article 7:151 of the Belgian Companies and Associations Code (relating to the granting of rights to third parties that substantially affect the Company’s assets and liabilities, or give rise to a substantial debt or commitment on its behalf, when the exercise of these rights is subject to the launching of a public takeover bid on the shares of the Company or to a change in the control exercised over it), including, without limitation, the automatic accelerated vesting mechanism upon acquisition as defined in the Plan. The general shareholders’ meeting grants a special power of attorney to each director of the Company, acting alone and with power of substitution, for the purpose of carrying out the formalities required by article 7:151 of the Belgian Companies and Associations Code with respect to this resolution. | | --- | --- |

| **Assemblée Générale Ordinaire et Extraordinaire des Actionnaires de MDxHealth SA - Procuration**<br><br>**Ordinary and Extraordinary General Shareholders’ Meetings of MDxHealth SA - Proxy** | 8/11 |

| --- | --- | | ► Instruction de vote: | | ► Voting instruction: | | | --- | --- | --- | --- | | 0 Pour / For | 0 Contre / Against | | 0 Abstention | | 3. Communication du rapport spécial du conseil d’administration conformément à l’article 7:199 du Code des sociétés et des associations relatif à la proposition de renouveler le capital autorisé Considération, discussion et communication du rapport spécial du conseil d’administration conformément à l’article 7:199 du Code des sociétés et des associations relatif à la proposition de renouveler les pouvoirs conférés au conseil d’administration dans le cadre du capital autorisé, tel que repris ci-dessous au point 4 de l’ordre du jour de l’assemblée générale extraordinaire des actionnaires, et exposant les circonstances spécifiques dans lesquelles le conseil d’administration pourra utiliser ses pouvoirs dans le cadre du capital autorisé, et les objectifs qu’il devra poursuivre. 4. Renouvellement de l’autorisation au conseil d’administration d’augmenter le capital dans le cadre du capital autorisé Afin de permettre au conseil d’administration de disposer de la flexibilité nécessaire pour lever des fonds propres supplémentaires lorsque le besoin s’en fait sentir ou qu’une opportunité se présente, le conseil d’administration propose de lui accorder des pouvoirs limités dans le cadre du capital autorisé pour augmenter le capital de la Société d’un montant maximum égal à 100% du montant du capital de la Société pendant une période de cinq (5) ans, le tout comme indiqué ci-dessous. Pour de plus amples informations sur les circonstances dans lesquelles le conseil d’administration pourrait faire usage du capital autorisé et sur les objectifs que le conseil d’administration poursuivrait avec le capital autorisé, voyez également le rapport spécial mentionné au point 3 de l’ordre du jour de l’assemblée générale extraordinaire des actionnaires. | 3. Submission of the special report of the board of directors in accordance with article 7:199 of the Belgian Companies and Associations Code relating to the proposal to renew the authorised capital Consideration, discussion and submission of the special report of the board of directors in accordance with article 7:199 of the Belgian Companies and Associations Code relating to the proposal to renew the powers granted to the board of directors under the authorised capital, as set out below in item 4 of the agenda of the extraordinary general shareholders’ meeting, and setting out the specific circumstances in which the board of directors will be able to use its powers under the authorised capital, and the purposes that it should pursue. 4. Renewal of the authorisation to the board of directors to increase the share capital within the framework of the authorised capital In order to allow the board of directors the flexibility to raise additional equity-based financing as and when the need may arise or an opportunity would present itself, the board of directors proposes that it be granted limited powers under the authorised capital to increase the Company’s share capital by a maximum amount of 100% during a term of five (5) years, all as further set out below. For further information on the circumstances in which the board of directors could make use of the authorised capital and the objectives that the board of directors would pursue with the authorised capital, see also the special report referred to in item 3 of the agenda of the extraordinary general shareholders’ meeting. | | --- | --- | | ► Proposition de résolution: | ► Proposed resolution: | | L’assemblée générale des actionnaires décide de renouveler l’autorisation donnée au conseil d’administration d’augmenter le capital en une ou plusieurs fois, pendant une période de cinq (5) ans à compter de la publication aux Annexes du Moniteur belge de la présente autorisation, d’un montant total jusqu’à 100% du montant du capital de la Société, et ce conformément aux conditions et modalités fixées dans le rapport spécial du conseil d’administration établi conformément à l’article 7:199 du Code des sociétés et des associations, tel que visé au point 3 de l’ordre du jour de la présente assemblée générale extraordinaire des actionnaires. En conséquence, l’assemblée générale des actionnaires décide de supprimer l’article 6 “Capital autorisé” des statuts de la Société et de le remplacer par le texte suivant (la date mentionnée dans la sous-section entre crochets étant la date de l’assemblée générale approuvant le capital autorisé renouvelé, et le montant mentionné dans la sous-section entre crochets étant le montant du capital de la Société au moment de l’assemblée générale approuvant le capital autorisé): | The general shareholders’ meeting resolves to renew the authorisation to the board of directors to increase the share capital in one or several times, during a period of five (5) years as from the publication in the Annexes to the Belgian Official Gazette of this authorisation, with an aggregate amount equal to up to 100% of the amount of the share capital of the Company, and this in accordance with the terms and conditions set forth in the special report of the board of directors prepared in accordance with article 7:199 of the Belgian Companies and Associations Code, as referred to in agenda item 3 of this extraordinary general shareholders’ meeting. Consequently, the general shareholders’ meeting resolves to delete article 6 “Authorised capital” of the articles of association of the Company entirely and to replace it with the following text (whereby the date referred to in the sub-section between square brackets shall be the date of the general shareholders’ meeting approving the renewed authorised capital, and the amount referred to in the sub-section between brackets shall be the amount of the Company’s share capital at the time of the general shareholders’ meeting approving the authorised capital): | | --- | --- | | “Article 6 : Capital Autorisé Le conseil d’administration est autorisé à augmenter le capital de la société en une ou plusieurs fois d’un montant total maximum de [100 % du capital de la société au moment de l’adoption du nouveau capital autorisé]. | “Article 6: Authorised capital The board of directors is authorised to increase the share capital of the company on one or several occasions by a maximum aggregate amount of [100% of the company’s share capital at the time of the adoption of the new authorised capital]. | | --- | --- |

| **Assemblée Générale Ordinaire et Extraordinaire des Actionnaires de MDxHealth SA - Procuration**<br><br>**Ordinary and Extraordinary General Shareholders’ Meetings of MDxHealth SA - Proxy** | 9/11 |

---	---
---	---
► Instruction de vote:		► Voting instruction:
---	---	---	---
0 Pour / For	0 Contre / Against		0 Abstention
II.Si les assemblées générales ordinaire et/ou extraordinaire des actionnaires sont ajournées ou suspendues, le mandataire spécial aura les pouvoirs de représenter le soussigné aux assemblées générales des actionnaires qui seront tenues avec le même ordre du jour, le cas échéant (étant entendu que, par rapport aux points susmentionnés de l’ordre du jour de l’assemblée générale extraordinaire des actionnaires, les votes susmentionnés s’appliqueront en tout état de cause également à la deuxième assemblée générale extraordinaire des actionnaires qui serait convoquée avec un ordre du jour identique à celui de la première assemblée générale extraordinaire des actionnaires dans le cas où le quorum de présence légalement requis pour délibérer et voter valablement sur ces points de l’ordre du jour n’aurait pas été atteint lors de la première assemblée générale extraordinaire des actionnaires):	II.In case the aforementioned ordinary and/or extraordinary general shareholders’ meetings would be postponed or suspended, the special proxy holder shall have the power to represent the undersigned at the general shareholders’ meetings that would be held having the same agenda, as relevant (it being understood that, in relation to the aforementioned agenda items on the agenda of the extraordinary general shareholders’ meeting, the aforementioned votes will in any event also apply to the second extraordinary general shareholders’ meeting which would be convened with an agenda identical to the agenda of the first extraordinary general shareholders’ meeting in case the legally required attendance quorum to validly deliberate and resolve on such agenda items would not be reached during the first extraordinary general shareholders’ meeting):
---	---
o oui	o yes
o non	o no
Veuillez remplir la case appropriée. Une absence d’instruction ou si, pour quelque raison, il y a une absence de clarté à propos de l’instruction donnée, le soussigné sera supposé avoir choisi “oui”. Veuillez noter qu’aux fins de s’appliquer à telle assemblée subséquente, les titulaires de titres doivent s’enregistrer à nouveau pour cette assemblée.	Please tick the appropriate box. In the absence of an instruction, or if, for whatever reason, there is a lack of clarity with regard to the instruction given, the undersigned shall be deemed to have selected “yes”. Please note that in order to apply for such subsequent meeting, holders of securities must again register for such meeting.
Si, pendant les assemblées, il y a des modifications à une proposition de résolution ou une nouvelle proposition de résolution:^1^	In case of amendments during the meetings to a proposed resolution or a new proposed resolution:^1^
o le mandataire spécial votera pour la résolution modifiée ou nouvelle	o the proxy holder shall vote for the amended or new resolution
o le mandataire spécial votera contre la résolution modifiée ou nouvelle	o the proxy holder shall vote against the amended or new resolution
o le mandataire spécial s’abstiendra de voter sur la résolution modifiée ou nouvelle	o the proxy holder shall abstain from the vote on the amended or new resolution
o le mandataire spécial votera sur la résolution modifiée ou nouvelle selon la manière supportée ou recommandée par le conseil d’administration de la Société	o the proxy holder shall vote on the amended or new resolution in the manner supported or recommended by the board of directors of the Company
^1^Veuillez cocher tel qu’approprié. Une absence d’instruction sera interprétée comme une instruction de voter pour la résolution modifiée ou nouvelle selon la manière supportée ou recommandée par le conseil d’administration de la Société.	^1^ Please complete as appropriate. An absence of instruction shall be tantamount to an instruction to vote for the amended or new resolution as will be supported or recommended by the board of directors of the Company.

| **Assemblée Générale Ordinaire et Extraordinaire des Actionnaires de MDxHealth SA - Procuration**<br><br>**Ordinary and Extraordinary General Shareholders’ Meetings of MDxHealth SA - Proxy** | 10/11 |

| --- | --- | | **III.**Si un ordre du jour supplémentaire est publié conformément à l’article 7:130 du Code des sociétés et des associations après que cette procuration ait été notifiée à la Société, le mandataire spécial aura le pouvoir de voter sur des nouveaux sujets qui ont été ajoutés à l’ordre du jour, le cas échéant: | **III.**If a supplemented agenda is published in accordance with article 7:130 of the Belgian Companies and Associations Code after this proxy has been notified to the Company, the special proxy holder shall have the power to vote on the new items that have been added to the agenda, as relevant: | | --- | --- | | o oui | o yes | | o non | o no | | Veuillez remplir la case appropriée. Une absence d’instruction ou si, pour quelque raison, il y a une absence de clarté à propos de l’instruction donnée, le soussigné sera supposé avoir choisi “oui”. Si la réponse ” oui ” est sélectionnée ou réputée l’être, le mandataire spécial votera de la manière soutenue par le conseil d’administration de la Société. | Please tick the appropriate box. In the absence of an instruction, or if, for whatever reason, there is a lack of clarity with regard to the instruction given, the undersigned shall be deemed to have selected “yes”. If ‘yes” is selected or deemed to be selected, the special proxy holder will vote in the manner supported by the board of directors of the Company. | | Conformément au Code des sociétés et des associations, le mandataire spécial peut, à propos des sujets auxquels il est fait référence à l’ordre du jour pour lesquels en vertu de l’article 7:130 du Code des sociétés et des associations de nouvelles propositions de résolutions ont été soumises, s’écarter à l’assemblée des instructions, le cas échéant, données par le soussigné, si l’exécution de ces instructions risquerait de compromettre les intérêts du soussigné. Le mandataire spécial doit en informer le soussigné. | In accordance with the Belgian Companies and Associations Code, the special proxy holder may, with respect to the items referred to in the agenda for which pursuant to article 7:130 of the Belgian Companies and Associations Code new proposed resolutions have been tabled, deviate at the meeting from the instructions, if any, given by the undersigned, if the execution of those instructions could prejudice the interests of the undersigned. The special proxy holder must notify the undersigned thereof. | | **IV.**Le mandataire spécial est autorisé, au nom et pour le compte du soussigné, à signer toutes listes de présence et procès-verbaux, à participer à toutes les délibérations, à prendre part au vote sur toutes les décisions ou sujets pouvant, conformément à cet ordre du jour, être soumis à l’assemblée. | **IV.**The special proxy holder has the power to, in the name of and on behalf of the undersigned, sign all attendance lists and minutes, participate in all deliberations, vote with respect to all decisions or items that can, pursuant to this agenda, be presented to said meetings. | | **V.**Le mandataire spécial est autorisé, en général, à faire tout ce qui semble nécessaire et/ou utile pour exercer cette procuration. | **V.**In general, the special proxy holder has the power to do all that appears necessary and/or useful for the exercise of this proxy. | | Le/la soussigné(e) ratifie et approuve par la présente tous les actes accomplis par le mandataire spécial susmentionné. Le mandataire spécial votera pour le compte du/de la soussigné(s) conformément aux instructions spécifiques données ci-dessus. La présente procuration vaut également notification au sens de l’article 7:134, §2, alinéa 3 du Code des sociétés et des associations en ce qui concerne les assemblées générales ordinaire et extraordinaire des actionnaires de la Société à tenir le jeudi 25 mai 2023. Le soussigné confirme que la traduction anglaise de la présente procuration n’est qu’une traduction libre en anglais et à titre informatif uniquement, et que la version française prévaut sur la version anglaise. BON POUR PROCURATION | The undersigned hereby ratifies and approves all acts carried out by the aforementioned proxy holder. The special proxy holder will vote on behalf of the undersigned in accordance with the specific instructions given above. The present proxy shall also serve as notification within the meaning of article 7:134, §2, paragraph 3 of the Belgian Companies and Associations Code with respect to the ordinary and extraordinary general shareholders’ meetings of the Company to be held on Thursday 25 May 2023. The undersigned confirms that the English translation of the present proxy is a free English translation and for information purposes only, and that the French version shall prevail over the English version. GOOD FOR PROXY | | ……………………………… 2023 (date) | | --- | | …………………………………………………….. (nom / name) | | …………………………………………………….. (signature) |

| **Assemblée Générale Ordinaire et Extraordinaire des Actionnaires de MDxHealth SA - Procuration**<br><br>**Ordinary and Extraordinary General Shareholders’ Meetings of MDxHealth SA - Proxy** | 11/11 |

| --- | --- |

Exhibit 99.4

AssemblÉes gÉnÉrales ordinaire et extraordinaire des Actionnaires<br><br> <br>25 mai 2023	ordinary and extraordinary general shareholders’ meetings<br><br> <br>25 May 2023
formulaire de vote par correspondance	Voting by mail form
Ce formulaire doit être utilisé par les titulaires de titres de MDxHealth SA (la “Société”) qui désirent voter par correspondance aux assemblées générales ordinaire et extraordinaire des actionnaires de la Société à tenir le jeudi 25 mai 2023 à 15h00 (heure belge).	This form should be used by holders of securities of MDxHealth SA (the “Company”) who want to vote by mail at the ordinary and extraordinary general shareholders’ meetings of the Company to be held on Thursday, 25 May 2023, at 15:00 p.m. (Belgian time).
Le formulaire de vote par correspondance doit être signé par écrit ou électroniquement. Si une signature électronique est utilisée, elle doit être une signature électronique qualifiée au sens du Règlement (UE) n° 910/2014 du Parlement européen et du Conseil du 23 juillet 2014 sur l’identification électronique et les services de confiance pour les transactions électroniques au sein du marché intérieur et abrogeant la directive 1999/93/CE, tel que modifié.	The voting by mail form must be signed in writing or electronically. In the event an electronic signature is used, it must be a qualified electronic signature in the sense of Regulation (EU) No 910/2014 of the European Parliament and of the Council of 23 July 2014 on electronic identification and trust services for electronic transactions in the internal market and repealing Directive 1999/93/EC, as amended.
Le formulaire de vote par correspondance signé et complété doit parvenir à la Société au plus tard le sixième jour calendrier qui précède les assemblées générales ordinaire et extraordinaire des actionnaires, soit le, ou avant le, vendredi 19 mai 2023 au plus tard. Jusqu’à cette date, les formulaires peuvent être envoyées à l’adresse suivante :	The signed and completed voting by mail form must reach the Company at the latest on the sixth calendar day prior to the ordinary and extraordinary general shareholders’ meetings, i.e. on or before Friday, 19 May 2023 at the latest. Until this date, forms can be sent to the following address:
MDxHealth SA	MDxHealth SA
A l’attention de M. Ron Kalfus	Attention Mr. Ron Kalfus
Secrétaire de la Société	Company Secretary
CAP Business Center	CAP Business Center
Zone Industrielle des Hauts-Sarts	Zone Industrielle des Hauts-Sarts
Rue d’Abhooz 31,	Rue d’Abhooz, 31
4040 Herstal	4040 Herstal,
Belgique	Belgium
ou par courrier électronique à :	or by e-mail to:
agsm@mdxhealth.com	agsm@mdxhealth.com
Les titulaires de titres de la Société qui désirent être représentés par voter par correspondance doivent aussi s’enregistrer aux assemblées générales ordinaire et extraordinaire des actionnaires, tel que décrit dans l’invitation aux assemblées générales ordinaire et extraordinaire des actionnaires. Les titulaires de titres dématérialisés doivent joindre à ce formulaire de vote par correspondance un certificat délivré par le teneur de compte agréé, l’organisme de liquidation compétent, ou de l’intermédiaire financier pour les titres concernés, confirmant le nombre de titres ayant été enregistrés à leur nom à la date d’enregistrement (soit le jeudi 11 mai 2023, à minuit (00h00, heure belge)) et avec lesquelles ils veulent participer aux assemblées générales ordinaire et extraordinaire des actionnaires.	Holders of securities of the Company who wish to vote by mail must also register for the ordinary and extraordinary general shareholders’ meetings, as described in the notice convening the ordinary and extraordinary general shareholders’ meetings. Holders of dematerialised securities must attach to the present voting by mail form a certificate issued by the certified account holder, the applicable settlement institution, or the relevant financial intermediary for the securities concerned, confirming the number of securities that have been registered in their name on the registration date (i.e., Thursday, 11 May 2023, at midnight (12:00 a.m., Belgian time)), with which they want to participate to the ordinary and extraordinary general shareholders’ meetings.
En cas de modification de l’ordre du jour ou si des nouvelles propositions de résolutions sont déposées, la Société publiera un ordre du jour complété avec, le cas échéant, les sujets à traiter additionnels de l’ordre du jour et les propositions de résolutions additionnelles. Ceci sera fait au plus tard le quinzième jour calendrier avant les assemblées générales ordinaire et extraordinaire des actionnaires, soit le, ou avant le, mercredi 10 mai 2023 au plus tard. En outre, la Société mettra aussi à disposition un formulaire modifié de vote par correspondance. Les formulaires qui parviennent à la Société antérieurement à la publication d’un ordre du jour complété demeurent valides pour les sujets à traiter inscrits à l’ordre du jour auxquels les formulaires de vote par correspondence s’appliquent, sous réserve, cependant, du droit applicable et des clarifications complémentaires décrites dans les formulaires de vote par correspondance. Conformément au Code des sociétés et des associations, un vote par correspondance pour un point de l’ordre du jour pour lequel une nouvelle proposition de résolution a été soumise par un ou plusieurs actionnaires détenant au moins 3 % du capital social, n’est pas valable.	In case of amendments to the agenda or if new draft resolutions are tabled, the Company will publish an amended agenda with, as the case may be, additional agenda items and additional draft resolutions. This will be done no later than on the fifteenth calendar day prior to the ordinary and extraordinary general shareholders’ meetings, i.e. on or before Wednesday, 10 May 2023 at the latest. In addition, the Company will also make amended forms available for voting by mail. Voting by mail forms that reach the Company prior to the publication of an amended agenda remain valid for the agenda items to which the voting by mail forms apply, subject, however, to applicable law and the further clarifications set out in the voting by mail form. In accordance with the Belgian Companies and Associations Code, a vote via vote by mail for an agenda item in relation to which a new proposed resolution has been submitted by one or more shareholders holding at least 3% of the share capital, is invalid.
La Société recommande d’utiliser le courrier électronique pour toute communication avec la Société concernant les assemblées générales d’actionnaires.	The Company recommends to use e-mail for all communication with the Company regarding the general shareholders’ meetings.

| **Assemblée Générale Ordinaire et Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance**<br><br>**Ordinary and Extraordinary General Shareholders’ Meetings of MDxHealth SA - Voting by mail form** | 1/13 |

| --- | --- | | Le/La soussigné(e), | The undersigned, | | --- | --- | | Prénom / First name: | | --- | | Nom de famille / Family name: | | Adresse / Address: | | ou / or | | Dénomination / Corporate name: | | Forme juridique / Corporate form: | | Siège / Registered office: | | Représenté par (prénom, nom de famille et qualité) / Represented by (first name, family name and capacity): | | titulaire du (des) nombre(s) suivant(s) de titres émis par MDxHealth SA, ayant son siège au CAP Business Center, Zone Industrielle des Hauts-Sarts, Rue d’Abhooz 31, 4040 Herstal, Belgique, | owner of the following number of securities issued by MDxHealth SA, with its registered office at CAP Business Center, Zone Industrielle des Hauts-Sarts, rue d’Abhooz 31, 4040 Herstal, Belgium, | | --- | --- | | Nombre d’actions / Number of shares: | ……………….. | | --- | --- | | Forme des actions susmentionnées / Form of the above mentioned shares: | | | (veuillez cocher la case appropriée / please tick the appropriate box) | | | ☐ Nominatives / Registered | | | ☐ Dématérialisées / Dematerialised | | | Nombre de droits de souscription / Number of subscription rights: ^1^ | ……………….. | | ^1^ Conformément à l’article 7:135 du Code des sociétés et des associations, les titulaires de droits de souscription ont le droit de participer à l’assemblée générale des actionnaires mais seulement avec voix consultative. | ^1^Pursuant to article 7:135 of the Belgian Companies and Associations Code, the holders of subscription rights have the right to attend the shareholders’ meetings, but only with an advisory vote. | | --- | --- | | vote irrévocablement, comme indiqué dans les cases correspondantes ci-dessous, sur les points inscrits à l’ordre du jour suivant : ^2^ | votes irrevocably, as indicated in the corresponding boxes below, on the items on the following agenda: ^2^ | | ^2^ Veuillez indiquer l’instruction de vote dans les cases appropriées pour les points à l’ordre du jour. En l’absence d’une instruction de vote pour un point de l’ordre du jour, ou dans le cas où, pour quelque raison que ce soit, il y aurait un manque de clarté concernant les instructions de vote, le/la soussigné(e) sera présumé(e) avoir voté “en faveur” des résolutions proposées soutenues par le conseil d’administration. | ^2^Please indicate the voting instructions in the appropriate boxes of the agenda items. In the absence of voting instructions for any agenda item or in the event that, for any reason whatsoever, any uncertainty would arise with regards to the voting instructions, the undersigned will be presumed to have voted in favour of the proposed resolutions supported by the board of directors. | | ORDRE DU JOUR assemblée générale ordinaire | | agenda Ordinary general meeting | | | --- | --- | --- | --- | | 1. | Rapport sur les comptes annuels statutaires et sur les comptes annuels consolidés Communication et discussion (a) du rapport annuel combiné du conseil d’administration sur les comptes annuels consolidés et statutaires (non consolidés) de la Société pour l’exercice social clôturé au 31 décembre 2022, (b) du rapport du commissaire sur les comptes annuels statutaires (non consolidés) de la Société pour l’exercice social clôturé au 31 décembre 2022, et (c) du rapport du commissaire sur les comptes annuels consolidés de la Société pour l’exercice social clôturé au 31 décembre 2022. | 1. | Report on the annual statutory financial statements and on the consolidated financial statements Submission of, and discussion on, (a) the combined annual report of the board of directors on the consolidated and (non-consolidated) statutory financial statements of the Company for the financial year ended on 31 December 2022, (b) the report of the statutory auditor on the (non-consolidated) statutory financial statements of the Company for the financial year ended on 31 December 2022, and (c) the report of the statutory auditor on the consolidated financial statements of the Company for the financial year ended on 31 December 2022. | | 2. | Approbation des comptes annuels statutaires (non consolidés) Communication, discussion et approbation des comptes annuels statutaires (non consolidés) pour l’exercice social clôturé au 31 décembre 2022 et approbation de l’affectation du résultat tel que proposé par le conseil d’administration. | 2. | Approval of the annual (non-consolidated) statutory financial statements Submission of, discussion on, and approval of the annual (non-consolidated) statutory financial statements for the financial year ended on 31 December 2022, and approval of the allocation of the result as proposed by the board of directors. | | ► | Proposition de résolution: L’assemblée générale des actionnaires décide d’approuver les comptes annuels statutaires (non consolidés) de la Société pour l’exercice social clôturé le 31 décembre 2022 et d’approuver l’affectation du résultat annuel tel que proposé par le conseil d’administration. | ► | Proposed resolution: The general shareholders’ meeting resolves to approve the annual (non-consolidated) statutory financial statements of the Company for the financial year ended on 31 December 2022 and to approve the allocation of the annual result as proposed by the board of directors. |

| **Assemblée Générale Ordinaire et Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance**<br><br>**Ordinary and Extraordinary General Shareholders’ Meetings of MDxHealth SA - Voting by mail form** | 2/13 |

| --- | --- | | ► Instruction de vote: | | ► Voting instruction: | | | --- | --- | --- | --- | | 0 Pour / For | 0 Contre / Against | | 0 Abstention | | 3. Comptes annuels consolidés Communication et discussion des comptes annuels consolidés de la Société pour l’exercice social clôturé le 31 décembre 2022. | 3. Consolidated financial statements Submission of, and discussion on, the consolidated financial statements of the Company for the financial year ended on 31 December 2022. | | --- | --- | | 4. Décharge de responsabilité des administrateurs Décharge de responsabilité des administrateurs pour l’exercice de leur mandat au cours de l’exercice social clôturé le 31 décembre 2022. | 4. Discharge from liability of the directors Discharge from liability of the directors for the exercise of their mandates during the financial year ended on 31 December 2022. | | ► Proposition de résolution: | ► Proposed resolution: | | L’assemblée générale des actionnaires décide d’accorder la décharge à chacun des administrateurs qui était en fonction au cours de l’exercice social clôturé le 31 décembre 2022 pour l’exercice de son mandat au cours de cet exercice social. | The general shareholders’ meeting resolves to grant discharge from liability to each of the directors who was in office during the financial year ended on 31 December 2022, for the performance of its, his or her mandate during that financial year. | | ► Instruction de vote: | | ► Voting instruction: | | | --- | --- | --- | --- | | 0 Pour / For | 0 Contre / Against | | 0 Abstention | | 5. Décharge de responsabilité du commissaire Décharge de responsabilité du commissaire pour l’exercice de son mandat au cours de l’exercice social clôturé le 31 décembre 2022. | 5. Discharge from liability of the statutory auditor Discharge from liability of the statutory auditor for the exercise of its mandate during the financial year ended on 31 December 2022. | | --- | --- | | ► Proposition de résolution: | ► Proposedresolution: | | L’assemblée générale des actionnaires décide d’accorder la décharge au commissaire qui était en fonction au cours de l’exercice social clôturé le 31 décembre 2022 pour l’exercice de son mandat au cours de cet exercice social. | The general shareholders’ meeting resolves to grant discharge from liability to the statutory auditor which was in office during the financial year ended on 31 December 2022, for the performance of its mandate during that financial year. | | ► Instruction de vote: | | ► Voting instruction: | | | --- | --- | --- | --- | | 0 Pour / For | 0 Contre / Against | | 0 Abstention | | 6. Rapport de rémunération Communication, discussion, et approbation du rapport de rémunération préparé par le comité de nomination et de rémunération et approuvé par le conseil d’administration, et inclus dans le rapport annuel combiné du conseil d’administration sur les comptes annuels consolidés et statutaires (non consolidés) pour l’exercice social clôturé le 31 décembre 2022. | 6. Remuneration report Submission of, discussion on, and approval of the remuneration report prepared by the nomination and remuneration committee and approved by the board of directors, and included in the combined annual report of the board of directors on the consolidated and (non-consolidated) statutory financial statements of the Company for the financial year ended on 31 December 2022. | | --- | --- | | ► Proposition de résolution: | ► Proposed resolution: | | L’assemblée générale des actionnaires décide d’approuver le rapport de rémunération inclus dans le rapport annuel du conseil d’administration sur les comptes annuels statutaires (non consolidés) pour l’exercice social clôturé le 31 décembre 2022. | The general shareholders’ meeting resolves to approve the remuneration report included in the combined annual report of the board of directors on the consolidated and (non-consolidated) statutory financial statements of the Company for the financial year ended on 31 December 2022. |

| **Assemblée Générale Ordinaire et Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance**<br><br>**Ordinary and Extraordinary General Shareholders’ Meetings of MDxHealth SA - Voting by mail form** | 3/13 |

| --- | --- | | ► Instruction de vote: | | ► votING INSTRUCTION: | | | --- | --- | --- | --- | | 0 Pour / For | 0 Contre / Against | | 0 Abstention | | 7. Renouvellement de mandats d’administrateurs En tenant compte de la recommandation du comité de nomination et de rémunération, le conseil d’administration recommande que (a) Hilde Windels BV, représentée par Hilde Windels en tant que représentante permanente, (b) Regine Slagmulder BV, représentée par Regine Slagmulder en tant que représentante permanente, et (c) Eric Bednarski, soient renouvelés en tant qu’administrateurs de la Société, chacun pour une durée de deux ans, et que (d) Michael K. McGarrity soit renouvelé en tant qu’administrateur de la Société pour une durée de trois ans. Pour de plus amples informations concernant ces administrateurs proposés, il est fait référence à la déclaration de gouvernement d’entreprise incluse dans le rapport annuel combiné du conseil d’administration pour l’exercice clôturé le 31 décembre 2022. Sur la base des informations fournies par Hilde Windels BV, représentée par Hilde Windels en tant que représentante permanente, et Regine Slagmulder BV, représentée par Regine Slagmulder, il apparaît que Hilde Windels BV et Hilde Windels, ainsi que Regine Slagmulder BV et Regine Slagmulder, respectivement, satisfont aux exigences applicables pour être nommés en tant qu’administrateurs indépendants conformément à l’article 7:87 du Code des sociétés et des associations et à la disposition 3.5 du Code belge de gouvernance d’entreprise 2020. | 7. Re-appointment of directors Taking into account the recommendation of the nomination and remuneration committee, the board of directors recommends that (a) Hilde Windels BV, represented by Hilde Windels as permanent representative, (b) Regine Slagmulder BV, represented by Regine Slagmulder as permanent representative, and (c) Eric Bednarski, be re-appointed as directors of the Company, each for a term of two years, and (d) Michael K. McGarrity be re-appointed as director of the Company for a term of three years. For further information regarding these proposed directors, reference is made to the corporate governance statement included in the combined annual report of the board of directors on the consolidated and (non-consolidated) statutory financial statements of the Company for the financial year ended on 31 December 2022. Based on information made available by respectively Hilde Windels BV, represented by Hilde Windels as permanent representative, and Regine Slagmulder BV, represented by Regine Slagmulder as permanent representative, it appears that respectively each of Hilde Windels BV and Hilde Windels, and each of Regine Slagmulder BV and Regine Slagmulder, satisfy the applicable requirements in order to be nominated as independent directors in accordance with article 7:87 of the Belgian Companies and Associations Code and provision 3.5 of the 2020 Belgian Corporate Governance Code. | | --- | --- | | ► Propositions de résolutions: (a) L’assemblée générale des actionnaires décide de renouveler le mandat de Hilde Windels BV, représentée par Hilde Windels en tant que représentant permanente, en tant qu’administrateur indépendant de la Société au sens de l’article 7:87 du Code des sociétés et des associations et de la disposition 3.5 du Code belge de gouvernance d’entreprise 2020, pour une durée de deux ans, s’étendant jusqu’à, et y compris, la clôture de l’assemblée générale ordinaire des actionnaires à tenir en 2025 qui statuera sur les comptes annuels de l’exercice social clôturé le 31 décembre 2024. La rémunération de l’administrateur est telle que déterminée dans la politique de rémunération de la Société, telle qu’approuvée de temps à autre par l’assemblée générale des actionnaires, et (sous réserve des dispositions de la politique de rémunération) telle que décidée par l’assemblée générale extraordinaire des actionnaires tenue le 30 juillet 2020 et l’assemblée générale ordinaire des actionnaires tenue le 27 mai 2021. | ► Proposed resolutions: (a) The general shareholders’ meeting resolves to re-appoint Hilde Windels BV, represented by Hilde Windels as permanent representative, as independent director of the Company within the meaning of article 7:87 of the Belgian Companies and Associations Code and provision 3.5 of the 2020 Belgian Corporate Governance Code, for a term of two years, up to and including the closing of the ordinary general shareholders’ meeting to be held in 2025 which will have decided upon the financial statements for the financial year ended on 31 December 2024. The remuneration of the director is as set out in the Company’s remuneration policy, as approved from time to time by the general shareholders’ meeting, and (subject to the provisions of the remuneration policy) as decided by the special general shareholders’ meeting held on 30 July 2020 and the ordinary general shareholders’ meeting held on 27 May 2021. | | ► Instruction de vote: | | ► votING INSTRUCTION: | | | --- | --- | --- | --- | | 0 Pour / For | 0 Contre / Against | | 0 Abstention | | (b) L’assemblée générale des actionnaires décide de renouveler le mandat de Regine Slagmulder BV, représentée par Regine Slagmulder en tant que représentant permanente, en tant qu’administrateur indépendant de la Société au sens de l’article 7:87 du Code des sociétés et des associations et de la disposition 3.5 du Code belge de gouvernance d’entreprise 2020, pour une durée de deux ans, s’étendant jusqu’à, et y compris, la clôture de l’assemblée générale ordinaire des actionnaires à tenir en 2025 qui statuera sur les comptes annuels de l’exercice social clôturé le 31 décembre 2024. La rémunération de l’administrateur est telle que déterminée dans la politique de rémunération de la Société, telle qu’approuvée de temps à autre par l’assemblée générale des actionnaires, et (sous réserve des dispositions de la politique de rémunération) telle que décidée par l’assemblée générale extraordinaire des actionnaires tenue le 30 juillet 2020 et l’assemblée générale ordinaire des actionnaires tenue le 27 mai 2021. | (b) The general shareholders’ meeting resolves to re-appoint Regine Slagmulder BV, represented by Regine Slagmulder as permanent representative, as independent director of the Company within the meaning of article 7:87 of the Belgian Companies and Associations Code and provision 3.5 of the 2020 Belgian Corporate Governance Code, for a term of two years, up to and including the closing of the ordinary general shareholders’ meeting to be held in 2025 which will have decided upon the financial statements for the financial year ended on 31 December 2024. The remuneration of the director is as set out in the Company’s remuneration policy, as approved from time to time by the general shareholders’ meeting, and (subject to the provisions of the remuneration policy) as decided by the special general shareholders’ meeting held on 30 July 2020 and the ordinary general shareholders’ meeting held on 27 May 2021. | | --- | --- |

| **Assemblée Générale Ordinaire et Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance**<br><br>**Ordinary and Extraordinary General Shareholders’ Meetings of MDxHealth SA - Voting by mail form** | 4/13 |

| --- | --- | | ► Instruction de vote: | | ► votING INSTRUCTION: | | | --- | --- | --- | --- | | 0 Pour / For | 0 Contre / Against | | 0 Abstention | | (c) L’assemblée générale des actionnaires décide de renouveler le mandat d’Eric Bednarski en tant qu’administrateur de la Société pour une durée de deux ans, s’étendant jusqu’à, et y compris, la clôture de l’assemblée générale ordinaire des actionnaires à tenir en 2025 qui statuera sur les comptes annuels de l’exercice social clôturé le 31 décembre 2024. La rémunération de l’administrateur est telle que déterminée dans la politique de rémunération de la Société, telle qu’approuvée de temps à autre par l’assemblée générale des actionnaires, et (sous réserve des dispositions de la politique de rémunération) telle que décidée par l’assemblée générale extraordinaire des actionnaires tenue le 30 juillet 2020 et l’assemblée générale ordinaire des actionnaires tenue le 27 mai 2021. | | (c) The general shareholders’ meeting resolves to re-appoint Eric Bednarski as director of the Company, for a term of two years, up to and including the closing of the ordinary general shareholders’ meeting to be held in 2025 which will have decided upon the financial statements for the financial year ended on 31 December 2024. The remuneration of the director is as set out in the Company’s remuneration policy, as approved from time to time by the general shareholders’ meeting, and (subject to the provisions of the remuneration policy) as decided by the special general shareholders’ meeting held on 30 July 2020 and the ordinary general shareholders’ meeting held on 27 May 2021. | | | ► Instruction de vote: | | ► votING INSTRUCTION: | | | --- | --- | --- | --- | | 0 Pour / For | 0 Contre / Against | | 0 Abstention | | (d) L’assemblée générale des actionnaires décide de renouveler le mandat de Michael K. McGarrity en tant qu’administrateur de la Société pour une durée de deux ans, s’étendant jusqu’à, et y compris, la clôture de l’assemblée générale ordinaire des actionnaires à tenir en 2026 qui statuera sur les comptes annuels de l’exercice social clôturé le 31 décembre 2025. La rémunération de l’administrateur est telle que déterminée dans la politique de rémunération de la Société, telle qu’approuvée de temps à autre par l’assemblée générale des actionnaires, et (sous réserve des dispositions de la politique de rémunération) telle que décidée par l’assemblée générale extraordinaire des actionnaires tenue le 30 juillet 2020 et l’assemblée générale ordinaire des actionnaires tenue le 27 mai 2021.µ | | (d) The general shareholders’ meeting resolves to re-appoint Michael K. McGarrity as director of the Company, for a term of three years, up to and including the closing of the ordinary general shareholders’ meeting to be held in 2026 which will have decided upon the financial statements for the financial year ended on 31 December 2025. The remuneration of the director is as set out in the Company’s remuneration policy, as approved from time to time by the general shareholders’ meeting, and (subject to the provisions of the remuneration policy) as decided by the special general shareholders’ meeting held on 30 July 2020 and the ordinary general shareholders’ meeting held on 27 May 2021. | | | --- | --- | --- | --- | | ► Instruction de vote: | | ► votING INSTRUCTION: | | | 0 Pour / For | 0 Contre / Against | | 0 Abstention | | Note: Si la résolution proposée au point 7 est approuvée par l’assemblée générale des actionnaires, le conseil d’administration de la Société sera composé de (1) Michael K. McGarrity, Chief Executive Officer (CEO), administrateur exécutif et administrateur délégué (jusqu’en 2026), (2) Ahok BV, représentée par Koen Hoffman, administrateur indépendant et président du conseil d’administration (jusqu’en 2025), (3) Donnie M. Hardison Jr., administrateur indépendant (jusqu’en 2025), (4) Hilde Windels BV, représentée par Hilde Windels, administrateur indépendant (jusqu’en 2025), (5) Qaly-Co BV, représentée par Lieve Verplancke, administrateur indépendant (jusqu’en 2024), (6) Valiance Advisors LLP, représentée par Jan Pensaert, administrateur non-exécutif (jusqu’en 2024), (7) Regine Slagmulder BV, représentée par Regine Slagmulder, administrateur indépendant (jusqu’en 2025), et (8) Eric Bednarski, administrateur non-exécutif (jusqu’en 2025). | Note: If the proposed resolutions set out in point 7 are approved by the general shareholders’ meeting, the Company’s board of directors will be composed of (1) Michael K. McGarrity, chief executive officer (CEO), executive director and managing director (until 2026), (2) Ahok BV, represented by Koen Hoffman, independent director and chair of the board of directors (until 2024), (3) Donnie M. Hardison JR, independent director (until 2025), (4) Hilde Windels BV, represented by Hilde Windels, independent director (until 2025), (5) Qaly-Co BV, represented by Lieve Verplancke, independent director (until 2024), (6) Valiance Advisors LLP, represented by Jan Pensaert, non-executive director (until 2024), (7) Regine Slagmulder BV, represented by Regine Slagmulder, independent director (until 2025), and (9) Eric Bednarski, non-executive director (until 2025). | | --- | --- |

| **Assemblée Générale Ordinaire et Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance**<br><br>**Ordinary and Extraordinary General Shareholders’ Meetings of MDxHealth SA - Voting by mail form** | 5/13 |

| --- | --- | | 8. Renouvellement du mandat du commissaire En tenant compte de la recommandation et de la préférence du Comité d’Audit, le conseil d’administration recommande que le mandat de BDO Réviseurs d’Entreprises SRL, représentée par Bert Kegels en tant que représentant permanent, en tant que commissaire de la Société soit renouvelé pour la durée légale de trois ans jusqu’à et y compris la clôture de l’assemblée générale ordinaire des actionnaires qui se tiendra en 2026 et qui aura statué sur les comptes annuels de l’exercice social clôturé le 31 décembre 2025, sous réserve des, et conformément aux, dispositions de l’article 3:61 du Code des sociétés et des associations et du règlement (UE) n° 537/2014 du Parlement européen et du Conseil du 16 avril 2014 relatif aux exigences spécifiques concernant le contrôle légal des comptes des entités d’intérêt public et abrogeant la décision 2005/909/CE de la Commission. | 8. Re-appointment of the statutory auditor Taking into account the recommendation and preference of the audit committee, the board of directors recommends that BDO Réviseurs d’Entreprises SRL, represented by Bert Kegels as permanent representative, be re-appointed as statutory auditor of the Company for a term of three years up to and including the closing of the ordinary general shareholders’ meeting to be held in 2026 which will have decided upon the financial statements for the financial year ended on 31 December 2025, subject to, and in accordance with, the provisions of article 3:61 of the Belgian Companies and Associations Code and Regulation (EU) No. 537/2014 of the European Parliament and of the Council of 16 April 2014 on specific requirements regarding statutory audit of public-interest entities and repealing Commission Decision 2005/909/EC. | | --- | --- | | ► Proposition de résolution*: En tenant compte de la recommandation du conseil d’administration sur recommandation et préférence du comité d’audit, l’assemblée générale des actionnaires décide de renouveler le mandat de BDO Réviseurs d’Entreprises SRL, représentée par Bert Kegels en tant que représentant permanent, en tant que commissaire de la Société pour une durée de trois ans jusqu’à et y compris la clôture de l’assemblée générale annuelle des actionnaires qui se tiendra en 2026 et qui aura statué sur les comptes annuels de l’exercice social clôturé le 31 décembre 2025, sous réserve des, et conformément aux, dispositions de l’article 3:61 du Code des sociétés et des associations et du règlement (UE) n° 537/2014 du Parlement européen et du Conseil du 16 avril 2014 relatif aux exigences spécifiques concernant le contrôle légal des comptes des entités d’intérêt public et abrogeant la décision 2005/909/CE de la Commission. Pour la durée de son mandat, la rémunération annuelle du commissaire de la Société sera de EUR 260.000,00 (hors TVA, taxes et frais, selon le cas) pour le contrôle des comptes consolidés du groupe et le contrôle des comptes annuels statutaires (non consolidés) de la Société. Ces honoraires sont soumis à une indexation annuelle basée sur l’indice standard. | ► Proposed resolution: Taking into account the recommendation of the board of directors upon recommendation and preference of the audit committee, the general shareholders’ meeting resolves to re-appoint BDO Réviseurs d’Entreprises SRL, represented by Bert Kegels as permanent representative, as statutory auditor of the Company for a term of three years up to and including the closing of the ordinary general shareholders’ meeting to be held in 2026 which will have decided upon the financial statements for the financial year ended on 31 December 2025, subject to, and in accordance with, the provisions of article 3:61 of the Belgian Companies and Associations Code and Regulation (EU) No. 537/2014 of the European Parliament and of the Council of 16 April 2014 on specific requirements regarding statutory audit of public-interest entities and repealing Commission Decision 2005/909/EC. For the duration of its mandate, the annual remuneration of the statutory auditor of the Company shall be EUR 260,000.00 (excluding VAT, taxes and expenses, as applicable) for the audit of the consolidated accounts of the group and the audit of the (non-consolidated) statutory financial statements of the Company. These fees are subject to a yearly indexation based on the standard index. | | ► Instruction de vote: | | ► votING INSTRUCTION: | | | --- | --- | --- | --- | | 0 Pour / For | 0 Contre / Against | | 0 Abstention | | 9. Approbation conformément à l’article 7:151 du Code des sociétés et des associations en ce qui concerne le loan and security agreement conclu par et entre la Société et Innovatus Life Sciences Lending Fund I, LP Le 2 août 2022, la Société a conclu un loan and security agreement avec Innovatus Life Sciences Lending Fund I, LP, en vertu duquel Innovatus Life Sciences Lending Fund I, LP a accepté de fournir une facilité de prêt d’un montant maximal de USD 70.000.000,00, qui peut être utilisée en plusieurs tranches. Les Sections 2.2(c), 7.2, 7.3 et 8.2 du loan and security agreement permettent à Innovatus Life Sciences Lending Fund I, LP de résilier le loan and security agreement et d’exiger le paiement/remboursement immédiat de tous les montants impayés dans le cadre du loan and security agreement en cas de changement de contrôle de la Société ou de toute filiale de la Société. | 9.*Approval in accordance with article 7:151 of the Belgian Companies and Associations Code with respect to the loan and security agreement entered into by the Company and Innovatus Life Sciences Lending Fund I, LP On 2 August 2022, the Company entered into a loan and security agreement with Innovatus Life Sciences Lending Fund I, LP, pursuant to which Innovatus Life Sciences Lending Fund I, LP agreed to provide a loan facility for up to USD 70,000,000.00, which can be drawn in multiple tranches. Sections 2.2(c), 7.2, 7.3 and 8.2 of the loan and security agreement allow Innovatus Life Sciences Lending Fund I, LP to terminate the loan and security agreement and demand immediate (re)payment of all amounts outstanding under the loan and security agreement in case of a change of control over the Company or any subsidiaries of the Company. | | --- | --- |

| **Assemblée Générale Ordinaire et Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance**<br><br>**Ordinary and Extraordinary General Shareholders’ Meetings of MDxHealth SA - Voting by mail form** | 6/13 |

| --- | --- | | ► Proposition de résolution: L’assemblée générale des actionnaires décide d’approuver et de ratifier, conformément à l’article 7:151 du Code belge des sociétés et des associations, toutes les clauses du loan and security agreement conclu par la Société et Innovatus Life Sciences Lending Fund I, LP (y compris, mais sans s’y limiter, les Sections 2.2(c), 7.2, 7.3 et 8.2) qui sont applicables au moment où un changement de contrôle se produit et qui tombent ou pourraient être considérés comme tombant dans le champ d’application de l’article 7:151 du Code belge des sociétés et des associations (relatif à l’octroi de droits à des tiers qui affectent substantiellement l’actif et le passif de la Société, ou qui donnent lieu à une dette ou un engagement substantiel pour son compte, lorsque l’exercice de ces droits est subordonné au lancement d’une offre publique d’achat sur les actions de la Société ou à un changement dans le contrôle exercé sur elle). L’assemblée générale des actionnaires donne également une procuration spéciale à chaque administrateur de la société, au Chief Financial Officer et à l’Executive Vice President of Corporate Development and General Counsel (chacun un “Mandataire”), chaque Mandataire agissant individuellement et avec droit de substitution, pour accomplir les formalités requises par l’article 7:151 du Code belge des sociétés et des associations en ce qui concerne la présente résolution, y compris, mais sans s’y limiter, la signature de tous les documents et formulaires requis pour la publication de la présente résolution dans les annexes du Moniteur Belge. | ► Proposed resolution: The general shareholders’ meeting resolves to approve and ratify, in accordance with article 7:151 of the Belgian Companies and Associations Code, all clauses in the loan and security agreement entered into by the Company and Innovatus Life Sciences Lending Fund I, LP (including, but not limited to, Sections 2.2(c), 7.2, 7.3 and 8.2) that are applicable at the time a change of control occurs and which fall or could be considered to fall within the scope of article 7:151 of the Belgian Companies and Associations Code (relating to the granting of rights to third parties that substantially affect the Company’s assets and liabilities, or give rise to a substantial debt or commitment on its behalf, when the exercise of these rights is subject to the launching of a public takeover bid on the shares of the Company or to a change in the control exercised over it). The general shareholders’ meeting also grants a special power of attorney to each Director of the Company, the Chief Financial Officer and the Executive Vice President of Corporate Development and General Counsel (each a “Proxy Holder”), each Proxy Holder acting individually and with the right of substitution, to complete the formalities required by article 7:151 of the Belgian Companies and Associations Code with regard to this resolution, including, but not limited to, the execution of all documents and forms required for the publication of this resolution in the annexes to the Belgian Official Gazette. | | --- | --- | | ► Instruction de vote: | | ► Voting instruction: | | | --- | --- | --- | --- | | 0 Pour / For | 0 Contre / Against | | 0 Abstention | | ORDRE DU JOUR assemblée générale extraordinaire | agenda extraordinary general meeting | | --- | --- | | 1. Communication des rapports - Plan d’Option sur Action de 2023 Communication des, discussion sur: a) le rapport du conseil d’administration de la Société conformément aux articles 7:180 et 7:191 du Code des sociétés et associations relatif à la proposition d’émettre 5.000.000 nouveaux droits de souscription de la Société (les “2023 Share Options”), en vertu d’un plan d’option sur action dénommé “le Plan d’Option sur Action de 2023”, et de supprimer, dans l’intérêt de la Société, le droit de préférence des actionnaires existants de la Société et, pour autant que de besoin, des détenteurs de droits de souscription en circulation (share options) ou American Depositary Shares (“ADSs”) de la Société, en faveur des membres du personnel de la Société et de ses filiales de temps à autre, au sens de l’article 1:27 du Code des sociétés et des associations (les “Participants Sélectionnés”); et b) le rapport du commissaire de la Société conformément aux articles 7:180 et 7:191 du Code des sociétés et des associations concernant la proposition d’émettre 5.000.000 2023 Share Options et de supprimer, dans l’intérêt de la Société, le droit de préférence des actionnaires existants de la Société et, pour autant que de besoin, des détenteurs de droits de souscription en circulation (share options) ou ADSs de la Société, en faveur des Participant Sélectionnés. | 1. Submission of reports - 2023 Share Option Plan Submission of, discussion on: a) the report of the board of directors of the Company in accordance with articles 7:180 and 7:191 of the Belgian Companies and Associations Code in relation to the proposal to issue 5,000,000 new subscription rights for shares of the Company (the “2023 Share Options”), pursuant to a share option plan named “the 2023 Share Option Plan”, and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) or American Depositary Shares (“ADSs”) of the Company, for the benefit of the members of the personnel of the Company and its subsidiaries from time to time, within the meaning of article 1:27 of the Belgian Companies and Associations Code (the “Selected Participant”); and b) the report of the statutory auditor of the Company in accordance with articles 7:180 and 7:191 of the Belgian Companies and Associations Code in relation to the proposal to issue 5,000,000 2023 Share Options, and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) or ADSs of the Company, to the benefit of the Selected Participants. | | --- | --- |

| **Assemblée Générale Ordinaire et Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance**<br><br>**Ordinary and Extraordinary General Shareholders’ Meetings of MDxHealth SA - Voting by mail form** | 7/13 |

| --- | --- | | 2. Proposition d’émettre 5.000.000 2023 Share Options ► Proposition de résolution: L’assemblée générale des actionnaires décide d’approuver l’émission de 5.000.000 2023 Share Options, en vertu d’un plan d’option sur action dénommé “le Plan d’Option sur Action de 2023”, et de supprimer, dans l’intérêt de la Société, le droit de préférence des actionnaires existants de la Société et, pour autant que de besoin, des détenteurs de droits de souscription en circulation (share options) ou ADSs de la Société, en faveur des Participants Sélectionnés. En conséquence, le conseil d’administration décide de ce qui suit: (a) Termes et conditions des 2023 Share Options: Les termes et conditions des 2023 Share Options (inclus, mais sans s’y limiter, le prix d’exercice des 2023 Share Options) seront tels que figurant dans l’annexe au rapport du conseil d’administration visé au point 1.(a) de l’ordre du jour (aux fins de la présente résolution, le “Plan”), dont une copie restera jointe au présent procès-verbal. Les 2023 Share Options ont une durée de 10 ans à partir de leur date d’émission. (b) Actions sous-jacentes: Chaque 2023 Share Option donne à son détenteur le droit de souscrire à une nouvelle action qui sera émise par la Société. Les nouvelles actions à émettre lors de l’exercice des 2023 Share Options auront les mêmes droits et avantages, et seront à tous égards pari passu, en ce compris en ce qui concerne les droits aux dividendes et autres distributions, avec les actions existantes et en circulation de la Société au moment de leur émission, et auront droit aux dividendes et autres distributions pour lesquelles la date d’enregistrement ou la date d’échéance tombe à, ou après la date d’émission des actions. (c) Suppression du droit de préférence en faveur des Participants Sélectionnés: L’assemblée générale des actionnaires décide, conformément à l’article 7:191 du Code des sociétés et des associations, de supprimer, dans l’intérêt de la Société, le droit de préférence des actionnaires existants de la Société et, pour autant que de besoin, des détenteurs de droits de souscription en circulation (share options) de la Société, en faveur des Participants Sélectionnés, et d’approuver la possibilité pour la Société d’octroyer les 2023 Share Options aux Participants Sélectionnés, comme expliqué plus en détail dans le rapport du conseil d’administration visé au point 1.(a) de l’ordre du jour et dans les termes et conditions du Plan. (d) Confirmation de la souscription de 2023 Share Options par la Société: L’assemblée générale des actionnaires décide d’approuver et de confirmer que la Société sera en mesure de souscrire aux 2023 Share Options, en vue de créer un pool de 2023 Share Options disponible pour des octrois ultérieurs aux Participants Sélectionnés. La Société ne peut cependant pas exercer les 2023 Share Options pour son compte propre. | 2. Proposal to issue 5,000,000 2023 Share Options ► Proposed resolution: The general shareholders’ meeting resolves to approve the issuance of 5,000,000 2023 Share Options, pursuant to a share option plan named “the 2023 Share Option Plan”, and to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) or ADSs of the Company, for the benefit of Selected Participant. In view thereof, the general shareholders’ meeting resolves as follows: (a) Terms and conditions of the 2023 Share Options: The terms and conditions of the 2023 Share Options (including, but not limited to, the exercise price of the 2023 Share Options) shall be as set out in the annex to the report of the board of directors referred to in item 1.(a) of the agenda (for the purpose of this resolution, the “Plan”), a copy of which shall remain attached to the minutes reflecting the present resolution. The 2023 Share Options have a term of ten years as from their issue date. (b) Underlying shares: Each 2023 Share Option shall entitle the holder thereof to subscribe for one new share to be issued by the Company. The new shares to be issued at the occasion of the exercise of the 2023 Share Options shall have the same rights and benefits as, and rank pari passu in all respects, including as to entitlements to dividends and other distributions, with the existing and outstanding shares of the Company at the moment of their issuance, and will be entitled to dividends and other distributions in respect of which the relevant record date or due date falls on or after the date of issue of the shares. (c) Dis-application of the preferential subscription right for the benefit of the Selected Participants: The general shareholders’ meeting resolves, in accordance with article 7:191 of the Belgian Companies and Associations Code, to dis-apply, in the interest of the Company, the preferential subscription right of the existing shareholders of the Company and, insofar as required, of the holders of outstanding subscription rights (share options) or ADSs of the Company, for the benefit of the Selected Participants, and to approve the possibility for the Company to grant the 2023 Share Options to the Selected Participants, as further explained in the report of the board of directors referred to in item 1.(a) of the agenda and the terms and conditions of the Plan. (d) Confirmation of the subscription of 2023 Share Options by the Company: The general shareholders’ meeting resolves to approve and confirm that the Company will be able to subscribe for the 2023 Share Options, with a view to creating a pool of outstanding 2023 Share Options available for further grants to Selected Participants. The Company may not, however, exercise the 2023 Share Options for its own account. | | --- | --- |

| **Assemblée Générale Ordinaire et Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance**<br><br>**Ordinary and Extraordinary General Shareholders’ Meetings of MDxHealth SA - Voting by mail form** | 8/13 |

| --- | --- | | (e) Augmentation de capital conditionnelle et émission de nouvelles actions: L’assemblée générale des actionnaires décide, sous réserve et dans la mesure de l’exercice des 2023 Share Options, d’augmenter le capital de la Société et d’émettre le nombre approprié de nouvelles actions pouvant être émises lors de l’exercice des 2023 Share Options. Sous réserve et conformément aux dispositions du Plan, lors de l’exercice des 2023 Share Options et de l’émission de nouvelles actions, le montant total du prix d’exercice des 2023 Share Options sera affecté au capital de la Société. Dans la mesure où le montant du prix d’exercice des 2023 Share Options, par action à émettre lors de l’exercice des 2023 Share Options, excède le pair comptable des actions de la Société existantes alors immédiatement avant l’émission des nouvelles actions concernées, une partie du prix d’exercice, par action à émettre lors de l’exercice des 2023 Share Options, égale à ce pair comptable sera comptabilisée en capital, le solde étant comptabilisé en prime d’émission. Suite à l’augmentation de capital et à l’émission de nouvelles actions, chaque action nouvelle et existante représentera la même fraction du capital de la Société. (f) Prime d’émission: Toute prime d’émission qui sera comptabilisée en relation avec les 2023 Share Options sera comptabilisée sur un compte indisponible au passif du bilan de la Société dans ses capitaux propres, et le compte sur lequel la prime d’émission sera comptabilisée constituera, au même titre que le capital de la Société, la garantie des tiers et, sauf possibilité de capitalisation de ces réserves, ne pourra être réduit ou supprimé que par une décision de l’assemblée générale des actionnaires statuant dans les conditions requises pour la modification des statuts de la Société. (g) Procurations: Le conseil d’administration est autorisé à mettre en œuvre et à exécuter les décisions prises par l’assemblée générale des actionnaires en rapport avec les 2023 Share Options, et à prendre toutes les mesures et à accomplir toutes les formalités requises en vertu du Plan, des statuts de la Société et de la loi applicable afin d’émettre ou transférer les actions lors de l’exercice des 2023 Share Options. En outre, chaque administrateur de la Société, Joe Sollee et Ron Kalfus, chacun agissant individuellement et avec possibilité de subdélégation et pouvoir de subrogation, auront le pouvoir, lors de l’exercice des 2023 Share Options, (i) de procéder à la constatation (A) de l’augmentation de capital et de l’émission de nouvelles actions résultant de cet exercice, (B) de l’allocation du capital et (le cas échéant) de la prime d’émission, et (C) de la modification des statuts de la Société afin de refléter le nouveau capital et nombre d’actions en circulation suite à l’exercice des 2023 Share Options, (ii) de signer et remettre, au nom de la Société, la documentation Euroclear, Euronext et bancaire pertinente, le registre des actions et tous les documents nécessaires en relation avec l’émission et la livraison des actions au Participant Sélectionné, et (iii) faire tout ce qui peut être nécessaire ou utile (y compris, mais sans s’y limiter, la préparation et l’exécution de tous les documents et formulaires) pour l’admission des actions émises lors de l’exercice des 2023 Share Options à la négociation sur le marché réglementé d’Euronext Brussels (ou tout autre marché sur lequel les actions de la Société seront négociées à ce moment). | (e) Conditional capital increase and issue of new shares: The general shareholders’ meeting resolves, subject to, and to the extent of the exercise of 2023 Share Options, to increase the Company’s share capital and to issue the relevant number of new shares issuable upon the exercise of the 2023 Share Options. Subject to, and in accordance with, the provisions of the Plan, upon exercise of the 2023 Share Options and issue of new shares, the aggregate amount of the exercise price of the 2023 Share Options will be allocated to the share capital of the Company. To the extent that the amount of the exercise price of the 2023 Share Options, per share to be issued upon exercise of the 2023 Share Options, exceeds the fractional value of the then existing shares of the Company existing immediately prior to the issue of the new shares concerned, a part of the exercise price, per share to be issued upon exercise of the 2023 Share Options, equal to such fractional value shall be booked as share capital, whereby the balance shall be booked as issue premium. Following the capital increase and issuance of new shares, each new and existing share shall represent the same fraction of the share capital of the Company. (f) Issue premium: Any issue premium that will be booked in connection with the 2023 Share Options shall be accounted for on a non-distributable account on the liabilities side of the Company’s balance sheet under its net equity, and the account on which the issue premium will be booked shall, like the share capital, serve as a guarantee for third parties and can only be reduced on the basis of a lawful resolution of the general shareholders’ meeting passed in the manner required for an amendments to the Company’s articles of association. (g) Powers of attorney: The board of directors is authorised to implement and execute the resolutions passed by the general shareholders’ meeting in connection with the 2023 Share Options, and to take all steps and carry out all formalities that shall be required by virtue of the Plan, the Company’s articles of association and applicable law in order to issue or transfer the shares upon exercise of the 2023 Share Options. Furthermore, each of the Company’s directors, Joe Sollee and Ron Kalfus, each such person acting individually and with possibility of sub-delegation and the power of subrogation, shall have the power, upon exercise of the 2023 Share Options, (i) to proceed with the recording of (A) the capital increase and issue of new shares resulting from such exercise, (B) the allocation of the share capital and (as applicable) the issue premium, and (C) the amendment of the Company’s articles of association in order to reflect the new share capital and number of outstanding shares following the exercise of the 2023 Share Options, (ii) to sign and deliver, on behalf of the Company, the relevant Euroclear, Euronext and bank documentation, the share register and all necessary documents in connection with the issuance and delivery of the shares to the beneficiary, and (iii) to do whatever may be necessary or useful (including but not limited to the preparation and execution of all documents and forms) for the admission of the shares issued upon the exercise of the 2023 Share Options to trading on the regulated market of Euronext Brussels (or such other markets on which the Company’s shares will be trading at that time). | | --- | --- |

| **Assemblée Générale Ordinaire et Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance**<br><br>**Ordinary and Extraordinary General Shareholders’ Meetings of MDxHealth SA - Voting by mail form** | 9/13 |

| --- | --- | | (h) Renonciation: L’assemblée générale des actionnaires reconnaît que les 2023 Share Options qui seront octroyés dans le cadre du “Plan d’Option sur Action de 2023” ne seront pas considérées comme une “rémunération variable”, une “rémunération fixe” ou une “rémunération annuelle” au sens du Code des sociétés et associations (y compris, sans limitation, aux fins des articles 3:6, §3, 7:89/1, 7:90, 7:91, 7:92, 7:100, 7:108 et 7:121 du Code des sociétés et associations) et du Code belge de gouvernance d’entreprise 2020 (y compris, sans limitation, aux fins de la disposition 11 du Code belge de gouvernance d’entreprise 2020). L’assemblée générale des actionnaires approuve les conditions et mécanismes d’acquisition définitive des 2023 Share Options, telles qu’elles sont inclues dans le Plan. Les dispositions des articles 7:91, 7:108 et 7:121 (selon le cas) du Code des sociétés et associations sont expressément écartées en ce qui concerne le Plan des 2023 Share Options. (i) Approbation conformément à l’article 7:151 du Code des sociétés et des associations: L’assemblée générale des actionnaires décide de prendre note, d’approuver et de ratifier, pour autant que de besoin conformément à l’article 7:151 du Code des sociétés et des associations, toutes les clauses incluses dans le Plan, qui entrent en vigueur au moment où un changement de contrôle se produit et qui tombent ou pourraient être considérées comme tombant sous le coup de l’article 7:151 du Code des sociétés et associations (relatif à l’octroi de droits à des tiers affectant substantiellement le patrimoine de la Société ou donnant naissance à une dette ou à un engagement substantiel à sa charge, lorsque l’exercice de ces droits dépend du lancement d’une offre publique d’acquisition sur les actions de la Société ou d’un changement du contrôle exercé sur), y compris, sans limitation, le mécanisme d’acquisition accélérée automatique lors d’une acquisition tel que défini dans le Plan. L’assemblée générale des actionnaires accorde une procuration spéciale à chaque administrateur de la Société, agissant seul et avec pouvoir de substitution, aux fins d’accomplir les formalités requises par l’article 7:151 du Code des sociétés et des associations en ce qui concerne la présente résolution. | (h) Waiver: The general shareholders’ meeting acknowledges that the 2023 Share Options to be granted under the “2023 Share Option Plan” shall not be considered “variable remuneration”, “fixed remuneration” or “annual remuneration” within the meaning of the Belgian Companies and Associations Code (including, without limitation, for the purpose of articles 3:6, §3, 7:89/1, 7:90, 7:91, 7:92, 7:100, 7:108 and 7:121 of the Belgian Companies and Associations Code) and the 2020 Corporate Governance Code (including, without limitation, for the purpose of provision 11 of the 2020 Corporate Governance Code). The general shareholders’ meeting approves the vesting conditions and mechanisms of the 2023 Share Options, as included in the Plan. The provisions of articles 7:91, 7:108 and 7:121 (as applicable) of the Belgian Companies and Associations Code are expressly dis-applied in relation to the 2023 Share Option Plan. (i) Approval in accordance with article 7:151 of the Belgian Companies and Associations Code: The general shareholders’ meeting resolves to take note, approve and ratify, insofar as required in accordance with article 7:151 of the Belgian Companies and Associations Code, all clauses included in the Plan, which come into effect at the moment a change of control occurs and which fall or could be considered to fall within the scope of article 7:151 of the Belgian Companies and Associations Code (relating to the granting of rights to third parties that substantially affect the Company’s assets and liabilities, or give rise to a substantial debt or commitment on its behalf, when the exercise of these rights is subject to the launching of a public takeover bid on the shares of the Company or to a change in the control exercised over it), including, without limitation, the automatic accelerated vesting mechanism upon acquisition as defined in the Plan. The general shareholders’ meeting grants a special power of attorney to each director of the Company, acting alone and with power of substitution, for the purpose of carrying out the formalities required by article 7:151 of the Belgian Companies and Associations Code with respect to this resolution. | | --- | --- | | ► Instruction de vote: | | ► Voting instruction: | | | --- | --- | --- | --- | | 0 Pour / For | 0 Contre / Against | | 0 Abstention | | 3. Communication du rapport spécial du conseil d’administration conformément à l’article 7:199 du Code des sociétés et des associations relatif à la proposition de renouveler le capital autorisé | 3. Submission of the special report of the board of directors in accordance with article 7:199 of the Belgian Companies and Associations Code relating to the proposal to renew the authorised capital | | --- | --- | | Considération, discussion et communication du rapport spécial du conseil d’administration conformément à l’article 7:199 du Code des sociétés et des associations relatif à la proposition de renouveler les pouvoirs conférés au conseil d’administration dans le cadre du capital autorisé, tel que repris ci-dessous au point 4 de l’ordre du jour de l’assemblée générale extraordinaire des actionnaires, et exposant les circonstances spécifiques dans lesquelles le conseil d’administration pourra utiliser ses pouvoirs dans le cadre du capital autorisé, et les objectifs qu’il devra poursuivre. | Consideration, discussion and submission of the special report of the board of directors in accordance with article 7:199 of the Belgian Companies and Associations Code relating to the proposal to renew the powers granted to the board of directors under the authorised capital, as set out below in item 4 of the agenda of the extraordinary general shareholders’ meeting, and setting out the specific circumstances in which the board of directors will be able to use its powers under the authorised capital, and the purposes that it should pursue. **** |

| **Assemblée Générale Ordinaire et Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance**<br><br>**Ordinary and Extraordinary General Shareholders’ Meetings of MDxHealth SA - Voting by mail form** | 10/13 |

---	---
---	---

| **Assemblée Générale Ordinaire et Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance**<br><br>**Ordinary and Extraordinary General Shareholders’ Meetings of MDxHealth SA - Voting by mail form** | 11/13 |

| --- | --- | | ► Instruction de vote: | | ► Voting instruction: | | | --- | --- | --- | --- | | 0 Pour / For | 0 Contre / Against | | 0 Abstention | | Le/la soussigné(e) confirme que les votes susmentionnés s’appliquent aux assemblées générales ordinaire et extraordinaire des actionnaires qui se tiendront le jeudi 25 mai 2023. Dans le cas où les assemblées générales ordinaire et/ou extraordinaire des actionnaires susmentionnées seraient reportées ou ajournées, les votes susmentionnés s’appliqueront également à la ou aux assemblées générales des actionnaires qui seront tenues avec le même ordre du jour, le cas échéant (étant entendu que, par rapport aux points susmentionnés de l’ordre du jour de l’assemblée générale extraordinaire des actionnaires, les votes susmentionnés s’appliqueront en tout état de cause également à la deuxième assemblée générale extraordinaire des actionnaires qui serait convoquée avec un ordre du jour identique à celui de la première assemblée générale extraordinaire des actionnaires dans le cas où le quorum de présence légalement requis pour délibérer et voter valablement sur ces points de l’ordre du jour n’aurait pas été atteint lors de la première assemblée générale extraordinaire des actionnaires): o oui o non Veuillez remplir la case appropriée. Une absence d’instruction ou si, pour quelque raison, il y a une absence de clarté à propos de l’instruction donnée, le soussigné sera supposé avoir choisi “oui”. Veuillez noter qu’aux fins de s’appliquer à telle assemblée subséquente, les titulaires de titres doivent s’enregistrer à nouveau pour cette assemblée. Si, pendant les assemblées, il y a des modifications à une proposition de résolution ou une nouvelle proposition de résolution:^1^ o le/la soussigné(e) votera pour la résolution modifiée ou nouvelle o le/la soussigné(e) votera contre la résolution modifiée ou nouvelle o le/la soussigné(e) s’abstiendra de voter sur la résolution modifiée ou nouvelle o la personne suivante sera consitutée comme mandataire spécial, avec droit de substitution, pour voter au nom du/ de la soussigné(e) sur la résolution modifiée ou nouvelle : le président du conseil d’administration de la Société^2^ ^1^Veuillez cocher tel qu’approprié. Une absence d’instruction sera interprétée comme une instruction de voter pour la résolution modifiée ou nouvelle selon la manière supportée ou recommandée par le conseil d’administration de la Société. ^2^ Si le président du conseil d’administration de la Société est constitué comme mandataire spécial, le président (ou, le cas échéant, un autre administrateur, un employé ou un remplaçant désigné par la Société si le président est empêché d’assister aux assemblées générales des actionnaires) vote dans ce cas sur les propositions de résolution modifiées ou nouvelles selon la manière supportée ou recommandée par le conseil d’administration. Veuillez noter que le président du conseil d’administration de la Société (ou, le cas échéant, le remplaçant du président) est un administrateur, un employé ou un remplaçant désigné de la Société et a donc un conflit d’intérêts potentiel tel que défini dans l’article 7:143, §4 du Code des sociétés et des associations. | The undersigned confirms that the aforementioned votes apply to the ordinary and extraordinary general shareholders’ meetings to be held on Thursday, 25 May 2023. In case the aforementioned ordinary and/or extraordinary general shareholders’ meetings would be postponed or suspended, the aforementioned votes will also apply to the general shareholders’ meeting(s) that would be held having the same agenda, as relevant (it being understood that, in relation to the aforementioned agenda items on the agenda of the extraordinary general shareholders’ meeting, the aforementioned votes will in any event also apply to the second extraordinary general shareholders’ meeting which would be convened with an agenda identical to the agenda of the first extraordinary general shareholders’ meeting in case the legally required attendance quorum to validly deliberate and resolve on such agenda items would not be reached during the first extraordinary general shareholders’ meeting): o yes o no Please tick the appropriate box. In the absence of an instruction, or if, for whatever reason, there is a lack of clarity with regard to the instruction given, the undersigned shall be deemed to have selected “yes”. Please note that in order to apply for such subsequent meeting, holders of securities must again register for such meeting. In case of amendments during the meetings to a proposed resolution or a new proposed resolution:^1^ o the undersigned shall vote for the amended or new resolution o the undersigned shall vote against the amended or new resolution o the undersigned shall abstain from the vote on the amended or new resolution o the following person will be appointed as proxy holder, with the right of substitution, to vote on behalf of the undersigned on the amended or new resolution: the chair of the board of directors of the Company^2^ ^1^ Please complete as appropriate. An absence of instruction shall be tantamount to an instruction to vote for the amended or new resolution as will be supported or recommended by the board of directors of the Company. ^2^ If the chair of the board of directors of the Company is appointed as a proxy holder, the chair (or, as the case may be, another director, an employee or a substitute designated by the Company if the chair is hindered to attend the general shareholders’ meeting) shall in such case vote on the amended or new proposed resolutions in the manner supported or recommended by the board of directors. Please note that the chair of the board of directors of the Company (or, as the case may be, his substitute) is a director, employee or substitute of the Company and therefore has a potential conflict of interest as defined in article 7:143, §4 of the Belgian Companies and Associations Code. | | --- | --- |

| **Assemblée Générale Ordinaire et Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance**<br><br>**Ordinary and Extraordinary General Shareholders’ Meetings of MDxHealth SA - Voting by mail form** | 12/13 |

---	---
---	---
……………………………… 2023 (date)
---
……………………………………………………..<br><br> <br>(nom / name)
……………………………………………………..<br><br> <br>(signature)

| **Assemblée Générale Ordinaire et Extraordinaire des Actionnaires de MDxHealth SA - Formulaire de vote par correspondance**<br><br>**Ordinary and Extraordinary General Shareholders’ Meetings of MDxHealth SA - Voting by mail form** | 13/13 |

| --- | --- |

Exhibit 99.5

Free English translation for information purposesonly

MDxHealth SA

Limited Liability Company(société anonyme)

CAP Business Center

Zone Industrielle des Hauts-Sarts

Rue d’Abhooz 31

4040 Herstal, Belgium

VAT BE 0479.292.440 (RLP Liège, division Liège)

Outstanding Shares and voting rights<br><br> <br>ORDINARY and extraordinary general shareholders’ MEETINGs**** to be held on Thursday, 25 May 2023, at 15:00 p.m.

This overview has been prepared by MDxHealth SA (the “Company”) in accordance with article 7:129, §3, 2° of the Belgian Companies and Associations Code.

On 25 April 2023, the total number of outstanding shares and voting rights of the Company amounted to 270,380,936.

Exhibit 99.7

English translation - For information purposesonly

MDXHEALTH

Limited Liability Company

CAP Business Center

Zone Industrielle des Hauts-Sarts

Rue d’Abhooz 31

4040 Herstal

Belgium

Registered with the Register of Legal Persons

VAT BE 0479.292.440 (RLP Liège, division Liège)

__________________________________________

Reportof the Board of Directorsin accordance with ARTICLES 7:180 and 7:191

ofthe Belgian Companies AND ASSOCIATIONS Code**__________________________________________**

1.	Introduction

This report has been prepared by the board of directors of MDxHealth SA (the “Company”) in accordance with Articles 7:180 and 7:191 of the Belgian Companies and Associations Code (as amended from time to time) (the “Belgian Companies and Associations Code”). It relates to the proposal of the board of directors to issue a total number of 5,000,000 share options in the form of subscription rights (the “2023Share Options”) in order to enable the Company to grant them to certain members of the personnel of the Company and its subsidiaries from time to time, within the meaning of article 1:27 of the Belgian Companies and Associations Code (the “Selected Participants”), in the framework of a share option plan, called the “2023 Share Option Plan”, and the proposal of the board of directors to dis-apply, in the interest of the Company, the statutory preferential subscription right of the Company’s existing shareholders and, insofar as required, of the Company’s existing holders of subscription rights (share options) or American Depositary Shares (“ADSs”), for the benefit of the Selected Participants. The proposals will be submitted to an extraordinary general shareholders’ meeting to be held before a notary public (the “EGM”).

In accordance with Article 7:180 of the Belgian Companies and Associations Code, the board of directors provides in this report a justification of the proposed issuance of 2023 Share Options, with notably a justification of the proposed exercise price of the 2023 Share Options and a description of the consequences of the proposed issuance of 2023 Share Options for the financial and shareholder rights of the shareholders of the Company.

In accordance with Article 7:191 of the Belgian Companies and Associations Code, the board of directors also provides in this report a justification of the proposed dis-application of the statutory preferential subscription right of the existing shareholders and, insofar as required, of the existing holders of subscription rights (share options) or ADSs, for the benefit of the Selected Participants in connection with the proposed issuance of 2023 Share Options and a description of the consequences thereof for the financial and shareholder rights of the shareholders.

This report must be read together with the report prepared in accordance with Articles 7:180 and 7:191 of the Belgian Companies and Associations Code by the Company’s statutory auditor, BDO Réviseurs d’Entreprises SRL, a cooperative company with limited liability organised and existing under the laws of Belgium, with registered office at Da Vincilaan 9 E.6, 1930 Zaventem, Belgium, represented by Mr. Bert Kegels.

1
*English translation - For information purposes only*

2.	proposed issuance of the 2023 share options

The board of directors proposes to issue a total number of 5,000,000 2023 Share Options to the Selected Participants in order to achieve the following goals:

(a)	encourage, motivate and retain the Selected Participants;
(b)	enable the Company and its subsidiaries to attract and retain Members of the Personnel with the required<br>experience and skills; and
---	---
(c)	link the interests of the Selected Participants closer to the interests of the shareholders of the Company<br>by giving them the opportunity to share in the increase of the value of the Company.
---	---

The Company has used share options in the past as a form of incentive and compensation for members of the personnel. For an overview of the outstanding share option plans, see also below in section 6.1(d). As the available headroom under the currently outstanding plans is no longer sufficient, the board of directors proposes to create the 2023 Share Options. In order to enable the Company to grant the 2023 Share Options to the Selected Participants in accordance with the proposed terms and conditions of the 2023 Share Option Plan attached hereto as Annex A, the board of directors proposes to dis-apply, in the interest of the Company, the statutory preferential subscription right of the Company’s existing shareholders and, insofar as required, of the Company’s existing holders of subscription rights (share options) or ADSs, for the benefit of the Selected Participants. The issuance of the 2023 Share Options and the resolution on the dis-application of the preferential subscription right shall be submitted to the EGM.

The main terms governing the 2023 Share Options can be summarized as follows:

(a)	Term of the 2023 Share Options: The duration of a 2023 Share Option shall be ten (10) years as<br>of the date on which they are issued. The board of directors shall, however, have the right to shorten such term.
(b)	Form of the 2023 Share Options: The 2023 Share Options shall be issued as subscription rights in<br>registered form.
---	---
(c)	Underlying shares: Each 2023 Share Option shall entitle the holder thereof to subscribe for one<br>new share to be issued by the Company. The new shares to be issued at the occasion of the exercise of the 2023 Share Options shall have<br>the same rights and benefits as, and rank pari passu in all respects, including as to entitlements to dividends and other distributions,<br>with the existing and outstanding shares of the Company at the moment of their issuance, and will be entitled to dividends and other distributions<br>in respect of which the relevant record date or due date falls on or after the date of issue of the shares. At the request of the relevant<br>holder of the 2023 Share Options, and as long as the Company has outstanding ADSs, the shares can also be delivered in the form of ADSs<br>(at a ratio of one (1) ADS for ten (10) shares).
---	---
(d)	Dis-application of the statutory preferential subscription right: The board of directors proposes<br>to dis-apply, in the interest of the Company, the statutory preferential subscription right of the Company’s existing shareholders and,<br>insofar as required, of the Company’s existing holders of subscription rights (share options) or ADSs, for the benefit of the Selected<br>Participants in accordance with Article 7:191 of the Belgian Companies and Associations Code.
---	---

2
*English translation - For information purposes only*

(e)	Confirmation of the subscription to the 2023 Share Options by the Company: Subject to the dis-application<br>of the statutory preferential subscription right of the Company’s existing shareholders and, insofar as required, of the Company’s existing<br>holders of subscription rights (share options) or ADSs, for the benefit of the Selected Participants in accordance with Article 7:191<br>of the Belgian Companies and Associations Code, the Company shall be able to subscribe for the 2023 Share Options, with a view to creating<br>a pool of outstanding 2023 Share Options available for further grants to Selected Participants. The Company may not, however, exercise<br>the 2023 Share Options for its own account.
(f)	Issuance price of the 2023 Share Options: The 2023 Share Options will be granted free of charge.
---	---
(g)	Exercise price of the 2023 Share Options: The exercise price of a 2023 Share Option shall be determined<br>by the board of directors of the Company on the date of the grant thereof.
---	---

Unless determined otherwise by the board of directors (or those to whom such power will have been delegated by the board of directors) prior to, at, or after the date of grant, the exercise price shall not be lower than the lower of (i) the price of the shares on the relevant regulated market on which the shares are listed and traded on the day prior to the date of grant of the relevant 2023 Share Option (should the shares be listed on Euronext Brussels, Euronext Brussels must be used as market of reference), and (ii) the average price of the shares on the relevant regulated market on which the shares are listed and traded during the period of 30 days preceding the date of grant of the relevant 2023 Share Option (should the shares be listed on Euronext Brussels, Euronext Brussels must be used as market of reference).

(h)	Vesting policy: Unless determined otherwise by the board of directors, the 2023 Share Options to<br>be granted to a Selected Participant in a capacity other than the capacity of director of the Company shall vest in instalments of twenty-five<br>percent (25%) per year during a period of four (4) years as of the date of grant of the relevant 2023 Share Options, as follows:
(i)	on the first anniversary date of the date of grant: 25%;
---	---
(ii)	during the second year from the date of grant: maximum 25%, i.e., maximum 50% in total over the first<br>two years after the date of grant;
---	---
(iii)	during the third year from the date of grant: maximum 25%, i.e., maximum 75% in total over the first three<br>years after the date of grant; and
---	---
(iv)	as from the fourth year from the date of grant: 25%, i.e., maximum 100% in total over the first four years<br>after the date of grant.
---	---

During the second, third, and fourth years after the date of grant, the 2023 Share Options granted to a Selected Participant in any capacity other than the capacity of (non-executive) director of the Company shall vest on a quarterly basis.

3
*English translation - For information purposes only*

The 2023 Share Options granted to a non-executive director of the Company shall all vest on the date of the ordinary general shareholders’ meeting that takes place in the calendar year following the calendar year in which the 2023 Share Options were granted, provided that on the date preceding the date of the former ordinary general shareholders’ meeting the mandate of such non-executive director of the Company has not terminated (without prejudice to section 7.1.3 of the 2023 Share Option Plan).

(i)	Exercisability: Provided that section 7.1.3 of the 2023 Share Option Plan is not applicable, all<br>vested 2023 Share Options shall be exercisable during any exercise period as of and from the moment where such 2023 Share Options became<br>vested 2023 Share Options.

A Selected Participant is allowed to exercise any vested 2023 Share Options during any exercise period following the exercisability date.

(j)	Transferability of the 2023 Share Options: The 2023 Share Options granted to the Selected Participants<br>will generally not be transferable (except in case of decease in the event of 2023 Share Options granted to a natural person and except<br>if the board of directors decides otherwise).
(k)	Exercise of the 2023 Share Options: Each of the 2023 Share Options may be exercised starting as<br>from the date of issuance until ten (10) years as of the date on which they are issued, at the times and in the manner specified in the<br>2023 Share Option Plan.
---	---
(l)	Increase of the share capital of the Company: Upon exercise of 2023 Share Options and issue of<br>new shares, the aggregate amount of the exercise price of the 2023 Share Options will be allocated to the share capital of the Company.<br>To the extent that the amount of the exercise price of the 2023 Share Options, per share to be issued upon exercise of the 2023 Share<br>Options, exceeds the fractional value of the then existing shares of the Company existing immediately prior to the issue of the new shares<br>concerned, a part of the exercise price, per share to be issued upon exercise of the 2023 Share Options, equal to such fractional value<br>shall be booked as share capital, whereby the balance shall be booked as issue premium. Following the capital increase and issuance of<br>new shares, each new and existing share shall represent the same fraction of the share capital of the Company.
---	---
(m)	Issue premium: Any issue premium that will be booked in connection with the 2023 Share Option Plan<br>shall be accounted for on a non-distributable account on the liabilities side of the Company’s balance sheet under its net equity, and<br>the account on which the issue premium will be booked shall, like the share capital, serve as a guarantee for third parties and can only<br>be reduced on the basis of a lawful resolution of the general shareholders’ meeting passed in the manner required for an amendments to<br>the Company’s articles of association.
---	---

For the sake of completeness, the board of directors will submit to the EGM the approbation and ratification, insofar as required in accordance with article 7:151 of the Belgian Companies and Associations Code, of all clauses included in the 2023 Share Option Plan, which come into effect at the moment a change of control occurs and which fall or could be considered to fall within the scope of article 7:151 of the Belgian Companies and Associations Code (relating to the granting of rights to third parties that substantially affect the Company’s assets and liabilities, or give rise to a substantial debt or commitment on its behalf, when the exercise of these rights is subject to the launching of a public takeover bid on the shares of the Company or to a change in the control exercised over it), including, without limitation, the automatic accelerated vesting mechanism in the event of a “Takeover Bid” (as further defined in the 2023 Share Option Plan).

4
*English translation - For information purposes only*

Insofar as required and applicable, the board of directors will also submit to the EGM for its approval that (i) the 2023 Share Options to be granted under the “2023 Share Option Plan” shall not be considered “variable remuneration”, “fixed remuneration” or “annual remuneration” within the meaning of the Belgian Companies and Associations Code (including, without limitation, for the purpose of articles 3:6, §3, 7:89/1, 7:90, 7:91, 7:92, 7:100, 7:108 and 7:121 of the Belgian Companies and Associations Code) and the 2020 Corporate Governance Code (including, without limitation, for the purpose of provision 11 of the 2020 Corporate Governance Code), and that (ii) in accordance with article 7:91, 7:108 and 7:121 (as applicable) of the Belgian Companies and Associations Code, the EGM approves the vesting conditions and mechanisms of the 2023 Share Options, as included in the 2023 Share Option Plan.

3.	Justification of the proposed issuance of 2023 share options

The board of directors of the Company deems the proposed issuance of the 2023 Share Options to be in the Company’s interest because, on the one hand, it enables the Company to receive new financial resources if and when the 2023 Share Options are exercised and, on the other hand, it enables the Company to offer to the Selected Participants a (potential) participation in the Company’s share capital, which, according to the board of directors, can be considered an appropriate tool to value the loyalty and motivation of the Selected Participants and to encourage such loyalty and motivation.

The Selected Participants that will be granted 2023 Share Options will also include the Company’s non-independent non-executive directors. This is contrary to provision 7.6 of the 2020 Belgian Corporate Governance Code, which provides that no share options should be granted to non-executive directors. The Company believes that this provision of the 2020 Belgian Corporate Governance Code is not appropriate and adapted to take into account the realities of companies in the biotech and life sciences industry that are still in a development phase. Notably, the ability to remunerate non-executive directors with share options allows the Company to limit the portion of remuneration in cash that the Company would otherwise need to pay to attract or retain renowned experts with the most relevant skills, knowledge and expertise. The Company is of the opinion that granting non-independent non-executive directors the opportunity to be remunerated in part in share-based incentives rather than all in cash enables the non-independent non-executive directors to link their effective remuneration to the performance of the Company and to strengthen the alignment of their interests with the interests of the Company’s shareholders. The Company believes that this is in the interest of the Company and its stakeholders. Furthermore, the Company believes that this is customary for directors active in companies in the life sciences industry.

For a more detailed description of the purpose and the objective of the proposed issuance of the 2023 Share Options, reference is made to Article 1 of the 2023 Share Option Plan attached hereto as Annex A.

Finally, the proposed issuance of the 2023 Share Options is also in line with the remuneration policy that, upon recommendation of the nomination and remuneration committee, was approved by the Company’s ordinary general shareholders’ meeting held on 27 May 2021.

For all of the above reasons, the board of directors believes that the proposed issuance of the 2023 Share Options is in the interest of the Company, its shareholders, and other stakeholders.

4.	justification of the proposed issuance price and exercise price of the 2023 share options

Pursuant to the terms and conditions of the 2023 Share Option Plan, the 2023 Share Options will be granted to the Selected Participants without any further consideration.

5
*English translation - For information purposes only*

The exercise price of the 2023 Share Options shall be determined as summarised in section 2(g) of this report. For a detailed overview of the conditions concerning the price and exercise price of the 2023 Share Options, reference is made to Articles 5.1 and 5.2 of the terms and conditions of the 2023 Share Option Plan attached hereto as Annex A.

The board of directors considers the fall-back mechanism for the proposed exercise price of the 2023 Share Options to be justified, since (amongst other things) it limits the potential financial dilution to a certain extent and it enables the Company to obtain additional cash resources as mentioned above and further described below. In any event, the terms and conditions of the 2023 Share Options also allow for a different mechanism. This will allow the Company to set the exercise price in such a manner and with reference to such price points as shall be appropriate in order to take into account the tax and social security situation of the relevant Selected Participants and the ultimate goals of the 2023 Share Options Plan.

Whether or not a 2023 Share Option will be exercised depends on the (sole) decision of the holder of the 2023 Share Option. Such decision will depend on the price of the share of the Company at the moment of the decision whether or not to exercise as compared with the exercise price of the 2023 Share Option, since essentially, the holder can realise a capital gain at the exercise of the 2023 Share Option if the price of the share of the Company at that moment is higher than the exercise price of the 2023 Share Option (not taking into account the possible tax related costs and assuming that the holder of the 2023 Share Option can sell the underlying share at such price on the market).

Upon exercise of the 2023 Share Options, the exercise price shall be booked as share capital and issue premium as further described in section 6.2 of this report.

Hence, in view of all of the foregoing, the board of directors believes that the proposed issue price and exercise price of the 2023 Share Options can be sufficiently justified.

5.	Justification of the dis-application of the preferential subscription right

The board of directors proposes to issue a total number of 5,000,000 2023 Share Options, to be offered to the Selected Participants, in accordance with the terms and conditions of the 2023 Share Option Plan.

Each 2023 Share Option shall entitle the Selected Participant to acquire one (1) share of the Company, to which the same rights and benefits as the outstanding shares of the Company are attached. All 2023 Share Options together entitle the holders thereof to subscribe for an aggregate 5,000,000 new shares of the Company, which equals to approximately 1.85% of the existing shares representing the share capital of the Company immediately prior to the issuance of the 2023 Share Options (assuming all the granted 2023 Share Options are fully exercisable and exercised under the terms and conditions of the 2023 Share Option Plan).

In order to be able to offer the 2023 Share Options to the Selected Participants in accordance with the proposed terms and conditions of the 2023 Share Option Plan, the board of directors proposes to dis-apply the statutory preferential subscription right of the Company’s existing shareholders and, insofar as required, of the Company’s existing holders of subscription rights (share options) or ADSs, for the benefit of the Selected Participants in accordance with Article 7:191 of the Belgian Companies and Associations Code.

For all of the above reasons, the board of directors is of the opinion that the proposed issuance of 2023 Share Options, with proposed dis-application of the statutory preferential subscription right, and notwithstanding the dilution following therefrom for the other shareholders and the holders of subscription rights (share options) or ADSs, is in the interest of both the Company and the existing shareholders and holders of subscription rights (share options) or ADSs.

6
*English translation - For information purposes only*

6.	Certain financial consequences
6.1.	Introductory comments
---	---

The following paragraphs provide an overview of certain financial consequences of the proposed issuance and exercise of 2023 Share Options. For further information with regard to the financial consequences of the proposed issuance and exercise of 2023 Share Options, reference is also made to the report prepared in accordance with Articles 7:180 and 7:191 of the Belgian Companies and Associations Code by the statutory auditor of the Company, BDO Réviseurs d’Entreprises SRL.

The actual financial consequences resulting from the proposed issuance and exercise of 2023 Share Options cannot yet be determined with certainty, as the final exercise price of the respective 2023 Share Options is still to be determined and will depend on the price of the Company’s shares on the relevant regulated market or trading platform prior to the date of the grant of the 2023 Share Options. In addition, whether or not certain financial consequences will materialise will depend on whether the 2023 Share Options will be granted to Selected Participants, and whether these 2023 Share Options will ultimately be exercised. The decision to exercise the 2023 Share Options is a decision that solely rests with the holder of the 2023 Share Options, and will likely be in function of the market price of the shares of the Company at the moment of exercise compared to the exercise price of the relevant 2023 Share Options (see also below).

Likewise, the actual financial consequences resulting from the exercise of the outstanding Share Options (as defined and further detailed below) and the issuance of new shares pursuant to (i) the contribution in kind of the Kreos Convertible Loan Payable (as defined and further detailed below), (ii) the contribution in kind of the Exact Sciences Earn-out Consideration (as defined and further detailed below), and (iii) the exercise of the Innovatus Conversion Right (as defined and further detailed below) cannot yet be determined with certainty.

Accordingly, thediscussion herein of the financial consequences of the proposed issuance and exercise of the 2023 Share Options for existing shareholdersis purely illustrative and hypothetical, and is based on purely indicative financial parameters (where relevant). The actual number ofshares to be issued upon exercise of the 2023 Share Options and their exercise price may vary significantly from the hypothetical valuesused in this report.

Subject to the foregoing reservations, for the purposes of the illustration of some of the financial consequences and notably the dilution for the shareholders, the following parameters and assumptions were used:

(a)	Exchange Rate: For the purpose of the simulations and illustrations below, the following Exchange<br>Rate is used: 1.0944 USD for 1 EUR, which is the exchange rate as published by the ECB on 20 April 2023 (which is the trading day before<br>the date of this report).
(b)	Hypothetical exercise price: The hypothetical exercise price of the 2023 Share Options to be issued<br>(to be determined as set out in paragraph 2(g) of this report) will be:
---	---
(i)	EUR 0.25 per 2023 Share Option (or, USD 0.2736) (representing a discount of 33.51% against the closing<br>price of the Company’s shares on Euronext Brussels on 20 April 2023 (which on the trading day before the date of this report));
---	---

7
*English translation - For information purposes only*

(ii)	EUR 0.30 per 2023 Share Option (or, USD 0.3283) (representing a discount of 20.21% against the closing<br>price of the Company’s shares on Euronext Brussels on 20 April 2023 (which is the trading day before the date of this report)); and
(iii)	EUR 0.6046 per 2023 Share Option (or, USD 0.6617) (representing a premium of 60.80% against the closing<br>price of the Company’s shares on Euronext Brussels on 20 April 2023 (which is the trading day before the date of this report)).
---	---
(c)	Current share capital: At the date of this report, the share capital of the Company amounts to<br>EUR 163,471,629.58 represented by 270,380,936 shares without nominal value, each representing the same fraction of the share capital,<br>i.e., (rounded) EUR 0.6046. The share capital is entirely and unconditionally subscribed for and is fully paid-up.
---	---
(d)	Share Options: Furthermore, the following 12,362,029 subscription rights issued by the Company<br>are still outstanding at the date of this report (the “Share Options”):
---	---
(i)	512,000 outstanding share options issued under the form of subscription rights on 23 June 2014<br>(“2014 Share Options”) (of which 68,500 share options have not yet been granted);
---	---
(ii)	1,936,155 outstanding share options issued under the form of subscription rights on 19 June 2017<br>(“2017 Share Options”) (which have all been granted);
---	---
(iii)	2,685,124 outstanding share options issued under the form of subscription rights on 21 June 2019<br>(“2019 Share Options”) (of which 26,500 share options have not yet been granted);
---	---
(iv)	3,538,750 outstanding share options issued under the form of subscription rights on 27 May 2021 (“2021Share Options”) (of which 5,000 share options have not yet been granted); and
---	---
(v)	3,690,000 outstanding share options issued under the form of subscription rights on 25 May 2022 (“2022Share Options”) (of which 1,222,500 share options have not yet been granted).
---	---

Each of the aforementioned Share Options entitles the holders thereof to subscribe for one new share of the Company upon exercise of the relevant Share Option. For the purpose of the full-dilution scenario calculations further below, it is assumed that all of the 12,362,029 outstanding Share Options (including the 68,500 outstanding 2014 Share Options, the 26,500 outstanding 2019 Share Options, the 5,000 outstanding 2021 Share Options and the 1,222,500 outstanding 2022 Share Options that can still be granted) have been effectively granted, have vested and are exercisable. On that basis, if all 12,362,029 Share Options were exercised, 12,362,029 new shares would need to be issued by the Company.

8
*English translation - For information purposes only*

(e)

Exact Sciences Earn-Out Consideration: On 2 August 2022, the Company entered into an asset purchase agreement with Genomic Health, Inc. (a subsidiary of Exact Sciences Corporation referred to herein as “Exact Sciences”), pursuant to which, among other things and subject to the terms and conditions included in the asset purchase agreement, Exact Sciences agreed to sell and assign, and the Company agreed to purchase and assume, the business of developing, marketing and performing the Oncotype DX Genomic Prostate Score test (the “GPS Test Business”) for an aggregate purchase price of up to USD 100,000,000.00 to be paid as follows: (i) an amount of USD 24,999,999.64, which was paid on the date of the asset purchase agreement, (ii) an amount of USD 5,000,000.36, which was contributed in kind by Exact Sciences to the Company on 11 August 2022, within the context of a capital increase by the Company within the framework of the authorised capital of the Company against the issuance by the Company of 6,911,710 new shares delivered in the form of 691,171 ADSs, and (iii) an additional aggregate earn-out amount of up to USD 70,000,000.00 to be paid by the Company to Exact Sciences upon achievement of certain revenue milestones related to fiscal years 2023 through 2025, with the maximum earn-out payable in relation to 2023 and 2024 not to exceed USD 30,000,000.00 and USD 40,000,000.00, respectively (the “ExactSciences Earn-Out Consideration”). At the option of the Company, amounts reflecting the Exact Sciences Earn-Out Consideration can be settled in cash or through the issuance of additional shares of the Company by contribution in kind of the relevant receivables due by the Company (at an issue price per share valued in function of a volume weighted average trading price of the Company’s shares at the end of the relevant earn-out period), to be delivered in the form of ADSs to Exact Sciences, provided that the aggregate number of shares representing the ADSs held by Exact Sciences shall not exceed more than 5% of the outstanding shares of the Company.

For the purpose of the full-dilution scenario calculations further below, it is assumed that the full Exact Sciences Earn-Out Consideration amount of USD 70,000,000.00 is converted, by applying the Exchange Rate (see paragraph 6.1(a)), into EUR 63,961,988.30 and is fully paid in kind by the Company to Exact Sciences by the issuance of new shares (or ADSs, at the ratio of 1 ADS per 10 new shares) of the Company at the hypothetical issue prices (see paragraph (6.1(b)) in consideration of the settlement through a contribution in kind of receivables due by the Company to Exact Sciences up to the Earn-Out Consideration. To reflect maximum dilution, the maximum 5% shareholding cap (as described above) is not taken into account in the simulations below. Should this 5% shareholding cap be applied, only 13,519,046 new shares could be issued to Exact Sciences on a fully diluted basis, taking into account the most dilutive parameters used herein.

(f)

Innovatus Conversion Right: On 2 August 2022, to finance the acquisition of the GPS Test Business, the Company entered into loan and security agreement with Innovatus Life Sciences Lending Fund I, LP (“Innovatus”) pursuant to which Innovatus agreed to provide a loan facility for up to USD 70,000,000.00, which can be drawn in multiple tranches. On 2 August 2022, an amount of USD 35,000,000.00 was drawn, with an additional USD 35,000,000.00 remaining available as a USD 20,000,000.00 term B loan and a USD 15,000,000.00 term C loan that can be drawn in 2024 and 2025 respectively, subject to certain conditions. Under the loan and security agreement, Innovatus has the right to convert (through contribution in kind of the relevant underlying receivables due by the Company), prior to 2 August 2025, up to 15% of the outstanding principal amount of the loans into ADSs of the Company at a 45% premium to the relevant volume-weighted average price before entering into the loan and security agreement, yielding at a conversion price per ADS equal to USD 11.21 (i.e., USD 1.121 per share on the basis of the ratio of 1 ADS per 10 shares), prior to 2 August 2025 (the “InnovatusConversion Right”). Amounts converted into ADSs of the Company will be reduced from the principal amount outstanding of the loan.

For the purpose of the full-dilution scenario calculations further below, it is assumed that (i) the full amount of USD 70,000,000.00 is drawn by the Company before 2 August 2025, (ii) the Innovatus Conversion Right is fully exercised by Innovatus, and (iii) the exchange rate applied to convert USD amounts in EUR amount is the same as the Exchange Rate (see paragraph 6.1(a)). On that basis, EUR 9,594,298.24 would be contributed in kind by Innovatus to the Company against the issuance 9,366,687 new shares of the Company at a conversion price of EUR 1.0243 per share.

9
*English translation - For information purposes only*

(g)

Kreos Convertible Loan Payable: On 23 September 2019, the Company entered into loan agreements with Kreos Capital VI (UK) Limited (“Kreos Capital”) with respect to a loan facility of up to EUR 9,000,000, which was fully drawn on 1 November 2019. The Company and Kreos Capital agreed that a drawdown fee equal to 7% of the amounts drawn down under the loan agreements (being EUR 630,000 in aggregate) would remain outstanding as a payable (without accruing interest), and would be convertible into ordinary shares by means of a contribution in kind to the share capital of the Company at a price of EUR 0.85 per share (the “Kreos Convertible Loan Payable”). As part of the Innovatus loan and security agreement, the Company’s loan facility with Kreos Capital was repaid in cash, except that the Kreos Convertible Loan Payable was not repaid, but will remain outstanding in accordance with its terms.

For the purpose of the full-dilution scenario calculations further below, it is assumed that the full amount of the Kreos Convertible Loan Payable has been converted into new shares of the Company, by means of a contribution in kind to the share capital of the Company at a price of EUR 0.85 per share. On that basis, 741,176 new shares would have to be issued by the Company to the benefit of Kreos Capital.

(h)	Allocation of the issue price of the outstanding dilutive instruments: Upon the issuance of new<br>shares upon exercise of the Innovatus Conversion Right, and/or the contribution of the Kreos Convertible Loan Payable, and/or the contribution<br>of the Exact Sciences Earn-Out Consideration, and/or the exercise of the Share Options, the amount of the issue price of the relevant<br>new shares will be booked as equity (in the form of share capital and share premium, as the case may be). The amount that shall be booked<br>as share capital shall, on a per share basis, be equal to the amount of the applicable fractional value of the Company’s shares at the<br>relevant time. The balance, as the case may be, shall be booked as issue premium.
(i)	Whether the outstanding Share Options, the Kreos Convertible Loan Payable or the Innovatus Conversion<br>Right will be effectively exercised or converted will ultimately depend on the decision of the Share Options holders, Kreos Capital and<br>Innovatus, respectively. Such decision will likely be in function of the market price of the shares of the Company at the moment of exercise<br>or conversion, compared to their respective exercise or conversion prices. The holders of Share Options, Kreos Capital and Innovatus will<br>likely not exercise or convert if the market price of the shares of the Company is less than the relevant exercise price or conversion<br>price, respectively.
---	---
(j)	Whether an Exact Sciences Earn-Out Consideration amount is due and converted into shares of the Company<br>will depend the fulfilment (or not) of the respective conditions provided by the asset purchase agreement. Furthermore, should an Exact<br>Sciences Earn-Out Consideration amount be due by the Company to Exact Sciences, the Company can also ultimately opt to pay such Exact<br>Sciences Earn-Out Consideration amount in cash rather than in shares.
---	---
(k)	In order to reflect the maximum dilution below, it is assumed that none of the existing shareholders,<br>holders of Share Options, Kreos Capital, Innovatus or Exact Sciences will be granted with and will exercise any of the 2023 Share Options.
---	---

In this report, when reference is made to “outstanding dilutive instruments”, it refers, respectively, to the issuance of new shares upon exercise of the Innovatus Conversion Right, contribution of the Kreos Convertible Loan Payable, contribution of the Exact Sciences Earn-Out Consideration and exercise of the outstanding Share Options.

10
*English translation - For information purposes only*

6.2.	Evolution of the share capital, voting power, participation in the results and other shareholder rights

Each share in the Company currently represents an equal part of the share capital of the Company and provides for one vote in function of the part of the capital it represents. The issuance of the new shares upon exercise of the 2023 Share Options will lead to a dilution of the existing shareholders of the Company and of the relative voting power of each share in the Company.

The dilution relating to the voting right also applies, mutatis mutandis, to the participation of each share in the profit and liquidation proceeds and other rights attached to the shares of the Company, such as the statutory preferential subscription right in case of a capital increase in cash through the issuance of new shares or in case of the issuance of new subscription rights or convertible bonds.

Specifically, prior to the issuance of the 2023 Share Options (and the issuance of new shares pursuant the other outstanding dilutive instruments), each share of the Company participates equally in the profit and liquidation proceeds of the Company and each shareholder has a statutory preferential subscription right in case of a capital increase in cash or in case of the issuance of new subscription rights or convertible bonds. Upon the issuance of the new shares upon exercise of the 2023 Share Options, the new shares to be issued will have the same rights and benefits as, and rank pari passu in all respects with, the existing and outstanding shares of the Company at the moment of their issuance and delivery, and will be entitled to dividends and other distributions in respect of which the relevant record date or due date falls on or after the date of issuance and delivery of the new shares. As a result (and to the extent the new shares will be issued and subscribed for pursuant to the exercise of the 2023 Share Options), the participation by the existing shareholders in the profit and liquidation proceeds of the Company and their holder’s statutory preferential subscription right in case of a capital increase in cash, shall be diluted accordingly.

A similar dilution occurs upon exercise or conversion of the other outstanding dilutive instruments.

Furthermore, should the final exercise price of the new shares be below the fractional value of the existing shares of the Company (i.e., currently rounded to EUR 0.6046), to some extent, the issuance of the new shares might have had a reduced voting right, a reduced participation in the profit and liquidation proceeds, and a reduced preferential subscription right. However, all of the new shares to be issued will have to have the same rights and benefits as, and rank pari passu in all respects with, the existing and outstanding shares of the Company. Therefore, in accordance with article 7:178 of the Belgian Companies and Associations Code, after the completion of the issuance of the new shares upon exercise of the 2023 Share Options, all of the Company’s outstanding shares will have the same (as the case may be adjusted) fractional value. This would also entail that, at least conceptually, there would be a dilution of the voting right, the right to participate in the profit and liquidation proceeds, and the preferential subscription right of the existing shares of the Company to the benefit of the new shares.

Subject to the methodological reservations noted in section 6.1, the evolution of the share capital and the number of shares, with voting rights attached thereto, of the Company as a result of the proposed issuance and exercise of all 5,000,000 2023 Share Options (and the subsequent issuance of 5,000,000 new shares resulting from it) is simulated below in a scenario before dilution due to outstanding dilutive instruments, as well as in a scenario after dilution due to outstanding dilutive instruments.

11
*English translation - For information purposes only*

Evolution of the numberof outstanding shares

	Exercise price
	0.25		0.30		0.6046
	Equivalent to <br> 0.2736		Equivalent to<br> 0.3283		Equivalent to<br> 0.6617
Before dilution due to outstanding dilutive instruments
(A) Outstanding shares
(B) New shares to be issued upon exercise of the 2023 Share Options
(C) Total number of shares outstanding after (B)
(D) Dilution		%		%		%
After dilution due to outstanding dilutive instruments but before the exercise of the 2023 Share Options
(A) Outstanding shares
(B) New shares to be issued upon exercise of the outstanding Share Options
(C) New shares to be issued upon contribution of the Kreos Convertible Loan Payable
(D) New shares to be issued upon contribution of the Exacts Sciences Earn-Out Consideration
(E) New shares to be issued upon exercise of the Innovatus Conversion Right
(F) Total number of new shares to be issued under (B), (C), (D) and (E)
(G) Total number of shares outstanding after (B), (C), (D) and (E)
After the exercise of the 2023 Share Options and after dilution due to outstanding dilutive instruments
(A) Outstanding shares after dilution due to outstanding dilutive instruments
(B) New shares to be issued in the Transaction
(C) Total number of shares outstanding after (B)
(D) Dilution		%		%		%

All values are in Euros.

12
*English translation - For information purposes only*

Subject to the methodological reservations noted in section 6.1, the table below reflects the evolution of the share capital, assuming the exercise of all 5,000,000 2023 Share Options and the subsequent issuance of 5,000,000 new shares resulting from it. The maximum amount of share capital increase (excluding issue premium) is computed by multiplying the number of new shares to be issued (i.e., 5,000,000) with the applicable issue price (as the relevant price is in each case lower than the fractional value of the shares of the Company (i.e., currently rounded to EUR 0.6046).

Evolution of the share capital^(1)^


	^^	0.30	^^	0.6046
	^^	Equivalent to 0.3283	^^	Equivalent to 0.6617
Before the exercise of the 2023 Share Options	^^		^^
(A) Share capital (in )	^^		^^
(B) Outstanding shares	^^		^^
(C) Fractional value (in ) (rounded)	^^		^^
Exercise of the 2023 Share Options	^^		^^
(A) Increase of share capital (in )(2)	^^		^^
(B) Number of new shares to be issued	^^		^^
After the exercise of the 2023 Share Options	^^		^^
(A) Share capital (in )	^^		^^
(B) Outstanding shares	^^		^^
(C) Fractional value (in ) (rounded)	^(3)^		^(3)^

All values are in Euros.

Notes:

(1)	This simulation does not take into account the exercise or conversion of outstanding dilutive instruments.
(2)	A portion of the issue price that is equal to the fractional value of the existing shares of the Company<br>(i.e., currently rounded to EUR 0.6046) shall be booked as share capital. The portion of the issue price in excess of the fractional value<br>shall be booked as issue premium, as the case may be.
---	---
(3)	In such simulations, the respective exercise price would be below the fractional value of the existing<br>shares of the Company (i.e., currently rounded to EUR 0.6046). Therefore, in accordance with article 7:178 of the Belgian Companies and<br>Associations Code, after the exercise of the 2023 Share Options, all of the Company’s outstanding shares will have the same fractional<br>value, i.e., EUR 0.5982 and EUR 0.5991.
---	---

6.3.	Participation in the consolidated accounting net equity

The evolution of the consolidated accounting net equity of the Company as a result of the exercise of the 2023 Share Options is simulated below.

The simulation is based on the audited consolidated annual financial statements of the Company for the financial year ended on 31 December 2022 (which have been prepared in accordance with the International Financial Reporting Standards, as adopted by the European Union (“IFRS”) and which have been submitted to the Company’s annual shareholders’ meeting for approval). The consolidated accounting net equity of the Company as at 31 December 2022 amounted to EUR 123,539,165.19 (i.e., USD 135,201,262.38), on the basis of the Exchange Rate) or EUR 0.7585 (rounded) per share (based on 162,880,936 outstanding shares as at 31 December 2022). The simulation does not take into account any changes in the consolidated accounting net equity since 31 December 2022, except, however, that for the purpose of the simulation, the impact of the capital increases completed on 7 February 2023 and 8 March 2023 will be taken into account.

13
*English translation - For information purposes only*

Notably, as a result of the closing of the abovementioned transactions (without taking into account the possible effects of accounting items other than share capital and issue premium (e.g., the costs of the said transaction)):

(i)	the Company’s share capital was increased, resulting in an increase of the Company’s equity by EUR 39,932,464.39,<br>for a total adjusted amount of EUR 163,471,629.58; and
(ii)	the number of outstanding shares of the Company following the abovementioned transactions amounts to 270,380,936<br>shares (as 107,500,000 new shares were issued in the framework of the abovementioned transactions).
---	---

For further information on the Company’s net equity position on 31 December 2022, reference is made to the financial statements of the Company, which are available on the Company’s website.

Based on the assumptions set out above, as a result of the exercise of 2023 Share Options, without taking into account the other dilutive instruments, the Company’s accounting net equity on a consolidated basis, would be increased as indicated below:

Evolution of the consolidated accounting netequity


	0.30	0.6046
	Equivalent to <br> 0.3283	Equivalent to <br> 0.6617
Consolidated net equity for FY 2022 (adjusted)
(A) Net equity (in ’000) (rounded)
(B) Outstanding shares
(C) Net equity per share (in ) (rounded)
Exercise of the 2023 Share Options
(A) Increase of net equity (in ’000)(1)
(B) Number of new shares to be issued
After exercise of the 2023 Share Options
(A) Net equity (in ’000) (rounded)(2)
(B) Outstanding shares
(C) Net equity per share (in ) (rounded)(2)

All values are in Euros.

Notes:

(1)	Consisting of the amount of the capital increase and the amount of the increase of issue premium, as the<br>case may be, but not reflecting that the accounting of this amount may be subject to further adjustments pursuant to IFRS or IAS 34.
(2)	Not taking into account changes in the consolidated net equity after 31 December 2022 (other than resulting<br>from the exercise of the 2023 Share Options and the abovementioned capital increases completed on 7 February 2023 and 8 March 2023), nor<br>taking into account the potential issuance of new shares pursuant to the other dilutive instruments.
---	---

14
*English translation - For information purposes only*

The table above demonstrates that the issuance of the 5,000,000 2023 Share Options and the subsequent exercise of all 2023 Share Options will, from a pure accounting point of view, lead to an increase of the amount represented by each share in the consolidated accounting net equity of the Company.

6.4.	Financial dilution

The evolution of the market capitalisation as a result of the exercise of the 2023 Share Options is simulated below.

Subject to the methodological reservations noted in section 6.1, the table below reflects the impact of the exercise of the 2023 Share Options, without taking into account other outstanding dilutive instruments, on the market capitalisation and the resulting financial dilution at various price levels, assuming the exercise of all 5,000,000 2023 Share Options and the subsequent issuance of 5,000,000 new shares resulting from it.

After close of trading on the day preceding the date of this report, i.e., 20 April 2023, the Company’s market capitalisation was EUR 101,663,231.94, on the basis of a closing price of EUR 0.3760 per share. Assuming that, following the exercise of the 2023 Share Options, the market capitalisation increases exclusively with the funds raised on the basis of the parameters set out above, the new market capitalisation would be rounded, respectively, to EUR 0.3737, EUR 0.3746 and EUR 0.3802 per share. This would represent a (theoretical) financial dilution of 0.61% and 0.37% and a financial accretion of 1.12% per share, respectively.

Evolution of the market capitalisationand financial dilution


		0.30		0.6046
		Equivalent to<br> 0.3283		Equivalent to<br> 0.6617
Market capitalisation before the exercise of the 2023 Share Options(1)
(A) Market capitalisation (in )
(B) Outstanding shares
(C) Market capitalisation per share (in )
Exercise of the 2023 Share Options
(A) Exercise of the 2023 Share Options (in )
(B) Number of new shares to be issued
Market capitalisation after the exercise of the 2023 Share Options
(A) Market capitalisation (in )
(B) Outstanding shares
(C) Market capitalisation per share (in ) (rounded)
Dilution/Accretion	%		%		%

All values are in Euros.

Notes:

(1)	At the date of this report and not taking into account the potential issuance of new shares pursuant to<br>the other dilutive instruments.

6.5.	Other financial consequences

It is expected that, in the context of the Company’s consolidated financial statements in accordance with the IFRS, the 2023 Share Options will be accounted for in accordance with (among others) IFRS 2 (“Share-based payment”). The actual application of the reporting standard, the timing of initial recognition and the valuation of the 2023 Share Options are still to be determined and assessed. The actual amount will ultimately depend on the actual exercise price of the relevant 2023 Share Options.

For a further discussion on the financial consequences of the proposed issuance of the 2023 Share Options and their subsequent exercise, the board of directors refers to the report prepared in connection therewith by the statutory auditor of the Company.

* * *

Done on 24 April 2023.

15
*English translation - For information purposes only*

On behalf of the board of directors,

	[SIGNED]		[SIGNED]
By:		By:
Director		Director

16
*English translation - For information purposes only*

ANNEX A

2023 SHAREOPTION PLAN

*English translation - For information purposes only*

Free English translation

This English version of the 2023 Share Option Plan of MDxHealth SA is a free translation of the original French version. In case of discrepancies between the original French version and this English version, the original French version shall prevail.

2023 SHARE OPTION PLAN

MDXHEALTH SA

MDxHealth SA • Rue d’Abhooz 31 - CAP Business Center, 4040 Herstal, Belgium

www.mdxhealth.com • Tel (32) 4.257.70.21 • Fax (32) 4.259.78.75

TVA BE 0479.292.440 RPM (Liège) • KBC Bank 736-0304341-19

*English translation - For information purposes only*

ARTICLE1 – PURPOSE OF THE PLAN

This 2023 Share Option Plan (the “Plan”) describes the general terms and conditions of the Share Options that the Company may grant to the Selected Participants.

The aim of the Plan is to realise the following corporate and human resources goals:

(i)	encourage, motivate and retain the Selected Participants;
(ii)	enable the Company and its Subsidiaries to attract and retain Members of the Personnel with the required<br>experience and skills; and
---	---
(iii)	link the interests of the Selected Participants closer to the interests of the shareholders of the Company<br>by giving them the opportunity to share in the increase of the value of the Company.
---	---

ARTICLE2 – DEFINITIONS AND INTERPRETATION

The following terms shall have the following meaning for the purpose of the Plan:

Belgian Companies and Associations Code	the Belgian Companies and Associations Code of 23 March 2019 (as amended from time to time).
Beneficiary	With respect to a natural person, a person validly designated by the Selected Participant, being either the Selected Participant’s spouse, or the cohabiting partner, or legal heirs, in order to exercise the rights of the Selected Participant under the Plan after the death of the Selected Participant. Designation, revocation and re-designation of a Beneficiary must be done in writing in accordance with the applicable law. In the absence of any valid designation, the heirs of the Selected Participant in accordance with the applicable law of inheritance shall be deemed to be the Beneficiary. In the event that there are several heirs, all heirs acting jointly or one person designated by all heirs acting jointly shall be deemed to be the Beneficiary.
Board of Directors	The board of directors of the Company.
Business Day	A day on which banks are open for business in Belgium, excluding Saturdays and Sundays.
Company	MDxHealth SA, a company established under Belgian law, having its registered office at Rue d’Abhooz 31 - Cap Business Center, 4040 Herstal, Belgium, registered with the register of legal persons under number 0479.292.440.
Control	The possibility de facto or de jure to exercise a decisive influence over the appointment of the majority of the members of the Board of Directors or the general orientation of the Company’s governance, as determined in articles 1:14 and following of the Belgian Companies and Associations Code.
Date of Grant	The date on which the offer of the Share Options to a Selected Participant is made.

1
*English translation - For information purposes only*

Date of Issuance	The date on which the Share Options will be issued pursuant to a resolution of the Extraordinary General Shareholders’ Meeting, i.e. 25 May 2023, or in case of absence of the required attendance quorum at such meeting, 30 June 2023.
Date of Termination of the Selected Participant’s Director’s mandate, employment agreement, management agreement or similar agreement	The effective date of termination of the Selected Participant’s Director’s mandate, employment agreement, management agreement or similar agreement for whatever reason, with the exception of a termination of a management agreement immediately followed by the signing of an employment agreement, a new management agreement or a similar agreement with the Company or a Subsidiary, a termination of an employment agreement immediately followed by the signing of a new employment agreement, management agreement or similar agreement with the Company or a Subsidiary, and the termination of a Director’s mandate immediately followed by the re-appointment as Director.
Director	A member of the board of directors of the Company or a Subsidiary.
Exercise Period	The period during which the Selected Participant can exercise the Share Options granted to him/her, provided and to the extent that the Share Options are exercisable in accordance with the conditions set forth in the Plan and in any other arrangement that may exist between the Selected Participant and the Company.
Exercise Price	The price at which each Share subject to a Share Option may be acquired/subscribed for upon the exercise of that Share Option.
Extraordinary General Shareholders’ Meeting	The extraordinary general shareholders’ meeting of the Company held before a notary public at the occasion of which the Share Options are issued by the Company.
Member of the Personnel	A member of the personnel of the Company or a Subsidiary as defined under article 1:27 of the Belgian Companies and Associations Code.
Notification	A written letter sent to the official domicile or registered office of the addressee by means of (i) a courier with notice of receipt, (ii) a registered letter or (iii) an e-mail sent to the addressee’s e-mail address. The date of the Notification is: (i) the date of signing for receipt, or (ii), in the absence thereof, the postmarked date of the registered letter, or (iii) the date of sending of the e-mail, provided that the e-mail was sent to the correct e-mail address of the addressee.
Plan	The present 2023 Share Option Plan.
Public Takeover Bid	The official notification by the FSMA of a public takeover bid within the meaning of article 3 § 1, 1° of the Belgian Act of 1 April 2007 on public takeover bids, as amended (or within the meaning of any other subsequent legislation replacing, amending or completing the foregoing).
Selected Participant(s)	Any Member of the Personnel to whom Share Options will be granted pursuant to, or under, this Plan.

2
*English translation - For information purposes only*

Share	A share of the Company, representing the share capital of the Company.
Share Option	A subscription right issued by the Company entitling the Selected Participant to acquire/subscribe for one (1) Share pursuant to the Plan during a certain period at a certain price.
Share Option Price	The price, if any, which the Selected Participant owes to the Company for the acquisition of the Share Option itself.
Subsidiary	Any company or organization which is directly or indirectly under the Control of the Company.
Transfer – Transferring	Any transaction under living persons which has as its purpose the sale, acquisition, granting or accepting of options, exchange, waiver, contribution to a company, transfer in any manner whether or not for consideration, the giving of payment or pledge, or the acceptance of payment or pledge, or generally any agreement which has as its object an immediate or future transfer of title.
Vested Share Options	Share Options that have become definitely acquired by the Selected Participant in accordance with the conditions set forth in the Plan, without prejudice to the possibility that the Share Options become void in cases where they are not exercised or can no longer be exercised pursuant to Plan.

Except insofar as the context otherwise requires, (i) words denoting the singular shall include the plural and vice versa and (ii) words denoting the masculine gender shall include the feminine gender and vice versa.

ARTICLE3 - TYPE AND NUMBER OF Share OPTIONS

The total number of Share Options issued under the Plan is of five million (5,000,000).

Each Share Option shall entitle a Selected Participant to acquire one (1) Share.

The new Shares to be issued at the occasion of the exercise of the Share Options shall have the same rights and benefits as, and rank pari passu in all respects, including with respect to entitlements to distributions and dividends, with the existing and outstanding Shares of the Company at the time of their issuance. They will be entitled to dividends and other distributions in respect of which the relevant record date or due date falls on or after the date of issue of the Shares.

A new Share shall represent the same fraction of the capital of the Company as the other outstanding Shares of the Company at that moment.

ARTICLE4 - ADMINISTRATION

The Board of Directors shall administer the Plan. The Board of Directors shall have the possibility to delegate its powers or certain of its powers to certain persons of the management and/or to certain committees that may be established by the Board of Directors, in compliance with the Belgian Companies and Associations Code and the Company’s Charter of Corporate Governance.

3
*English translation - For information purposes only*

Subject to the provisions of the Plan and in as far as the decisions are in line with the purpose of the Plan, the Board of Directors is entitled to determine, define and interpret all rules, regulations or other measures required or desirable for the administration of the Plan. The Board of Directors may terminate the Plan at any time. Share Options granted prior to such termination shall remain valid and exercisable in accordance with the Plan.

ARTICLE5 - CONDITIONS OF THE Share OPTIONS

5.1****ShareOption Price

Except where the Board of Directors decides otherwise, on a one to one basis, the Selected Participant shall owe no Share Option Price to the Company upon subscription for, or acceptance of, the Share Options.

5.2****ExercisePrice

The Exercise Price of a Share Option shall be determined by the Board of Directors of the Company on the Date of the Grant thereof. Unless determined otherwise by the Board of Directors (or those to whom such power will have been delegated by the Board of Directors) prior to, at, or after the Date of Grant, the Exercise Price shall not be lower than the lower of (i) the price of the Shares on the relevant regulated market on which the Shares are listed and traded on the day prior to the Date of Grant (should the Shares or securities be listed on Euronext Brussels, Euronext Brussels must be used as market of reference), and (ii) the average price of the Shares on the relevant regulated market on which the Shares are listed and traded during the period of 30 days preceding the Date of Grant of the relevant 2023 Share Option (should the Shares or securities be listed on Euronext Brussels, Euronext Brussels must be used as market of reference).

Upon exercise of Share Options and issue of new shares, the aggregate amount of the exercise price of the Share Options will be allocated to the share capital of the Company. To the extent that the amount of the exercise price of the Share Option, per share to be issued upon exercise of the Share Option, would exceed the fractional value of the then existing shares of the Company existing immediately prior to the issue of the new shares concerned, a part of the exercise price, per share to be issued upon exercise of the Share Option equal to such fractional value shall be booked as share capital, whereby the balance shall be booked as issue premium. In accordance with article 7:178 of the Belgian Companies and Associations Code, following the capital increase and issuance of new shares, each new and existing share shall represent the same fraction of the share capital of the Company.

5.3****Term (duration) of the Share Options

The duration of a Share Option shall be ten (10) years as of their Date of Issuance. However, the Board of Directors shall have the right to shorten this term. Unless a shorter term is provided by the Board of Directors, a Share Option is therefore (in any event) automatically null, void and of no value at 24:00 (midnight) on the tenth (10th) anniversary date of the Date of Issuance.

5.4****Registerednature

The Share Options are and shall remain registered, and shall be entered in the register of subscription right holders that shall be held at the registered office of the Company. The Company shall deliver to each Selected Participant and Beneficiary, free of charge, a certificate confirming that the Participant or Beneficiary is duly registered in the register of subscription right holders as owner of the Share Options.

4
*English translation - For information purposes only*

5.5****Rights as a shareholder

The Selected Participant (in the Selected Participant’s capacity as holder of a Share Option) is not a shareholder of the Company, nor shall the Selected Participant have any rights or privileges, which as a rule belong to a shareholder of the Company, as long as the Share Options held by the Selected Participant have not been exercised.

ARTICLE6 – TRANSFER OF THE Share OPTIONS

6.1****Decease

In case the holder of a Share Option is a natural person, the following will apply: in the event of the decease of a Selected Participant, all Share Options (including the Vested Share Options at the time of decease) shall be transferred to the Beneficiary of the Selected Participant and shall be (or remain as far as the Vested Share Options are concerned) exercisable at the time and under the terms established in this Plan.

6.2****Transferabilityof the Share Options

Except for the transfer contemplated under article 6.1 above and except if the Board of Directors were to allow a Transfer of the Share Options, the Share Options cannot be Transferred by a Selected Participant once they have been granted to a Selected Participant.

ARTICLE7 - EXERCISE OF THE Share OPTIONS

Share Options can only be exercised during an Exercise Period (as specified in article 7.2 below) provided and to the extent that they have become Vested Share Options and have become exercisable (in accordance with article 7.1 below) prior to or during a certain Exercise Period.

7.1****Vestingand exercisability of the Share Options

The vesting schedule of a Share Option, i.e. the dates and conditions upon which it shall become a Vested Share Option, shall be as set forth in this Plan, except where, for Share Options granted to Selected Participants in any capacity other than the capacity of director of the Company, the Board of Directors determines otherwise and, for Share Options granted to Selected Participants in their capacity of director of the Company, the general shareholders’ meeting determines otherwise. The vesting schedule and the period before a Share Option can become exercisable can therefore be shorter than the periods as referred to below in this article 7.1.

7.1.1 Generalvesting mechanism of the Share Options

Unless otherwise determined by the Board of Directors, the Share Options subscribed for by a Selected Participant in any capacity other than the capacity of director of the Company shall vest, i.e. become Vested Share Options, in installments of twenty-five percent (25%) per year during a period of four (4) years as of the Date of Grant, as follows:

●	on the first anniversary date of the Date of Grant: 25%;
●	during the second year from the Date of Grant: maximum 25%, i.e. maximum 50% in total over the first two<br>years after the Date of Grant;
---	---
●	during the third year from the Date of Grant: maximum 25%, i.e. maximum 75% in total over the first three<br>years after the Date of Grant;
---	---
●	as from the fourth year from the Date of Grant: 25%, i.e. maximum 100% in total over the first four years<br>after the Date of Grant.
---	---

5
*English translation - For information purposes only*

During the second, the third, and the fourth years after the Date of Grant, the Share Options subscribed for by a Selected Participant in any capacity other than the capacity of (non-executive) director of the Company shall vest on a quarterly basis, i.e. for a number that bears the same proportion to the maximum number of Share Options that can vest during that period as the number of (full) quarters that have passed during said given period bears to the total number of quarters of that period. For example, one year and seven months after the Date of Grant, a maximum of 37.5% of the Share Options granted to a Selected Participant could be Vested Share Options.

Unless determined otherwise by the Extraordinary General Shareholders’ Meeting, non-executive directors of the Company that are not independent Directors shall not be entitled to a remuneration in cash, but shall each year be entitled to receive share options for a maximum of 10,000 Shares of the Company.

The Share Options granted to a non-executive director of the Company shall all vest, i.e. become Vested Share Options, on the date of the ordinary shareholders’ meeting that takes place in the calendar year following the calendar year where the Share Options were granted, provided that on the date preceding the date of the former ordinary shareholders’ meeting the mandate of such non-executive director of the Company has not terminated (without prejudice to section 7.1.3 of the Plan).

Notwithstanding the foregoing, all Share Options subscribed for by a Selected Participant shall automatically vest (if not yet vested) and become Vested Share Options in the event of a Public Takeover Bid.

7.1.2	Exercisability of the Share Options

The Selected Participants are allowed to exercise any Vested Share Options during any Exercise Period as of and from the moment where such Share Options became Vested Share Options. The rules set forth in section 7.1.3. below however prevail over the rules set forth in this section 7.1.2.

7.1.3	Consequences of termination of a Director’s mandate, employmentagreement, management agreement or similar agreement

Without prejudice to the provisions of the following paragraphs and unless otherwise determined by the Board of Directors or the Chief Executive Officer (Managing Director) of the Company, when (i) the Director’s mandate of a Selected Participant is terminated for other reasons than for breach of his duties as a Director, (ii) the employment agreement of a Selected Participant is terminated for other reason than for serious cause, or (iii) management or similar agreement of the Selected Participant is terminated for other reasons than breach of said agreement, in each such case the Selected Participant may exercise all his Share Options that have become Vested Share Options at the Date of Termination of the Selected Participant’s Director’s mandate, employment agreement, management agreement or similar agreement, as relevant, at the time and in accordance with the conditions set forth in the Plan, within a period of one year as from the Date of Termination of the employment agreement, management agreement or similar agreement.

The Vested Share Options that are not exercised within the period referred to in the previous paragraph shall automatically lapse and become null and void. The Share Options that have not become Vested Share Options at the Date of Termination of the Selected Participant’s Director’s mandate, employment agreement, management agreement or similar agreement, as relevant, automatically lapse and become null and void.

6
*English translation - For information purposes only*

Upon termination of (i) the Director’s mandate of the Selected Participant for breach of his duties as a Director, (ii) the employment agreement of the Selected Participant for serious cause, or (iii) management or similar agreement of the Selected Participant for breach of said agreement, all Share Options granted to the Selected Participant shall, unless determined otherwise by the Board of Directors, whether vested or not, automatically become definitely non-exercisable as from the Date of Termination of the Selected Participant’s Director’s mandate, employment agreement, management agreement or similar agreement, as relevant.

7.1.4	Consequences of legal retirement, disability or serious disease

In case the holder of a Share Option is a natural person, the following will apply: in the event of termination of the Director’s mandate, employment agreement, management agreement or similar agreement of the Selected Participant, as relevant, as a consequence of legal retirement, disability or serious disease, the (at that time) Vested Share Options shall remain exercisable for the remaining term of the Share Options pursuant to the terms and conditions set forth in the Plan.

7.2****ExercisePeriod

Vested Share Options can only be exercised during the following periods: during the term of the Share Options, between 1 March and 31 March, and between 1 September and 30 September. Each Exercise Period shall close on the last Business Day of the particular Exercise Period.

The Board of Directors may, however, in its absolute discretion, provide for additional Exercise Periods and do so for instance in case of a Public Takeover Bid (e.g. in case all Share Options automatically vest in accordance with 7.1.1 in fine above).

7.3****Partialexercise

A Selected Participant may exercise all or part of his/her Vested Share Options. However, it is not possible to exercise a Share Option with respect to fractions of Shares.

7.4****Exerciseprocedure

A Share Option shall be deemed to have been exercised upon receipt by the Company, at the latest on the last Business Day of the Exercise Period, of:

(i)	a Notification signed by the Selected Participant and stating that a Share Option or a specified number<br>of Share Options is exercised;
(ii)	evidence of complete payment of the Exercise Price, within thirty (30) calendar days following the last<br>Business Day of the Exercise Period in which the Share Options were exercised, for the number of Shares as indicated in the Notification<br>provided sub (i), by bank transfer to a blocked account of the Company whose number is communicated by the Company;
---	---
(iii)	in the event that a Share Option is exercised by a person or persons other than the Selected Participant,<br>suitable proof of the right of this person or these persons to exercise the Share Option; and
---	---
(iv)	Any and all statements and documents, which the Board of Directors deems desirable or necessary in order<br>to comply with all applicable legal and regulatory provisions, and the submission of which the Board of Directors consequently requests.
---	---

7
*English translation - For information purposes only*

7.5****Conditionsfor the issuance of Shares

7.5.1	The Company shall only be obliged to issue the Shares as a result of the exercise of the Share Options,<br>by registration in the Company’s share register or any other manner prescribed by the Belgian Companies and Associations Code, after all<br>of the preceding conditions set forth in article 7.4 have been fulfilled and following the completion of the capital increase mentioned<br>below.
7.5.2	The Board of Directors, or one member thereof or any other person specifically delegated for such purpose,<br>shall, in accordance with article 7:187 of the Belgian Companies and Associations Code (or any other provision having the same purport),<br>have the capital increase resulting from the exercise of the Share Options, and the fully paid in Shares thus subscribed for, acted before<br>a notary public within sixty (60) days after the closing of the Exercise Period in which the Share Options were exercised.
---	---
7.5.3	If, at the time of exercise of the Share Options, the Shares are admitted to listing and/or trading on<br>the regulated market of Euronext Brussels, another regulated market or another trading platform, the Company shall use reasonable efforts<br>in order to take such actions and make such filings as shall be necessary to have the Shares that are issued upon exercise of the relevant<br>Share Options admitted to listing and/or trading on the regulated market of Euronext Brussels, such other regulated market or such other<br>trading platform under the timeline as shall be decided by the Board of Directors.
---	---
7.5.4.	The Company may at its discretion postpone the delivery of the Shares, if this is necessary in order to<br>comply with the applicable regulations or provisions of whatever nature, including but not limited to public offer, registration and other<br>obligations with respect to the Shares of the Company, as the Company deems appropriate.
---	---
7.5.5	At the request of the relevant holder of the 2023 Share Options, and as long as the Company has outstanding<br>ADSs, the shares can also be delivered in the form of ADSs (at a ratio of one (1) ADS for ten (10) shares).
---	---

ARTICLE8 – CHANGE IN THE CAPITAL STRUCTURE OF THE COMPANY – EXERCISE OF THE Share OPTIONS BY VIRTUE OF LAW

8.1****Changein the capital structure of the Company

Contrary to article 7:71 of the Belgian Companies and Associations Code, the Company explicitly reserves the right to take all possible decisions and to enter into all possible transactions that may have an impact on its capital, on the distribution of profits or on the distribution of liquidation proceeds or that may otherwise affect the rights of the Selected Participants.

Should the rights of the Selected Participant be affected by such decision or transaction, then the Selected Participant shall not be entitled to a change of the Exercise Price, a change of the exercise conditions or any other form of (financial or other) compensation, unless such a decision or transaction would have as its main purpose to prejudice the rights of the holders of the Share Options.

In case of a merger, de-merger or share split of the Company, the rights attached to the outstanding Share Options and/or Exercise Price of the Share Options, shall be adapted in accordance with the conversion ratios applied at the occasion of the merger, de-merger or share split to the other shareholders.

8
*English translation - For information purposes only*

8.2****Exerciseof the Share Options by virtue of law

If a Share Option which is not exercisable or which cannot be exercised pursuant to the issuance conditions (as determined in this Plan) becomes prematurely exercisable on the basis of article 7:71 of the Belgian Companies and Associations Code and is also exercised pursuant to said article, the Shares obtained by exercising the Share Option shall not be transferable, unless explicitly agreed upon by the Board of Directors, until the time the underlying Share Options would have become exercisable in accordance with the Plan.

ARTICLE9 – MISCELLANEOUS

9.1****Taxesand social security

The Company or a Subsidiary shall be entitled, in accordance with the applicable law or practice, to withhold from any cash payment made to a Selected Participant, and/or the Selected Participant shall be obliged to pay to the Company or to a Subsidiary (if requested for by the Company or a Subsidiary), the amount of any tax and/or social security contributions, if any, attributable to or payable in connection with the grant, vesting or exercise of any Share Options or attributable to or payable in connection with the delivery of the Shares.

The Company or a Subsidiary shall also be entitled, in accordance with the applicable law or practice, to make the necessary reporting, required as a result of the grant of Share Options, their vesting, their exercisability or the delivery of the Shares.

9.2 C****osts

Stamp duties and other similar duties or taxes levied upon exercise of the Share Options and/or the delivery of the new Shares shall be borne by the Selected Participant.

Costs related to the capital increase that shall take place upon the exercise of the Share Options shall be borne by the Company.

9.3****Applicablelaw and competent courts

Belgian law governs the Plan. Disputes shall fall under the exclusive jurisdiction of the courts and tribunal of the jurisdiction where the Company has its registered office.

Share Options subscribed for in the framework of this Plan shall be governed by and construed in accordance with the laws of Belgium.

9.4****Notifications

Each Notification to a Selected Participant shall be made to the address mentioned in the register of subscription rights holders or the relevant notice details as set out in the agreement between the Company and the Selected Participant pursuant to which the Share Options were granted. Each Notification to the Company, a Subsidiary or the Board of Directors shall be validly made to the address of the registered office of the Company. Address changes must be communicated in accordance with this provision.

9.5****Relationto Selected Participant’s agreement

Notwithstanding any provision of the plan, the rights and obligations of a Selected Participant as determined under the terms of the Selected Participant’s employment agreement or management agreement or similar agreement with the Company or any Subsidiary shall not be affected by the Selected Participant’s participation in the Plan or by any right that the Selected Participant may have to participate therein. A Selected Participant who subscribes for Share Options pursuant to the Plan shall have no rights to compensation or damages in consequence of the termination of the Selected Participant’s employment agreement, or management agreement or similar agreement with the Company or a Subsidiary for any reason whatsoever, insofar as those rights arise or may arise from the termination of the rights which the Selected Participant would have or of the claims which the Selected Participant could make relating to the exercise of the Share Options under the Plan as a result of the termination of such Selected Participant’s employment agreement, or management agreement or similar agreement, or from the loss or reduction in value of the rights or advantages.

Exhibit 99.8

Free English translation - For information purposes only

Free English translation

2023 SHARE OPTION PLAN

MDXHEALTH SA

MDxHealth SA • Rue d’Abhooz 31 - CAP Business Center, 4040 Herstal, Belgium

www.mdxhealth.com • Tel (32) 4.257.70.21 • Fax (32) 4.259.78.75

TVA BE 0479.292.440 RPM (Liège) • KBC Bank 736-0304341-19

*Free English translation - For information purposes only*

ARTICLE1 – PURPOSE OF THE PLAN

This 2023 Share Option Plan (the “Plan”) describes the general terms and conditions of the Share Options that the Company may grant to the Selected Participants.

The aim of the Plan is to realise the following corporate and human resources goals:

(i)	encourage, motivate and retain the Selected Participants;
(ii)	enable the Company and its Subsidiaries to attract and retain Members of the Personnel with the required<br>experience and skills; and
---	---
(iii)	link the interests of the Selected Participants closer to the interests of the shareholders of the Company<br>by giving them the opportunity to share in the increase of the value of the Company.
---	---

ARTICLE2 – DEFINITIONS AND INTERPRETATION

The following terms shall have the following meaning for the purpose of the Plan:

Belgian Companies and Associations Code	the Belgian Companies and Associations Code of 23 March 2019 (as amended from time to time).
Beneficiary	With respect to a natural person, a person validly designated by the Selected Participant, being either the Selected Participant’s spouse, or the cohabiting partner, or legal heirs, in order to exercise the rights of the Selected Participant under the Plan after the death of the Selected Participant. Designation, revocation and re-designation of a Beneficiary must be done in writing in accordance with the applicable law. In the absence of any valid designation, the heirs of the Selected Participant in accordance with the applicable law of inheritance shall be deemed to be the Beneficiary. In the event that there are several heirs, all heirs acting jointly or one person designated by all heirs acting jointly shall be deemed to be the Beneficiary.
Board of Directors	The board of directors of the Company.
Business Day	A day on which banks are open for business in Belgium, excluding Saturdays and Sundays.
Company	MDxHealth SA, a company established under Belgian law, having its registered office at Rue d’Abhooz 31 - Cap Business Center, 4040 Herstal, Belgium, registered with the register of legal persons under number 0479.292.440.
Control	The possibility de facto or de jure to exercise a decisive influence over the appointment of the majority of the members of the Board of Directors or the general orientation of the Company’s governance, as determined in articles 1:14 and following of the Belgian Companies and Associations Code.

1
*Free English translation - For information purposes only*

Date of Grant	The date on which the offer of the Share Options to a Selected Participant is made.
Date of Issuance	The date on which the Share Options will be issued pursuant to a resolution of the Extraordinary General Shareholders’ Meeting, i.e. 25 May 2023, or in case of absence of the required attendance quorum at such meeting, 30 June 2023.
Date of Termination of the Selected Participant’s Director’s mandate, employment agreement, management agreement or similar agreement	The effective date of termination of the Selected Participant’s Director’s mandate, employment agreement, management agreement or similar agreement for whatever reason, with the exception of a termination of a management agreement immediately followed by the signing of an employment agreement, a new management agreement or a similar agreement with the Company or a Subsidiary, a termination of an employment agreement immediately followed by the signing of a new employment agreement, management agreement or similar agreement with the Company or a Subsidiary, and the termination of a Director’s mandate immediately followed by the re-appointment as Director.
Director	A member of the board of directors of the Company or a Subsidiary.
Exercise Period	The period during which the Selected Participant can exercise the Share Options granted to him/her, provided and to the extent that the Share Options are exercisable in accordance with the conditions set forth in the Plan and in any other arrangement that may exist between the Selected Participant and the Company.
Exercise Price	The price at which each Share subject to a Share Option may be acquired/subscribed for upon the exercise of that Share Option.
Extraordinary General Shareholders’ Meeting	The extraordinary general shareholders’ meeting of the Company held before a notary public at the occasion of which the Share Options are issued by the Company.
Member of the Personnel	A member of the personnel of the Company or a Subsidiary as defined under article 1:27 of the Belgian Companies and Associations Code.
Notification	A written letter sent to the official domicile or registered office of the addressee by means of (i) a courier with notice of receipt, (ii) a registered letter or (iii) an e-mail sent to the addressee’s e-mail address. The date of the Notification is: (i) the date of signing for receipt, or (ii), in the absence thereof, the postmarked date of the registered letter, or (iii) the date of sending of the e-mail, provided that the e-mail was sent to the correct e-mail address of the addressee.
Plan	The present 2023 Share Option Plan.
Public Takeover Bid	The official notification by the FSMA of a public takeover bid within the meaning of article 3 § 1, 1° of the Belgian Act of 1 April 2007 on public takeover bids, as amended (or within the meaning of any other subsequent legislation replacing, amending or completing the foregoing).

2
*Free English translation - For information purposes only*

Selected Participant(s)	Any Member of the Personnel to whom Share Options will be granted pursuant to, or under, this Plan.
Share	A share of the Company, representing the share capital of the Company.
Share Option	A subscription right issued by the Company entitling the Selected Participant to acquire/subscribe for one (1) Share pursuant to the Plan during a certain period at a certain price.
Share Option Price	The price, if any, which the Selected Participant owes to the Company for the acquisition of the Share Option itself.
Subsidiary	Any company or organization which is directly or indirectly under the Control of the Company.
Transfer – Transferring	Any transaction under living persons which has as its purpose the sale, acquisition, granting or accepting of options, exchange, waiver, contribution to a company, transfer in any manner whether or not for consideration, the giving of payment or pledge, or the acceptance of payment or pledge, or generally any agreement which has as its object an immediate or future transfer of title.
Vested Share Options	Share Options that have become definitely acquired by the Selected Participant in accordance with the conditions set forth in the Plan, without prejudice to the possibility that the Share Options become void in cases where they are not exercised or can no longer be exercised pursuant to Plan.

ARTICLE3 - TYPE AND NUMBER OF Share OPTIONS

The total number of Share Options issued under the Plan is of five million (5,000,000).

Each Share Option shall entitle a Selected Participant to acquire one (1) Share.

A new Share shall represent the same fraction of the capital of the Company as the other outstanding Shares of the Company at that moment.

3
*Free English translation - For information purposes only*

ARTICLE4 - ADMINISTRATION

ARTICLE5 - CONDITIONS OF THE Share OPTIONS

5.1Share Option Price

5.2****ExercisePrice

5.3 Term (duration) of the Share Options

4
*Free English translation - For information purposes only*

5.4 Registered nature

5.5 Rights as a shareholder

ARTICLE6 – TRANSFER OF THE Share OPTIONS

6.1 Decease

6.2 Transferability of the Share Options

ARTICLE7 - EXERCISE OF THE Share OPTIONS

7.1 Vesting and exercisability of the Share Options

5
*Free English translation - For information purposes only*

7.1.1	General vesting mechanism of the Share Options

●	on the first anniversary date of the Date of Grant: 25%;
●	during the second year from the Date of Grant: maximum 25%, i.e. maximum 50% in total over the first two<br>years after the Date of Grant;
---	---
●	during the third year from the Date of Grant: maximum 25%, i.e. maximum 75% in total over the first three<br>years after the Date of Grant;
---	---
●	as from the fourth year from the Date of Grant: 25%, i.e. maximum 100% in total over the first four years<br>after the Date of Grant.
---	---

7.1.2	Exercisabilityof the Share Options

7.1.3	Consequences of termination of a Director’s mandate, employment agreement, management agreement orsimilar agreement

6
*Free English translation - For information purposes only*

7.1.4	Consequencesof legal retirement, disability or serious disease

7.2 Exercise Period

7.3 Partial exercise

A Selected Participant may exercise all or part of his/her Vested Share Options. However, it is not possible to exercise a Share Option with respect to fractions of Shares.

7.4 Exercise procedure

A Share Option shall be deemed to have been exercised upon receipt by the Company, at the latest on the last Business Day of the Exercise Period, of:

(i)	a Notification signed by the Selected Participant and stating that a Share Option or a specified number<br>of Share Options is exercised;
(ii)	evidence of complete payment of the Exercise Price, within thirty (30) calendar days following the last<br>Business Day of the Exercise Period in which the Share Options were exercised, for the number of Shares as indicated in the Notification<br>provided sub (i), by bank transfer to a blocked account of the Company whose number is communicated by the Company;
---	---

7
*Free English translation - For information purposes only*

(iii)	in the event that a Share Option is exercised by a person or persons other than the Selected Participant,<br>suitable proof of the right of this person or these persons to exercise the Share Option; and
(iv)	Any and all statements and documents, which the Board of Directors deems desirable or necessary in order<br>to comply with all applicable legal and regulatory provisions, and the submission of which the Board of Directors consequently requests.
---	---

7.5 Conditions for the issuance of Shares

7.5.1	The Company shall only be obliged to issue the Shares as a result of the exercise of the Share Options,<br>by registration in the Company’s share register or any other manner prescribed by the Belgian Companies and Associations Code, after all<br>of the preceding conditions set forth in article 7.4 have been fulfilled and following the completion of the capital increase mentioned<br>below.
7.5.2	The Board of Directors, or one member thereof or any other person specifically delegated for such purpose,<br>shall, in accordance with article 7:187 of the Belgian Companies and Associations Code (or any other provision having the same purport),<br>have the capital increase resulting from the exercise of the Share Options, and the fully paid in Shares thus subscribed for, acted before<br>a notary public within sixty (60) days after the closing of the Exercise Period in which the Share Options were exercised.
---	---
7.5.3	If, at the time of exercise of the Share Options, the Shares are admitted to listing and/or trading on<br>the regulated market of Euronext Brussels, another regulated market or another trading platform, the Company shall use reasonable efforts<br>in order to take such actions and make such filings as shall be necessary to have the Shares that are issued upon exercise of the relevant<br>Share Options admitted to listing and/or trading on the regulated market of Euronext Brussels, such other regulated market or such other<br>trading platform under the timeline as shall be decided by the Board of Directors.
---	---
7.5.4.	The Company may at its discretion postpone the delivery of the Shares, if this is necessary in order to<br>comply with the applicable regulations or provisions of whatever nature, including but not limited to public offer, registration and other<br>obligations with respect to the Shares of the Company, as the Company deems appropriate.
---	---
7.5.5	At the request of the relevant holder of the 2023 Share Options,<br>and as long as the Company has outstanding ADSs, the shares can also be delivered in the form of ADSs (at a ratio of one (1) ADS for<br>ten (10) shares).
---	---

ARTICLE8 – CHANGE IN THE CAPITAL STRUCTURE OF THE COMPANY – EXERCISE OF THE Share OPTIONS BY VIRTUE OF LAW

8.1 Change in the capital structure of the Company

8
*Free English translation - For information purposes only*

8.2 Exercise of the Share Options by virtue of law

ARTICLE9 – MISCELLANEOUS

9.1 Taxes and social security

9.2 Costs

Stamp duties and other similar duties or taxes levied upon exercise of the Share Options and/or the delivery of the new Shares shall be borne by the Selected Participant.

Costs related to the capital increase that shall take place upon the exercise of the Share Options shall be borne by the Company.

9.3 Applicable law and competent courts

Belgian law governs the Plan. Disputes shall fall under the exclusive jurisdiction of the courts and tribunal of the jurisdiction where the Company has its registered office.

Share Options subscribed for in the framework of this Plan shall be governed by and construed in accordance with the laws of Belgium.

9.4 Notifications

9.5 Relation to Selected Participant’s agreement

Exhibit 99.9

***Unofficial English translation - For information purposes only ***

MDXHEALTH

Limited Liability Company

(Société anonyme)

CAP Business Center

Zone Industrielle des Hauts-Sarts

Rue d’Abhooz 31

4040 Herstal

Belgium

Registered with the Register of Legal Persons

VAT BE 0479.292.440 (RLP Liège, Section Liège)

SPECIALReport of the Board of Directorsin accordance with Article 7:199 OF the Belgian Companies AND ASSOCIATIONS Code

1.	INTRODUCTION

This special report has been prepared by the board of directors of MDxHealth SA (the “Company”) in accordance with article 7:199 of the Belgian Companies and Associations Code (as amended from time to time) (the “BCCA”). It relates to the proposal to renew the powers of the board of directors of the Company to increase the Company’s share capital within the framework of the authorised capital within the limits set out in this special board report, and sets out the circumstances in which the board of directors will be able to use its powers under the authorised capital and the purposes that it should pursue. This proposal shall be submitted to the extraordinary general shareholders’ meeting of the Company to be held before a notary public on 25 May 2023 (or on 30 June 2023 should the required attendance quorum not be reached at the first meeting).

2.	PROPOSAL TO RENEW THE AUTHORISED CAPITAL

The current authorisation to the board of directors to increase the share capital of the Company within the framework of the authorised capital was granted by the extraordinary general shareholders’ meeting held on 27 May 2021, and expires on 1 June 2026, but has been substantially used by the Company. In addition, under existing agreements and facilities, the Company may be required to issue additional new shares on an expedited basis, within the framework of the authorised capital.

In accordance with article 7:199 of the BCCA, the board of directors proposes to the extraordinary general shareholders’ meeting of the Company to be authorised, for a period of five years as from the publication of such authorisation in the Annexes to the Belgian Official Gazette, to increase the share capital of the Company in one or several times with a maximum amount of up to hundred percent (100%) of the share capital at the time of the general shareholders’ meeting approving the authorised capital.

It should be noted that the aforementioned authorisation is not intended as a defence mechanism against a takeover bid as it does not authorise the board of directors to increase the share capital of the Company with restriction or cancellation of the preferential subscription right of the shareholders after the Financial Services and Markets Authority (FSMA) has notified the Company of a public takeover bid for the Company’s shares, subject to the provisions of article 7:202 of the BCCA.

***Unofficial English translation - For information purposes only ***

If approved by the shareholders, article 6 of the articles of association of the Company will read as follows (whereby the date referred to in the sub-section between square brackets shall be the date of the general shareholders’ meeting approving the renewed authorised capital, and the amount referred to in the sub-section between brackets shall be the amount of the Company’s share capital at the time of the general shareholders’ meeting approving the authorised capital):

“Article 6: Authorised capital

3.	CIRCUMSTANCES AND PURPOSES FOR THE USE OT THE AUTHORISED CAPITAL

The board of directors is of the opinion that the renewal of the authorised capital is necessary to meet the needs of the Company as a listed company.

In principle, changes to the share capital are decided by the Company’s general shareholders’ meeting. Such resolution by the general shareholders’ meeting must satisfy the quorum and majority requirements that apply to an amendment of the articles of association. This means that a shareholders’ resolution to increase the Company’s share capital is only passed provided that at least 50% of the share capital of the Company is present or represented at the general shareholders’ meeting, and provided that the resolution is approved by 75% of the votes cast at the meeting. In the event the required attendance quorum of 50% is not present or represented at the first meeting, a second meeting can be convened through a new notice, and the second general shareholders’ meeting may validly deliberate and decide regardless of the number of shares present or represented.

Subject to the same quorum and majority requirements for an increase of the share capital, the Company’s general shareholders’ meeting may also authorise the board of directors, within certain limits, to increase the Company’s share capital without further approval of the shareholders. This is the so-called authorised capital.

***Unofficial English translation - For information purposes only ***

The technique of the authorised capital offers the board of directors a degree of flexibility and expedience that may be necessary to ensure an optimal management of the Company and the financing of its operations. The prior disclosures, formalities and time windows to convene a general shareholders’ meeting and obtain a general shareholders’ meeting approval to effect a capital increase are detailed, numerous, and often cannot be reconciled with the speed with which market opportunities arise and disappear again. For example, the time to convene a general shareholders’ meeting (including a second meeting if the required attendance quorum of 50% of the shares is not reached at the first meeting) can take approximately two months. During this period, market circumstances can change significantly. If the board of directors is not able to seize potential market opportunities that arise, this could be to the disadvantage of the Company. In addition, if market circumstances no longer allow for a capital increase at favourable conditions after a general shareholders’ meeting has been convened, this could also be to the disadvantage of the Company.

The board of directors intends to use the abovementioned powers under the authorised capital in circumstances where, in the interest of the Company, the convening of a general shareholders’ meeting would be undesirable or not appropriate. Such circumstances could for instance arise when:

●	it appears to be necessary to be able to respond quickly to<br>certain market opportunities; or
●	there is a financing need, whereby the relevant market circumstances<br>are not appropriate for an offering or issuance to all shareholders; or
---	---
●	under existing agreements, facilities or instruments, the<br>Company is required to issue shares on an expedited basis, irreconcilable with the formalities for convening an extraordinary general<br>shareholders’ meeting; or
---	---
●	a prior convening of a general shareholders’ meeting would<br>lead to an untimely announcement of the transaction, which could be to the disadvantage of the Company; or
---	---
●	the costs related to the convening of a general shareholders’<br>meeting are not in balance with the amount of the proposed capital increase; or
---	---
●	due to the urgency of the situation it appears that a capital<br>increase within the framework of the authorised capital is necessary in the interests of the Company.
---	---

The board of directors would be able to use its powers under the authorised capital to issue shares, share options, subscription rights, or other securities with disapplication of the preferential subscription right to the benefit of the members of the personnel of the Company or of its subsidiaries, or to the benefit of one or more specified persons other than members of the personnel of the Company or of its subsidiaries.

The board of directors would be able to use its powers under the authorised capital to raise capital, inter alia:

●	with a view to strengthening the share capital or net equity<br>of the Company;
●	to attract possible new partners, or important shareholders,<br>or specialist investors from one or several selected jurisdictions (in or outside Belgium or the United States) to the share capital<br>structure of the Company, to increase the liquidity in the listing of the Company’s shares and/or American Depositary Shares;
---	---
●	to finance the existing business activities or new business<br>initiatives of the Company and its subsidiaries;
---	---
●	to finance the future growth and development of the business<br>activities of the Company and its subsidiaries;
---	---
●	to finance (in whole or in part) takeovers or acquisitions<br>of companies, businesses or assets (such as, but not limited to, intellectual property rights), corporate partnerships, in-licensing<br>deals or other types of mergers, partnerships or strategic alliances; and/or
---	---
●	share based compensation plans for members of the personnel,<br>consultants and other service providers of the Company and its subsidiaries (from time to time); and/or
---	---
●	for other general working capital purposes.
---	---

* * *

Done on 24 April 2023,

[signature page follows]

***Unofficial English translation - For information purposes only ***

On behalf of the board of directors,

[Signed]		[Signed]
By:		By:
	Director		Director

Exhibit 99.10

NEWS RELEASE –REGULATED INFORMATION

APRIL 25, 2023, 4:00 pm ET/ 22:00 CET

MDxHealth Announces its Ordinary and Extraordinary

General Shareholders’ Meetings

IRVINE, CA, and HERSTAL, BELGIUM – April 25, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH) (the “Company” or “mdxhealth”), a commercial-stage precision diagnostics company, today invites the holders of securities issued by the Company to its ordinary and extraordinary general shareholders’ meetings that will be held on Thursday, May 25, 2023 at 3:00 p.m., Belgian time.

The items on the agenda of the ordinary and extraordinary general shareholders’ meetings include the proposed approval of a number of resolutions relating to the financial year ended on 31 December 2022, as well as the renewal of board mandates, the issuance of a new share option plan called the “2023 Share Option Plan” and the renewal of the authorization to the board of directors to increase the share capital within the framework of the authorized capital.

In order to participate to the ordinary and extraordinary general shareholders’ meetings of the Company, the holders of securities issued by the Company must comply with article 7:134, §2, first indent of the Belgian Companies and Associations Code and the articles of association of the Company, and fulfill the formalities described in the convening notice. The convening notice, forms and other documents relating to the ordinary and extraordinary general shareholders’ meetings can be consulted on the Company’s website.

The Company recommends holders of its securities to use e-mail for all communication with the Company regarding the general shareholders’ meetings. The Company’s email address for such communication is: agsm@mdxhealth.com.

About mdxhealth®

mdxhealth is a commercial-stage precision diagnostics company that provides actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests are based on proprietary genomic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis and prognosis of urologic cancers and other urologic diseases. The Company’s U.S. headquarters and laboratory operations are in Irvine, California, with additional laboratory operations in Plano, Texas. European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.

For more information:

mdxhealth

info@mdxhealth.com

LifeSci Advisors (IR & PR)

US: +1 949 271 9223

ir@mdxhealth.com

***NOTE:***The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS and Monitor mdx are trademarks or registeredtrademarks of MDxHealth SA. The GPS test was formerly known as and is frequently referenced in guidelines, coverage policies, reimbursementdecisions, manuscripts and other literature as Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate Score, and OncotypeDx Prostate Cancer Assay, among others. The Oncotype DX trademark, and all other trademarks and service marks, are the property of theirrespective owners.